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Abstract 
Background 
Pertussis (whooping cough) remains an important public health problem in Australia. 
Although mortality and morbidity from pertussis declined dramatically following the 
introduction of mass vaccination programs in 1953, the level of morbidity remains 
unacceptably high for a vaccine-preventable disease. 
Aims and methods 
The primary aims of this thesis were (i) to ascertain the epidemiology of pertussis in 
Australia between 1993 and 2000 by analysing and interpreting sources of routinely 
collected data on pertussis; and (ii) to examine the effectiveness of vaccination against 
pertussis in a number of ways. Data from three primary national sources (notifications 
of disease, hospitalisations for pertussis and death certificates) were used to examine 
the burden from pertussis in Australia over these eight years. Analyses included the 
age distribution of cases, temporal and geographic trends, comparisons of notification 
and hospitalisation data, and the impact of differences in the method of diagnosis of 
notified cases between years and age groups. In addition to analyses at the national 
level using data from the national databases, further detailed analyses were 
undertaken at the State level for New South Wales (NSW), the most populous 
Australian State.  
 
Pertussis vaccine coverage was estimated using data from the recently established 
Australian Childhood Immunisation Register (ACIR); these data were also used to 
track the transition from whole-cell to acellular pertussis vaccines.  
 
The different types of studies used to evaluate vaccine effectiveness were reviewed, 
and a method suitable for ongoing estimation of vaccine effectiveness in Australia 
was developed. This was then applied to the NSW data, to determine the effectiveness 
of pertussis vaccination in this State. 
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Main findings 
The annual notification rate for pertussis in Australia ranged from 23–59 per 100 000 
population over the eight years. Infants had the highest notification and hospitalisation 
rates in Australia — they accounted for 5% of notifications, 61% of hospitalisations 
and 100% of deaths. Age-specific notification and hospitalisation rates in children 
aged less than two years strongly suggested a protective effect of vaccination, with the 
greatest reduction in rate coinciding with eligibility to receive a second dose of 
pertussis vaccine at four months of age. Notification rates among 5–9 year olds 
progressively decreased in successive age cohorts, consistent with an effect of the 
introduction in 1994 of a pertussis vaccine booster for preschool-aged children. 
Although adults (persons aged 15 years or more) accounted for half the notifications, 
they had the lowest notification rate. 
 
The highest numbers of pertussis notifications were in 1997, when most jurisdictions 
experienced an epidemic. Notification and hospitalisation rates varied across the 
States and Territories and also across smaller geographic regions in NSW. Areas and 
years with high notification rates tended to also have high hospitalisation rates, 
suggesting that trends in notifications reflected trends in incidence. The number of 
infant hospitalisations in NSW between July 1993 and June 1999 exceeded the 
number of notifications by 32%, highlighting the extent of under-notification. 
 
Overall, and particularly amongst those aged more than 12 months, the majority of 
cases notified in NSW were based on the results of serological tests. The proportion 
diagnosed by culture of the organism was greatest in infants; the proportion diagnosed 
by serological tests increased with age. There was no evidence that the use of 
serology had increased since 1994 in NSW, hence changes in notification rates after 
this time are unlikely to be attributable to increased use of serological diagnosis. 
 
ACIR records indicated that in December 2000, 92% of one-year-old children had 
received three doses of diphtheria-tetanus-pertussis (DTP) vaccine and 90% of two-
year-olds had received four doses. Vaccine coverage varied by jurisdiction. Since 
1997, there was an increased use of DTP vaccines containing acellular pertussis 
components with a corresponding decrease in the use of vaccines containing whole-
 3
cell components. In 2000, almost all DTP vaccines administered contained acellular 
pertussis components. 
 
The results of the vaccine effectiveness study showed that pertussis vaccination was 
highly effective at preventing pertussis in NSW children, as measured by notified 
cases. Vaccine effectiveness was highest (91%) in the youngest age group (8–23 
months) and lowest (78%) in the oldest age group (9–13 years). The screening method 
has not previously been used to estimate pertussis vaccine effectiveness in Australia. 
Conclusions 
This thesis demonstrates the value of integrating varied data sources in estimating the 
disease burden from pertussis. The data presented here show that the disease burden is 
substantial in all age groups, despite high levels of vaccine coverage in infants and 
children. This problem of disease control does not appear to be due to lack of vaccine 
effectiveness, but there is evidence of waning immunity over time.  
 
The analyses presented here form a basis for the ongoing monitoring of trends in 
pertussis epidemiology following the replacement of whole -cell by acellular pertussis 
vaccines, and will assist consideration of the need for additional booster doses in 
adolescents and adults. 
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ARV  attack rate in vaccinated (cases) 
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indicate a reduced dose for adults compared with child formulations 
DTPw  diphtheria-tetanus-whole -cell pertussis (vaccine) 
ELISA  enzyme-linked immunosorbent assay 
GPII  General Practitioners Immunisation Incentives 
HOIST  Health Outcomes and Information Statistical Toolkit 
ICD   International Classification of Disease 
ISCOS  Inpatient Statistics Collection Online System 
LOS   length of stay 
NCIRS  National Centre for Immunisation Research and Surveillance of 
Vaccine Preventable Diseases 
NDD   Notifiable Diseases Database (NSW) 
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NNDSS  National Notifiable Diseases Surveillance System 
NSW   New South Wales 
PCR  polymerase chain reaction 
PCV   proportion of cases vaccinated 
PD  principal diagnosis 
PPV  proportion of the population vaccinated 
VE   vaccine effectiveness 
VIVAS Vaccine Information and Vaccine Administration Service 
WHO  World Health Organization 
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The disease 
Pertussis (whooping cough) is a bacterial illness involving the respiratory tract. It is 
usually caused by the bacterium Bordetella pertussis but is occasionally caused by 
Bordetella parapertussis.1,2 The illness generally begins with an irritating cough that 
gradually becomes paroxysmal and lasts for 1–2 months or longer. Paroxysms are 
characterised by repeated violent coughs which may be followed by a characteristic 
crowing or high-pitched inspiratory whoop and vomiting. Infants aged less than 6 
months, adolescents and adults often do not have the paroxysms or whoop.3 Pertussis 
is highly infectious, spreading via respiratory droplets to about 80% of unvaccinated 
household contacts.4 With current standards of medical care in developed countries, 
mortality from pertussis is estimated to be 0.3% overall, but it is higher (0.5%) in 
infants aged less than six months.5 Complications include hypoxic encephalopathy, 
which may result in brain damage and death. 5 Although antibiotic therapy given 
during the incubation or early catarrhal stage may prevent or modify clinical disease, 
treatment initiated after the onset of the paroxysmal cough does not affect the duration 
or severity of the clinical illness.6 Complete vaccination of all children is the most 
important preventive measure for the control of pertussis.7 
Vaccines 
In Australia, the Commonwealth Serum Laboratories (CSL) began manufacturing 
whole-cell pertussis vaccine in 1920. 8 However, mass vaccination programs did not 
commence until 1942.8 A more potent vaccine was licensed in 1953 which 
incorporated pertussis into the ‘triple antigen’ vaccine, together with tetanus and 
diphtheria toxoids.4 This diphtheria-tetanus-pertussis vaccine is also known as DTP. 
At the same time as this vaccine was licensed, the three-dose schedule of DTP for 
infants commenced, although the timing of doses varied by State/Territory. 8 A 
national vaccination schedule was introduced in 1975, which recommended 
vaccination with DTP for infants at 3, 4, and 5 months of age, plus a booster dose at 
15–18 months.8 The booster dose was subsequently removed from the schedule in 
1978, following a case-series in the United Kingdom which suggested a temporal 
association between the vaccine and brain damage in infants.8 In 1982, the national 
schedule was changed to recommend vaccination with DTP for infants at two, four 
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and six months of age and vaccination with combined diphtheria-tetanus (CDT) for 
children at 18 months and prior to school entry.8 
 
In the early 1980s there was a marked increase in the number of laboratory confirmed 
cases of pertussis and also an increase in the proportion of notifications involving 
preschool age groups, compared with the 1970s when the highest proportion was in 
younger children.9 A working party, appointed by the National Health and Medical 
Research Council (NHMRC) to investigate this trend, concluded that the alteration in 
vaccination schedule from four to three doses of pertussis vaccine in 1978 had been 
partly responsible.9 As a result of this finding, in 1985 a fourth dose at 18 months of 
age was re-introduced.9 The working party also found that batches of the vaccine 
produced from 1978 to early 1980 were of low potency; this problem was rectified in 
1984 by the addition of an aluminium adjuvant.9 In the fifth edition of The Australian 
Immunisation Procedures Handbook, first published in October 1994, a fifth dose of 
DTP for children 4–5 years of age was added to the schedule to replace CDT.10 In the 
seventh edition of the Handbook , first published in March 2000, the recommended 
age for the fifth dose of DTP was changed from 4–5 years to four years.5 
 
Estimates of the efficacy of  whole -cell pertussis vaccine vary considerably.11,12 
Efficacy estimates of whole-cell vaccines following three doses range from as low as 
36% for the Connaught vaccine tested in Italy 12,13 to between 86% and 98% for 
Behring, Aventis Pasteur and Wyeth-Lederle vaccines tested in Germany and 
Senegal.12,14 The effectiveness of the whole-cell pertussis vaccine used in Australia 
has not been tested. 15 Studies indicate that, although vaccination does not always 
provide absolute protection against pertussis, when vaccinated children have become 
infected with pertussis the ensuing disease has generally been milder and associated 
with fewer complications than in unvaccinated children. 9,16 Unfortunately, vaccination 
does not confer long-term immunity.17 So even in well vaccinated communities there 
may be pools of individuals with waning immunity, such as parents or health care 
workers, who may develop milder or atypical episodes of pertussis and pass the 
infection on to infants.  
 
Chapter 1. Introduction   
 21
In the past, non-compliance with pertussis vaccination was often thought to be due to 
concerns about the side effects of whole-cell vaccines. As a result, acellular vaccines 
have been developed. These new acellular vaccines have fewer side effects18 and 
appear to be efficacious,19 although they are more costly than the whole -cell 
vaccines.9,20 GlaxoSmithKline’s Infanrix,Ô  a three-component acellular pertussis 
vaccine combined with diphtheria and tetanus toxoids (DTPa), was licensed for use in 
Australia in 1997. The Commonwealth Government initially funded acellular 
vaccines in the national immunisation program for the fourth (18 month) and fifth 
(preschool) boosters, but since 1999 has also funded acellular vaccines to replace 
whole-cell vaccines in the primary vaccination course. Exceptions to this were South 
Australia and the Northern Territory, where the State and Territory governments 
funded DTPa for all doses in 1997. The efficacy of this vaccine was calculated to be 
84% in a randomised controlled trial conducted in Italy in 199313 and 89% in a 
household-contact study undertaken in Germany in 1994. 14 InfanrixÔ is also available 
combined with the hepatitis B vaccine as Infanrix-hepB.Ô The only other DTPa 
vaccine licensed for use in Australia is Tripacel,Ô manufactured by Aventis Pasteur 
Connaught and distributed by CSL. 
Burden of disease 
Pertussis is a major cause of morbidity and mortality in infants throughout the world. 
The true incidence of pertussis cannot be directly measured and estimates are 
generally based on data sources such as deaths, hospitalisations, notifications or 
studies designed for this purpose. The World Health Organization (WHO) estimates 
that there are 200 000–300 000 deaths and 20–40 million infections from pertussis 
each year.21  
 
In Australia, after a prolonged period of apparent low pertussis activity following the 
introduction of mass vaccination programs, there appears to have been a resurgence of 
disease since 1993.7 For the years in which data are available (national compilation of 
pertussis notifications ceased in 1949 and did not recommence until 197922), the low 
notification rate in the post-vaccination years is evident (Figure 1.1). Similarly, the 
number of deaths Australia-wide each year due to pertussis decreased dramatically 
after the introduction of vaccination programs (Figure 1.2). However, from late 1996 
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to 1997 pertussis was responsible for ten infant deaths. One State, South Australia, did 
not discontinue pertussis surveillance and is the only source of continuous notification 
data since 1917.23 The dramatic reduction in South Australian mortality and 
notification rates following the introduction of a mass vaccination program in 1953 is 
striking (Figure 1.3).23 However, since 1993 notification rates have risen again.23 
 
Figure 1.1. Annual adjusted pertussis notification rate, Australia, 1917–2000 
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Source: Hall. 22 Rates were adjusted to estimate a national rate for the years when data were 
not available from all States and Territories. This was done by defining the denominator 
populations at risk as the total populations of those States and Territories where the disease 
was notifiable. The original graph has been updated with notification data from 1992–2000. 
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Figure 1.2. Deaths due to pertussis, Australia, 1907–1997  
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Source: Australian Bureau of Statistics, Causes of Death Collection.24 
 
 
Figure 1.3. Pertussis crude death rate, 1893–1996, and notification rate, 1917–1996, 
South Australia 
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Figure reproduced from Scheil et al.23 
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In both the mortality and notification graphs, peaks can be seen every three to five 
years prior to the introduction of mass vaccination programs (Figures 1–3). This 
cyclic pattern has been documented elsewhere and reflects the time needed for the 
number of susceptible people in a population to increase sufficiently to overcome the 
threshold for herd immunity.25 This time period may vary and is dependent upon such 
factors as the birth rate, the population and vaccination. Even with high vaccine 
uptake rates, epidemics may still occur every three to four years, but these outbreaks 
are much smaller and have greatly reduced associated morbidity and mortality. 15,26 
 
Similar patterns in disease have been noted overseas with the introduction of 
vaccination programs. In the United Kingdom, an inverse correlation between 
pertussis incidence and pertussis vaccine uptake rates in different parts of the country 
were observable once pertussis vaccine was widely available in 1940.26 However, 
pertussis vaccine uptake in the United Kingdom decreased in the mid 1970s from over 
80% to less than 40% of all children, following adverse publicity about possible side 
effects of the vaccine.9 Following this decline in vaccine uptake there was a dramatic 
increase in the number of notifications.26 By 1993 public confidence in the vaccine 
had been restored and the vaccine uptake was estimated to be 93%.26 As vaccine 
coverage increased, pertussis notifications fell dramatically, from 65 810 during the 
epidemic year of 1982 to 3963 cases during the epidemic year of 1994.27 Similarly in 
Sweden, pertussis incidence in infants rose to pre-vaccination levels within four years 
of the withdrawal of locally produced pertussis vaccines in 1979.28  
 
Pertussis vaccine coverage in Australia did not decline as it did in the United 
Kingdom and Sweden, and it was not until 1993 that notifications began to rise. In 
1997, the Australian crude notification rates were reported as being ten times higher 
than those of the United States of America and three times those of England and 
Wales, in spite of similar levels of vaccine coverage.29 In addition, there were 
differences in the age distribution of notified cases compared with the United States 
and Italy.29 It was not clear whether these differences reflected variations in case 
definitions/ascertainment or true differences which could in turn be attributable to 
differences in vaccine coverage or the effectiveness of the vaccination program. 
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What this thesis contributes 
While morbidity and mortality from pertussis have dramatically declined since the 
pre-vaccine era, the level of morbidity and mortality from pertussis remain 
unacceptably high for a vaccine-preventable disease. In order to reduce morbidity 
from pertussis we need to improve our knowledge and understanding of its 
epidemiology. In the guidelines for the control of pertussis in Australia, the Pertussis 
Working Party identified several areas in which research was needed.7 This thesis 
addresses some of these issues as well as others which will improve understanding of 
the current epidemiology and control of pertussis in Australia. 
 
Although routinely collected data have limitations, they are grossly under-utilised and 
can provide valuable insights into the epidemiology of pertussis, especially when two 
or more data sources are examined concurrently. In Chapter 2, Pertussis in Australia: 
notifications, hospitalisations and deaths, I bring together the most recent routinely 
collected national data available on the morbidity and mortality of pertussis — 
notifications to public health authorities, hospital discharge diagnosis data and death 
certificate data. Analyses include examination of the age distribution of pertussis 
cases, particularly among five to ten year olds, to assess the impact of the introduction 
of the fifth dose of vaccine, and assessment of geographic and temporal trends. 
Measuring the consistency in the magnitude and direction of notification and 
hospitalisation trends, particularly among infants who have high hospitalisation rates, 
can provide insights into the reliability of the data. An earlier draft of this chapter was 
included in Vaccine preventable diseases and vaccination coverage in Australia, 
1993-1998,30 which was published as an 84-page supplement to Communicable 
Diseases Intelligence.  
 
Data collected at the State level in New South Wales (the most populous Australian 
State, accounting for 34% of the Australian population) are more comprehensive than 
the national data presented in Chapter 2. In Chapter 3, Pertussis notifications and 
hospitalisations in New South Wales, I provide more detailed analyses and 
interpretation of the New South Wales data than was possible using those reported to 
the national database. Additional data fields in the New South Wales Notifiable 
Diseases Database include exact age, method of diagnosis, the number of doses of 
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pertussis-containing vaccine received, whether the case was hospitalised and health 
area of residence. The New South Wales hospitalisation data include age in months 
and health area of residence, neither of which was available from the national 
hospitalisation data.  
 
Information on the method by which notified pertussis cases are diagnosed is essential 
for the interpretation of trends in notifications over time and also for making 
international comparisons. It has been suggested that the increase in notifications 
could represent increased use of serological testing rather than an increase in pertussis 
incidence.23 In Chapter 3, my analyses of the method of diagnosis of pertussis and 
differences over time and between age groups are presented.  
 
Infants suffer the greatest morbidity from pertussis. Therefore it is important to 
examine the exact age at which infants are most at risk of disease onset and/or 
hospitalisation with pertussis. These analyses have not been previously undertaken 
and the results provide useful information about the impact of infant vaccination. A 
comparison of pertussis infant notifications and hospitalisations highlights the extent 
of under-reporting and how this varies by geographic region. 
 
The vaccination status of cases is necessary to calculate vaccine effectiveness, a 
concept further developed in later chapters. The demonstrated utility of the additional 
information collected at a State level in New South Wales should encourage the 
collation of this information at a national level. 
 
The examination of trends in uptake of pertussis vaccine (coverage) at a population 
level is essential for the interpretation of pertussis notification and hospitalisation 
data, and also for the estimation of vaccine effectiveness using the method described 
in Chapter 6. The Australian Childhood Immunisation Register (ACIR) is a national 
population-based register which commenced operation in 1996. In Chapter 4, The 
Australian Childhood Immunisation Register and pertussis vaccination, the 
background to the development of the ACIR is provided, followed by a presentation 
of pertussis vaccine coverage data from the ACIR, at both a national level and a State 
level for New South Wales. The New South Wales vaccine coverage data are 
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examined by month of age and health area of residence to determine the most 
appropriate coverage figures to be used later in the vaccine effectiveness estimations 
(Chapter 6). Data from the ACIR are also examined to track the uptake of the new 
acellular pertussis vaccines. From these analyses we can conclude that very few, if 
any, acellular vaccines were administered to cases included in the vaccine 
effectiveness study. 
 
Chapter 5, Observational methods in epidemiologic assessment of vaccine 
effectiveness, provides a comprehensive review of the different studies which can be 
used to evaluate vaccine effectiveness. Observational methods are important in the 
measurement of vaccine effectiveness as experimental designs cannot be used for 
vaccines already on the vaccination schedule. Furthermore, efficacy measured in 
clinical trials under ideal conditions may differ from effectiveness in the field under 
non-ideal conditions and in different populations. Of the five observational study 
types reviewed (cohort studies, household contact studies, case-control studies, the 
screening method and case-cohort studies), the screening method is the cheapest and 
most rapid method.  
 
The only other comprehensive reviews on this topic were published over 12 years 
ago. Many changes to the vaccination schedule have been made since then, including 
the introduction of new vaccines. This has increased the need for repeatable methods 
to monitor vaccine effectiveness in a timely fashion. This review includes references 
to practical examples and attempts to identify all observational studies of vaccine 
effectiveness in Australia and New Zealand since 1987. A shorter version of this 
chapter has been submitted to European Journal of Epidemiology. 
 
Estimates of the effectiveness of pertussis vaccination in Australia was one of the key 
deficits identified by the Pertussis Working Party in 1997. 7 In Chapter 6, Effectiveness 
of pertussis vaccination in New South Wales children , I develop a method suitable for 
ongoing estimation of vaccine effectiveness. I then apply this method using data from 
New South Wales, collected during a period when the Australian whole-cell pertussis 
vaccine was in routine use, to estimate the effectiveness of pertussis vaccination in 
children aged less than 14 years. Vaccine effectiveness is calculated using the 
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screening method in a logistic regression model which includes age group, year of 
disease onset and area of residence as potential confounding variables.  
 
This chapter has two parts. Part A uses notification data from 1993–1998. Due to 
limitations in the accuracy of vaccine coverage data from 1993–1995, more restricted 
analyses (using data from the years 1996–1998) were subsequently undertaken and 
are presented in Part B. A paper using the 1996–1998 data has been submitted to 
International Journal of Epidemiology and is included as Appendix 2. 
 
Although the screening method has many potential sources of bias, trends in vaccine 
effectiveness may still be monitored over time, assuming these biases remain 
constant. Such ongoing monitoring will be important to evaluate vaccine effectiveness 
following Australia’s change to an acellular vaccine. The method developed in this 
chapter for the vaccine effectiveness estimations could be incorporated into routine 
surveillance to monitor changes in vaccine effectiveness over time, and could also be 
applied to other vaccine-preventable diseases. This is the first Australian study of its 
kind and few international studies have used multivariate methods. Even where 
multivariate methods have been used, regional vaccine coverage data have not been 
available. The availability of regional coverage data, the accuracy of which has 
improved since 1996, means that this method is particularly useful in the Australian 
setting. 
 
A summary of the main findings of the thesis and recommendations for further 
research are included in Chapter 7.  
 
In an attempt to estimate the extent of under-notification of pertussis cases and to 
obtain an alternate incidence estimate for pertussis, I designed a cough survey in 5-14 
year old children living in western Sydney. The study proposal for this survey is 
included as Appendix 1, Study proposal for a survey of cough and pertussis 
immunisation status in children. As data analysis is not complete and some of the 
results are included in another student’s thesis, the results of this study are not 
presented here. 
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Background 
In this chapter I bring together the most recent routinely collected data on pertussis 
available nationally from three sources (notifications, hospitalisations and deaths), for 
all age groups in Australia. An earlier draft of this chapter was included in the 
Communicable Diseases Intelligence supplement Vaccine preventable diseases and 
vaccination coverage in Australia, 1993-1998 .1 
Methods 
Notification data were obtained from the National Notifiable Diseases Surveillance 
System (NNDSS), hospitalisation data from the Australian Institute of Health and 
Welfare (AIHW) National Hospital Morbidity Database, and mortality data from the 
Australian Bureau of Statistics (ABS) Causes of Death Collection. SAS for Windows2 
and Excel3 were used for the analyses. 
Notifications 
The NNDSS is coordinated by the National Centre for Disease Control, 
Commonwealth Department of Health and Aged Care. The NNDSS database was 
established in its current form in 1991, and includes cases of pertussis reported to 
State/Territory authorities under their current public health legislation. This legislation 
requires medical practitioners to notify cases of pertussis to the appropriate health 
authority. Laboratories in all States/Territories except Western Australia are also 
required by legislation to notify cases of pertussis. State/Territory notification criteria 
are based on the National Health and Medical Research Council (NHMRC) 
surveillance case definitions,4 which for pertussis is: 
· Isolation of Bordetella pertussis from a clinical specimen; or 
· Elevated Bordetella pertussis specific IgA in serum or Bordetella pertussis 
antigen in a nasopharyngeal specimen using immunofluorescence with a history of 
clinically compatible illness; or 
· An illness lasting 2 weeks or more with one of the following: 
Þ Paroxysms of coughing, 
Þ Inspiratory ‘whoop’ without other apparent causes, 
Þ Post-tussive vomiting; or 
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· An illness characterised by a cough illness lasting at least 2 weeks in a patient who 
is epidemiologically related to a laboratory confirmed case. 
 
Some States/Territories use variations of this case definition and the extent to which 
States and Territories verify that notified cases meet case definitions is unknown. This 
means there is no way of confirming that NNDSS notified cases uniformly meet the 
case definition criteria. 
 
Unit record notification data for pertussis were extracted from NNDSS for cases with 
an onset between 1 January 1993 and 31 December 2000 (8 years). Data were updated 
in February 2001. Data for the year 2000 are preliminary and may therefore be subject 
to revision. The variables analysed were date of disease onset, age at onset, sex and 
State/Territory of residence. The fields for laboratory confirmation, date of birth, 
vaccination status and Aboriginality were too incomplete to warrant analysis.  
Hospitalisations 
Since July 1993, the AIHW National Hospital Morbidity Database has recorded 
administrative, demographic and clinical information on all patients admitted to 
public and private hospitals in Australia.5 Cases discharged between 1 July 1993 and 
30 June 1998 (5 years) were analysed. Cases admitted before 1 July 1993 were 
excluded, as were cases admitted in 1997/1998 but discharged after 30 June 1998. The 
variables extracted for analysis were date of admission (reported by financial year of 
admission, which in Australia starts at the beginning of July and ends at the end of 
June), age at admission (five year age group), sex, State/Territory of residence, 
State/Territory of hospitalisation, length of stay (LOS) and diagnosis (principal and 
other diagnoses — up to 26 diagnoses were recorded for each admission). Age in 
years was available for all States and Territories except South Australia and 
Queensland. As data on hospitalisations are collated by financial year of discharge 
from hospital, discharges for a particular year may include episodes of care for which 
the admission was in a previous year.5 State/Territory of residence was not available 
for all records and so State/Territory of hospitalisation was used.  
 
Data were extracted on the basis of International Classification of Disease, 9th 
Revision, Clinical Modification (ICD-9-CM). The first Australian version of the ICD-
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9-CM was used for the 1995/1996 data and the second version for 1996/1997 and 
1997/1998 data. The ICD-9/ICD-9-CM code 033 (whooping cough) was used to 
identify pertussis hospitalisations. This code includes codes for Bordetella pertussis 
(033.0), Bordetella parapertussis (033.1) and whooping cough with no organism 
mentioned (033.9).  
Deaths 
Summary death data were obtained from the ABS Causes of Death Collection for 
those deaths coded with the ICD-9 code 033. The Causes of Death Collection 
classifies death records based on the reported underlying cause of death. Data were 
available for deaths registered from 1993 to the end of 1997 (5 years). The variables 
extracted for each death were age at death, year death was reported, sex and 
State/Territory in which death was recorded. 
Calculations 
Rates were calculated using ABS mid-year estimated resident populations. Rates are 
presented as annual rates or average annual rates per 100 000 total population or 
population in age, sex or geographic subgroups, as appropriate. Average annual rates 
were calculated by dividing the total number of cases for the period of investigation 
by the sum of each year’s population for the same period. For hospitalisation data, the 
mid year population estimate for the first half of the financial year was used as the 
denominator. Averages were calculated for rates of notifications and hospitalisations, 
and for bed days per year. Medians and ranges, rather than averages, were used to 
describe the distribution of notifications and hospitalisations per month, and length of 
stay per admission, as these data were not normally distributed. 
Results  
Secular trends 
There were 45 455 notifications of pertussis received by the NNDSS with dates of 
onset between 1 January 1993 and 31 December 2000. Pertussis notifications peaked 
in 1997 (Figure 2.1) when 10 907 cases were notified, approximately double the 
number in previous and following years. The median number of notifications was 416 
cases per month, with a range from 115 to 1606. The average annual notification rate 
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for the eight year period was 30.9 per 100 000 population. The lowest rate was 23.2 in 
1999 and the highest was 58.9 in 1997. 
 
A seasonal pattern was apparent with the highest number of notifications occurring in 
the spring and summer months between August and February each year. 
Hospitalisations followed a similar pattern to notifications for the years in which 
hospitalisation data were available but there was less variation in the numbers of 
hospitalisations. Although a seasonal pattern was clearly apparent in school-aged 
children and in adults (5-14 & 15+ years), it was less obvious in pre-school aged 
children (0-4 years), particularly in the non-epidemic years (Figure 2.2). 
 
Figure 2.1. Pertussis notifications, 1993–2000, and hospitalisations, July 1993–June 
1998, by month of onset or admission, Australia  
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Note varying scales between notifications and hospitalisations. 
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Figure 2.2. Pertussis notifications by month of onset and age group, Australia, 1993–
2000  
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Severe morbidity and mortality 
From July 1993 to June 1998, 4804 persons were hospitalised with pertussis (ICD-
9/ICD-9-CM code 033, Table 2.1), compared with 31 709 pertussis notifications in 
the same period. Of the hospitalisations, 4014 (84%) had a principal diagnosis of 
pertussis (average annual rate 4.4 per 100 000 population). Bordetella pertussis (ICD-
9/ICD-9-CM code 033.0) was recorded for 1429 (30%) hospitalisations and was the 
principal diagnosis for 1210 (25%). Bordetella parapertussis (033.1) was recorded for 
55 (1%) hospitalisations and was the principal diagnosis in 25 (0.5%) cases. The 
remaining cases were coded as whooping cough (033.9). A total of 19 582 bed days 
(average 5263 days per year) were recorded for patients with pertussis. The median 
length of stay per admission was 3 days. 
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Table 2.1. Pertussis hospitalisations July 1993–June 1998 and deaths 1993–1997, by 
age group, Australia  
Age 
group 
(years) 
Hospitalisations 
 
July 1993–June 1998 
LOS* per 
admission 
(days) 
Deaths 
 
1993–1997 
 Total (PD†) Rate‡ (PD†) Median No. Rate‡ 
0–4 3427 (3009) 52.9  (46.4) 3 9 0.1 
5–14 741   (608) 5.7   (4.7) 2 0 - 
15–24 108     (68) 0.8   (0.5) 3 0 - 
25–59 345   (220) 0.8   (0.5) 4 0 - 
60+ 183   (109) 1.3   (0.8) 7 0 - 
All ages 4804 (4014) 5.3   (4.4) 3 9 0.0 
*LOS = length of stay in hospital. 
† PD = principal diagnosis. 
‡ Average annual age-specific rate per 100 000 population. 
 
Between 1993 and 1997 there were nine deaths recorded as due to pertussis — one in 
1995, two in 1996 and the remaining six in 1997. Five of the deaths were in New 
South Wales, two in Queensland and one each in Victoria and Western Australia.  
Age and sex distribution 
The highest notification rate for the period 1993–2000, was the 10–14 year old age 
group (Figure 2.3). However, infants aged less than one year had considerably higher 
notification rates than 1–4 year olds, and combining these two groups masks this 
important difference. When infants aged less than one year and 1–4 year olds are 
separated it is clear that the highest notification rate, both overall and for all years 
prior to 1999, was in infants aged less than one year (Table 2.2  & Figure 2.4 ). Infants 
aged less than one year accounted for 5% of all notifications and children aged less 
than five years for 12% (Table 2.2 ). 
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Figure 2.3. Pertussis notification rates by five year age group, Australia, 1993–2000 
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Table 2.2. Pertussis notifications and average annual notification rates, by age group, 
Australia, 1993–2000  
Age group Notifications 
n                       %  
Average annual rate per 
100 000 population 
<1 year 2 212 5 109 
1-4 years 3 404 7 41 
5-9 years 8 211 18 78 
10–14 years 8 881 20 85 
15+ years 22 747 50 20 
Total 45 455 100 30 
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Figure 2.4. Pertussis age-specific notification rates by year of onset, Australia, 1993–
2000  
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In contrast with notifications, a much greater proportion of hospitalisations were in 
young children, with children aged less than five years accounting for 71% of 
hospitalisations. Where year of age was available (all States and Territories except 
South Australia and Queensland), 61% of hospitalisations were in children aged less 
than one year (Table 2.3 ). The average annual hospitalisation rate for infants aged less 
than one year was 207 per 100 000 (Table 2.4). The number of infants aged less than 
one year hospitalised from July 1993 to June 1998 was 45% greater than the number 
notified in the same period (1965 hospitalisations compared with 1356 notifications). 
In infants aged less than one year hospitalisation rates were greater than notification 
rates for all years (Figure 2.5). All fatal cases of pertussis were in children aged less 
than 12 months. 
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Table 2.3. Pertussis hospitalisations b y State/Territory of residence and financial year 
of admission, Australia, July 1993–June 1998 
Year ACT NSW NT Qld SA Tas Vic WA Total 
93/94 6 480 5 274 145 13 140 60 1123 
94/95 12 238 45 253 52 21 157 107 885 
95/96 5 199 11 171 86 15 164 57 708 
96/97 7 261 3 88 157 8 275 124 923 
97/98 9 439 8 213 123 11 125 237 1165 
Total 39 1617 72 999 563 68 861 585 4804 
<5 yr 28 1215 61 652 316 48 642 465 3427 
<1 yr 24 963 50 N/A N/A 41 525 362 1965 
N/A=not available. 
 
 
Table 2.4. Pertussis hospitalisation rate s per 100 000 population by State/Territory of 
residence and financial year of admission, Australia, July 1993–June 1998 
Year ACT NSW NT Qld SA Tas Vic WA Total 
93/94 2.0 8.0 2.9 8.8 9.9 2.8 3.1 3.6 6.4 
94/95 4.0 3.9 26.0 7.9 3.5 4.4 3.5 6.3 5.0 
95/96 1.6 3.2 6.2 5.2 5.9 3.2 3.6 3.3 3.9 
96/97 2.3 4.2 1.6 2.6 10.6 1.7 6.0 7.0 5.0 
97/98 2.9 7.0 4.3 6.3 8.3 2.3 2.7 13.2 6.3 
Total* 2.6 5.3 8.1 6.1 7.7 2.9 3.8 6.7 5.3 
<5 yr* 25 55 69 55 64 28 40 73 53 
<1 yr* 108 220 279 N/A N/A 123 167 291 207 
*Average annual rate. 
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Figure 2.5. Pertussis hospitalisation rates by age group (all ages) and notification 
rates in infants aged less than 1 year by financial year of admission/onset, Australia, 
July 1993–June 1998 
0
50
100
150
200
250
300
93/94 94/95 95/96 96/97 97/98
Financial year of admission/onset
R
at
e 
pe
r 
10
0 
00
0 
po
pu
la
tio
n
<1 year
1-4 years
5-9 years
10-14 years
15+ years
<1 year notifications
 
 
School-aged children (5–9 and 10–14 years) accounted for 38% of all notifications 
(compared with 15% of all hospital admissions, Tables 2.1 & 2.2) and had higher 
notification rates than any of the other five-year age groups (Figure 2.3). From 1996 
to 1998, there was little difference between the notification rates among 5–9 year olds 
and 10–14 year olds (Figure 2.4). This contrasted with 1994 and 1995, when the rates 
for 5–9 year olds were approximately 40% higher than the rates for 10–14 year olds. 
However, in 1999 and 2000, the rate for 10–14 year olds was more than three times 
higher than for 5–9 year olds. In fact, in 1999 and 2000, 10–14 year olds had the 
highest notification rates of any age group, even exceeding those in infants aged less 
than 12 months. Within the 10–14 year age group, 11 year olds have had the highest 
notification rate since 1998. 
 
Since the introduction of the fifth dose of pertussis vaccine for preschoolers in 1994, 
the distribution of notifications by year of age within the 5–9 year age group has 
shifted upwards. In 1993 and 1994, 5–6 year olds had higher notification rates than 7–
9 and 10–14 year olds (Figure 2.6). In 1995, 5–6 and 7–9 year olds had equal rates 
which were higher than those for 10–14 year olds. However, since 1996 the rates 
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among 7–9 year olds have been higher than for 5–6 year olds. This difference was 
greatest in the years 1996 to 1998. Since 1999, the rates for 5–6 and 7–9 year olds 
have both been lower than for 10–14 year olds. This change in age distribution over 
time can be seen in more detail by examining notification rates by year of age in 5–11 
year olds (Figure 2.7 ). In 2000, notification rates in this group increased with each 
increasing year of age. However, there was no meaningful difference in rates between 
5–8 year olds, 9 year olds had only a slightly higher rate, but the 10 and 11 year olds 
had much higher rates. 
 
Figure 2.6. Pertussis notification rates in 5–14 year olds by age group and year of 
onset, Australia, 1993–2000 
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Figure 2.7. Pertussis notification rates in 5–11 year olds, by year of age and year of 
onset, Australia, 1993–2000 
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Adults (persons aged 15 years or more), like all age groups, experienced an increase 
in notification rates during the epidemic year of 1997. Although adults accounted for 
50% of notifications, they had the lowest average annual notification rate (19.6 per 
100 000, Figure 2.4). The adult notification rate was not consistent among all age 
groups (Figure 2.3). The 15–19 year olds had the highest adult notification rate (33 
per 100 000), falling to 15 per 100 000 in 20–24 year olds. Rates then gradually 
increased, peaking at 26 per 100 000 in the 35–44 year old age group and then 
decreased down to 12 per 100 000 in persons aged 65 years and over. 
Male to female ratio 
The overall male to female ratio was 1:1.2 for notifications and 1:1.1 for 
hospitalisations. The number of female notifications exceeded the number of male 
notifications in all age groups, but the difference was greatest in the 25–45 year age 
groups, in which females accounted for over 60% of all notifications. However, of the 
nine deaths, all of which occurred in infants, seven were in males compared with only 
two in females. 
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Geographic variation 
There was substantial variation in notification numbers and rates between regions and 
years (Figures 2.8a & 2.8b, Tables 2.5 & 2.6 ). South Australia had the highest overall 
notification rate. However the Northern Territory and Western Australia had the 
highest notification rates in children aged less than five years (Table 2.6). 
 
Hospitalisation rates also varied considerably between jurisdictions (Table 2.4 ). As 
most pertussis hospitalisations were in children aged less than five years, the 
geographic distribution of hospitalisations and notifications for this age group was 
compared. Nationally, in children aged less than five years, the notification rate (58 
per 100 000, Table 2.6) and hospitalisation rate (53 per 100 000, Table 2.4) were 
similar. However, hospitalisation rates exceeded notification rates in Queensland and 
Victoria. Western Australia had the highest average annual notification and 
hospitalisation rates, while Tasmania, the Australian Capital Territory and Victoria 
had the lowest rates (Tables 2.4 & 2.6). In infants aged less than one year, the number 
of hospitalisations were greater than the number of notifications for all jurisdictions 
where these data were available. 
 
In New South Wales, South Australia, Victoria and Western Australia, the year with 
the highest number and rate of notifications was 1997 (Tables 2.3 & 2.4, Figure 2.8). 
In South Australia, Victoria and Western Australia, the financial years 1996/97 and 
1997/98 also had the highest hospitalisation rates (Table 2.4). In the Northern 
Territory and Queensland, 1994 had the highest notification rates (Table 2.6  & Figure 
2.8), with corresponding high hospitalisation rates (Table 2.4). The highest annual 
notification rate was 130 per 100 000, recorded in Tasmania in 1999 (Table 2.6 — 
note that hospitalisation data for 1999 were not available for comparison). This was 
followed by 113 per 100 000 in South Australia in 1997 and 109 per 100 000 in the 
Northern Territory in 1994 (Table 2.6). The highest annual hospitalisation rate was 26 
per 100 000, recorded in the Northern Territory in 1994/95 (Table 2.4). This was 
followed by 13.2 per 100 000 in Western Australia in 1997/98 and 10.6 per 100 000 
in South Australia in 1996/97 (Table 2.4 ). 
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Figure 2.8a. Notification rates by State/Territory and year of onset, Australia, 1993–
2000, Australian Capital Territory, New South Wales, Northern Territory and 
Western Australia  
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Figure 2.8b. Notification rates by State/Territory and year of onset, Australia, 1993–
2000, Queensland, South Australia, Tasmania and Victoria 
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Table 2.5. Pertussis notifications by State/Territory and year of onset, Australia, 
1993–2000 
Year ACT NSW NT Qld SA Tas Vic WA Total 
1993 48 1 548 7 687 1 351 56 496 261 4 454 
1994 19 1 427 182 1 923 748 34 448 662 5 443 
1995 35 1 385 132 1 354 454 110 438 339 4 247 
1996 40 1 146 14 774 774 31 1 378 227 4 384 
1997 105 4 328 24 1 902 1 675 120 1 584 1 204 10 942 
1998 100 2 313 24 1 306 579 55 1 078 284 5 739 
1999 83 1 429 2 963 217 610 998 96 4 398 
2000 205 3 616 9 532 558 143 710 75 5 848 
Total 635 17 192 394 9 441 6 356 1 159 7 130 3 148 45 455 
<5yr 52 1 678 86 696 440 73 728 729 4 482 
<1yr 25 881 46 208 201 35 506 310 2 212 
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Table 2.6. Pertussis notification rates per 100 000 population by State/Territory and 
year of onset, Australia, 1993–2000  
Year ACT NSW NT Qld SA Tas Vic  WA Total 
1993 16.0 25.8 4.1 22.1 92.5 11.9 11.1 15.6 25.2 
1994 6.3 23.5 105.0 60.3 51.0 7.2 10.0 38.9 30.5 
1995 11.5 22.6 74.3 41.5 30.9 23.2 9.7 19.6 23.5 
1996 13.0 18.5 7.7 23.2 52.5 6.5 30.2 12.9 23.9 
1997 33.9 69.0 12.8 55.9 113.2 25.3 34.4 67.0 59.1 
1998 32.4 36.5 12.6 37.8 38.9 11.7 23.1 15.5 30.6 
1999 26.8 22.3 1.0 27.4 14.5 129.7 21.2 5.2 23.2 
2000 66.1 56.4 4.7 15.1 37.4 30.4 15.1 4.0 30.8 
Total* 25.9 34.5 26.9 35.2 53.8 30.7 19.4 22.1 30.9 
<5yr* 39.1 63.7 81.3 48.4 75.1 35.7 38.2 95.9 57.7 
<1yr* 70.9 127.6 160.5 55.3 132.4 67.9 102.9 155.6 109.2 
*Average annual rate. 
Discussion  
The greatest burden of pertussis is borne by infants aged less than one year, amongst 
whom the average annual notification rate was 109 per 100 000, with rates remaining 
high throughout the study period. This group had an even higher hospitalisation rate 
(207 per 100 000) and accounted for the majority of hospitalisations (61%) and all the 
deaths. This is clearly the group requiring the greatest protection from pertussis 
infection. 
 
Notification rates are known to underestimate incidence. This is illustrated by the 
finding that the number of hospitalisations in infants aged less than one year exceeded 
the number of notifications. In spite of this age group having the greatest need of 
protection from pertussis and therefore requiring careful monitoring, these data clearly 
show substantial under-notification. Hospitalisation data may be more useful than 
notification data as an indicator of pertussis incidence in this age group. The 
notification and hospitalisation patterns in young children were similar to those during 
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an epidemic in New Zealand where, from June 1995 to May 1997, children aged less 
than 15 months accounted for 82% of hospitalisations but only 21% of notifications.6 
Temporal and geographic distribution 
The highest numbers of pertussis notifications were seen in 1997, with most 
jurisdictions experiencing an epidemic in that year. This epidemic affected all age 
groups with more deaths recorded than in any other year since 1960. 7 The State and 
Territory which did not experience an epidemic in 1997 were the Northern Territory, 
where 1994 was an epidemic year, and Tasmania, where an epidemic occurred in 
1999. Tasmania and the Northern Territory both have small populations and low 
population densities and are relatively isolated, so it is not surprising that these areas 
experienced outbreaks in different years to other States and Territories. Jurisdictions 
with these characteristics may also experience outbreaks less often. Even within a 
State/Territory, isolated communities may exist which may not follow the pattern of 
the State/Territory. Such was the case in a community in the north-west of Western 
Australia, which experienced a pertussis outbreak in late 1999. 8 Prior to this outbreak, 
there had been no notifie d cases of pertussis in this community since 1988, despite an 
epidemic in the rest of the State in 1997. 8 
 
Where the data were available, areas and years with high notification rates also tended 
to have high hospitalisation rates, especially among infants, suggesting that 
notifications reflect incidence. As pertussis epidemics tend to occur in three to four 
year cycles, some variation by geographic area is to be expected depending upon the 
timing of the last epidemic and also on geographic differences in past or present 
pertussis vaccination coverage. 
 
Some of the observed differences in notification rates between jurisdictions may also 
reflect differences in surveillance methodologies. Some jurisdictions may be more 
active than others in case-finding, particularly during an outbreak. The use of 
serological tests for diagnosis may vary between jurisdictions. This would have the 
greatest impact on adolescent and adult notification rates and the least impact on 
infants aged less than 12 months (see Chapter 3 for a discussion of diagnostic tests). 
Information on method of diagnosis is useful when making comparisons and 
interpreting trends over time. Unfortunately, information on the method of diagnosis 
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is not currently collected at a national level. However, the NNDSS is being upgraded 
so that this information can be collected nationally in the future. 
Adult pertussis  
Adults (³15 years of age) accounted for half the notifications and 13% of the 
hospitalisations. Pertussis in adolescents and adults has been documented for many 
years in many countries, so is not a new phenomenon. 9-15 The proportion of adolescent 
and adult pertussis cases in Australia during this review period was far greater than 
that in the United States.16 This is probably due to older persons in the United States 
being less likely to be notified than in Australia, as the United States does not include 
serological diagnosis in its case definition. The proportion of adolescent and adult 
cases in Australia is also greater than in the Netherlands.17 In the Netherlands, 
serological diagnosis is included, but the serological case definition is much stricter 
than in Australia and requires a significant increase (at least fourfold) in antibody 
levels.18 
 
Since the early 1990s, a commercially available enzyme-linked immunosorbent assay 
(ELISA) for IgA against whole -cell B. pertussis has been widely used in diagnostic 
laboratories throughout Australia. Australia is unique in having serological tests for 
pertussis widely available through public and private sector laboratories. Although the 
validity of these tests is difficult to evaluate without a diagnostic reference standard, a 
study undertaken in western Sydney found that cases notified on the basis of positive 
whole-cell serology reported clinically consistent pertussis almost uniformly. 19 The 
results of the western Sydney study suggest that notifications based on positive 
serology underestimate, rather than overestimate, the true incidence of pertussis.19 Up 
until 1997, no ELISA technique for the routine diagnosis of pertussis was approved in 
the United States.20  
 
No significant rise in adult notifications was seen in the review period. However, 
adult notifications increased in South Australia just prior to 1993, corresponding with 
an increased use of serological tests.21 Surveillance data from various other countries 
indicate that an increasing proportion of reported cases are occurring in adolescents 
and adults.22 In the United States, the incidence of notified adolescent and adult 
pertussis cases has recently increased, with the incidence among persons aged ten 
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years and older doubling during 1994–1996 compared with 1990–1993.11 The contrast 
in the proportion of adolescent and adult cases between Massachusetts and the rest of 
the United States was striking, with Massachusetts accounting for 23% of cases in 
persons aged 10 years and older from 1989 to 1998, in spite of Massachusetts 
constituting only 2% of the national population.23 The incidence of notified cases in 
Massachusetts in 1998 was 70.9 per 100 000 in adolescents (10–19 years of age) and 
5.0 in adults (³20 years), much greater than national rates of 5.0 for adolescents (11–
19 years of age) and 0.82 in adults (³20 years).23 Interestingly, and in contrast with the 
rest of the United States, since late 1997 the Massachusetts State Laboratory Institute 
of the Massachusetts Department of Public Health has performed a single -serum 
ELISA for IgG to pertussis toxin in person 11 years of age and over.11,23 These 
differences highlight the importance of diagnostic criteria when making comparisons. 
The adolescent rates in Massachusetts in 1998 were higher than Australia’s rates from 
1993–2000 (59.0 per 100 000 in 10–19 year olds) but the adult rates in Massachusetts 
were lower than those in Australia (18.3 per 100 000).  
 
Although the morbidity of pertussis is well known in children, far less is known about 
the morbidity in adolescents and adults.24,25 A Canadian study of 664 adolescents and 
adults notified as having pertussis found that the mean duration of cough was 10 
weeks in adolescents and 12 weeks in adults, 97% of cases coughed for three weeks 
or longer and 52% coughed for nine weeks or longer.24 Other symptoms included 
post-tussive apnoea (87%), inspiratory whoop (69%), post-tussive vomiting (65%), 
rhinorrhoea (49%), pharyngitis (46%), sweating attack (32%), fever (31%) and fatigue 
(21%).24 Complications from this group of adolescents and adults included sinusitis 
(13%), otitis media (4%), urinary incontinence (4%), pneumonia (4%), weight loss 
(3%), rib fracture (2%) and fainting (2%).24 Authors of a study of notified cases in 
western Sydney described similar findings.25 
 
In addition to the unpleasant symptoms and complications of pertussis in adults, there 
may be considerable work and social disruption. In the western Sydney study, 71% 
(34/48) of employed adults lost work days because of the illness, with a mean of ten 
work days lost for each employed adult.25 Notified cases generally represent the more 
severe end of the clinical spectrum, even more so in adolescents and adults than in 
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younger children as many of the classical symptoms may not be present. In the 
Canadian study, a surprisingly high proportion (30%) of the passively reported 
adolescent and adult cases were culture-positive.24 Because adults may not suffer from 
the classic pertussis symptoms and there may be a perception that pertussis is a 
childhood disease, a diagnosis of pertussis is frequently not considered. 13 In a study 
undertaken amongst university students in the United States, 26% of students with a 
cough lasting one week or longer had serological evidence of pertussis infection.9 
Similarly, in a study undertaken in New South Wales in 1985/1986, 26% of adults 
with a cough lasting one month or longer, who had been referred to a consultant 
physician, had serological evidence of pertussis infection. 10 Another study undertaken 
in the United States, this time of patients presenting to a hospital emergency 
department with a cough lasting two weeks or longer, found that 21% (16 of 75 
patients) met the serologic criteria for pertussis infection, reinforcing the notion that 
pertussis is a common cause of persistent cough in adults and should be considered in 
the differential diagnosis.13 
 
One of the main concerns of such high levels of adult pertussis is that adults may 
serve as a reservoir for pertussis in susceptible children. The overall secondary attack 
rate in household contacts in the Canadian study was 15% but was higher in children 
(29% in 0-4 year olds and 25% in 5–11 year olds) and particularly high in infants 
aged less than 12 months (43%).24 The secondary attack rate in adult household 
contacts in a German study, which was based around a vaccine trial rather than 
passively notified cases, was 26.7%.12 Therefore reducing adult pertussis would 
prevent morbidity not only among adults, but also among children, particularly infants 
who are at most risk of serious disease. 
Impact of the fifth dose 
Prior to the introduction of the fifth dose of diphtheria-tetanus-pertussis (DTP) 
vaccine in late 1994 (this is a preschool dose so few children would have received it 
before the beginning of 1995), the 1–4 year age group was the most completely 
vaccinated group and, amongst persons aged less than 15 years, had the lowest 
notification rates. This is evidence of an effect of vaccination. After the introduction 
of the fifth dose, as more of the 5–9 year age group became immune, the gap between 
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the 1–4 and 5–9 year age groups narrowed, and by 1999 the notification rates of the 
two age groups were similar.  
 
The notification rate for 5–6 year olds was higher than for 7–9 year olds before the 
introduction of the fifth dose. By 1996, when most of the 5–6 year olds would have 
been eligible for a fifth dose, the rates were equal. Then, as relatively more of the 5–6 
year olds would have received a fifth dose compared with 7–9 year olds, the rates for 
5–6 year olds dropped considerably lower than 7–9 year olds. As more of the 7–9 year 
olds became eligible to have received the fifth dose, the gap narrowed such that by 
1999 the 7–9 year olds had only a slightly higher rate than 5–6 year olds. In the year 
2000, by which time all the 5–9 year olds would have been eligible to have received 
the fifth dose, the notification rates in this group increased with each increasing year 
of age. This increase in notifications with time since eligibility for vaccination could 
be suggestive of waning immunity, improved coverage with the fifth dose each year 
following its introduction or a combination of the two. The trend suggesting an impact 
of the fifth dose was first reported in 1997. 26 The relative rates within the 5–9 year 
olds, together with the overall reduction in notification rates for 5–9 year old, relative 
to rates in 10–14 year olds, provides further evidence of an impact from the 
introduction of the fifth dose of pertussis vaccine for pre-schoolers.  
 
It will be important to monitor notification rates in the 10–14 year age group carefully 
as the cohort of children eligible for the fifth dose enter this age group. Children who 
were five years of age in 1995, and hence would have been eligible for the fifth dose, 
would have been ten years of age in the year 2000. In spite of this, rates among ten 
year olds increased rather than decreased in 2000, although they still remained less 
than rates among eleven year olds. Also, uptake of the fifth dose was low when this 
cohort (children aged ten years in 2000) was aged five years (see Chapter 4). 
Information on the vaccination status of these cases would clearly aid the 
interpretation of these trends. If the vaccine provides only short-term immunity (say 5 
years) then a decrease in the 10–14 year old notification rates may not be observed. If 
there is no change in these rates, an additional pertussis booster in adolescence, as has 
been implemented in France,27 may need to be considered.  
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Adult and adolescent booster 
A combined diphtheria-tetanus-acellular pertussis vaccine (dTpa — the lower case 
letters indicating a reduced dose compared with child formulations), Boostrixä 
manufactured by GlaxoSmithKline, was recently licensed (March 2001) for use for 
booster vaccination of persons aged ten years and over in Australia. At present there 
are no national recommendations for the use of this vaccine. Currently, a booster dose 
of diphtheria and tetanus is recommended for 15–19 year olds.28 Immunity from the 
diphtheria-tetanus booster is long lasting, provided all previous doses have been 
given, and another booster is not required until 50 years of age.28 Now that Boostrixä 
is available, consideration is being given to replacing this diphtheria-tetanus booster 
with Boostrix.ä  
 
In contrast to the diphtheria and tetanus components of the vaccine, immunity from 
pertussis is not long lasting. The relatively short period of immunity to pertussis poses 
problems for maintaining adequate protection from pertussis in adults. If the pertussis 
vaccine provides shorter term immunity than infection with the disease, then routine 
boosting of adolescents with Boostrixä may merely shift the age distribution of 
pertussis. This would mean that instead of 10–14 year olds having the highest 
notification rate for pertussis it could be persons in their twenties. This older age 
group are more likely than 10–14 year olds to become parents, hence infants, who 
require the greatest protection from pertussis exposure, could in fact have greater 
exposure to the disease. However, there may be a role for a pertussis booster for 
prospective or new parents and select occupational groups such as health-care 
workers, school teachers and childcare workers.  
Male to female ratio  
The reason for female notifications exceeding male notifications in all age groups is 
not clear. Where this difference was the most noticeable, in the 25–45 year age group, 
it may be at least partly explained by more females in this age group having closer 
contact with children than males, as females are more commonly the primary care 
giver. In addition, professions with substantial contact with children, such as teachers 
or childcare workers, generally have a greater proportion of females than males. 
Hence females may be more exposed to pertussis. 
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Limitations of the data 
Comparisons between the notification, hospitalisation and death data should be made 
with caution as these databases differ in their purpose, reporting mechanisms and 
accuracy. To provide the most recent information available and to account for the 
varied reporting formats, different time periods have been reviewed for each data set. 
As there were no unique identifying codes to link records for the same individual 
across data bases and because of differences in the accuracy of each data base, it was 
not possible to analyse deaths and hospitalisations as a subset of notifications. 
 
The rates presented here are crude rates and may be confounded by jurisdictional 
differences in the population structure, such as age, ethnicity and population density. 
It is also important to note that jurisdictions with small populations may have high 
rates even with low absolute numbers of cases, so that a small change in numbers 
results in a large change in rates. As the data presented here are not random samples 
that are subject to sampling variability, confidence intervals were not calculated. 
 
A major limitation of the notification data is that they represent only a proportion of 
the total cases occurring in the community. Data accuracy may also vary between 
States/Territories due to the use of different surveillance methods. In addition, data 
accuracy may change over time as new diagnostic tests are introduced or surveillance 
practices change. Information on the method of diagnosis is not collected. This 
information would aid the interpretation of the data. In interpreting the geographic 
distribution of notification data, it is important to note that Western Australia, while 
receiving some laboratory notifications, is the only State/Territory that does not have 
legislation for mandatory laboratory notification. 
 
Comparisons over time and between jurisdictions should be more valid for 
hospitalisation data than for notification data, because methods of collecting 
hospitalisation data are more uniform. However, some variation in hospital access, 
admission practices and record coding may occur between regions and over time. 
There are also limitations associated with the use of ICD-9 codes to identify cases. 
Hospital coding errors have been reported to occur at a frequency of at least 40%, and 
to be more common for diseases with which the coder is less familiar (eg, rare 
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diseases) and for admissions with multiple diagnoses.29 Assignation of codes is based 
on information in medical records, as recorded by clinicians, and there are no strict 
case definitions. This is in contrast to the more stringent case definitions used for 
notification data, although it is not possible to determine whether these case 
definitions have been applied. It must also be noted that the hospitalisation data base 
contains a record for each admission, which means that there are separate records for 
each re-admission or inter-hospital transfer. Unique identifiers were not available and 
so some re-admissions may have been included. This is unlikely to have a major 
impact on case numbers for pertussis, as it is an acute illness. For hospitalisations 
where the pertussis code was not the principal diagnosis, the pertussis code will have 
been recorded as a co-morbidity (additional or secondary diagnosis), the relative 
importance of which cannot be gauged. 
 
Age in months was not available for either the hospitalisation or notification data. 
From the New South Wales hospitalisation data collected at a State level (see Chapter 
3) it can be seen that hospitalisations in 0–5 month olds were nearly six times higher 
than in 6–11 month olds. Since 1996, attempts have been made to collect date of birth 
in NNDSS. At present these data are too incomplete to warrant analysis but as data 
collection improves these analyses will be possible. Vaccination status is clearly 
essential information and attempts to collect this in a uniform manner are currently 
under way. 
 
The problems associated with using ICD-9 codes to select hospitalisations may also 
apply to the causes of death data held by the Australian Bureau of Statistics. However, 
unlike hospitalisations, only a single underlying cause of death was recorded until 
1997. Hence some deaths for which an ICD-9 code for pertussis was recorded may be 
missed if this code was not recorded as the underlying cause of death.  
Conclusions 
Routinely collected data, although they have limitations, provide comprehensive 
information about pertussis. Although pertussis notifications underestimate incidence 
considerably, the similarities in geographic and temporal trends in notifications and 
hospitalisations, especially amongst infants aged less than one year, suggest that these 
trends are real. The adoption of uniform case definitions and methods of 
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ascertainment throughout Australia, or at least the provision of information on the 
method of diagnosis, would improve our ability to accurately interpret national 
notification data. In the future, when date of birth and vaccination status of notified 
cases are adequately recorded, more in-depth analyses will be possible. 
 
Pertussis remains a cause of considerable morbidity, especially in infants aged less 
than one year. Over the time period studied there have been some changes in the age-
specific notification rates. The reduction in notifications among 5–9 year olds 
suggests an effect of the introduction of the fifth dose for pre-schoolers in 1994. Rates 
in adolescents are now the highest of any age group and need to be monitored closely. 
Although adult pertussis rates are relatively low, they account for half the number of 
notifications. As adults with pertussis may serve as reservoirs of infection, continuing 
the circulation of the organism in the community, reducing the incidence in this age 
group may be an important goal of future vaccination strategies. 
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Background 
In this chapter I present the analyses of pertussis notification and hospitalisation data 
from New South Wales (NSW) between 1993 and 1999. Although NSW notifications 
and hospitalisations were included as part of the national data (Chapter 2), they 
warranted additional analyses, as more information about cases was recorded at a 
State level compared with the national data. Additional fields included in the NSW 
Notifiable Diseases Database (NDD) included age in months, method of diagnosis, 
the number of doses of pertussis-containing vaccine received, whether the case was 
hospitalised and health area of residence. The NSW hospitalisation database included 
age in months and health area of residence, neither of which was available from the 
national hospitalisation data. This additional information allowed analyses to be 
undertaken at the State level which were not possible at the national level.  
 
NSW is divided into 17 health areas, eight of which are classified as rural (Figure 
6.1). Each health area has a public health unit whose responsibilities include pertussis 
notifications for their area. Each public health unit enters information onto the NDD. 
Public health units may vary in size and function, depending upon the health needs 
and priorities of the area. 
 
Infants generally suffer the greatest morbidity from pertussis, so it is helpful to know 
the age in months of infant cases. Also, because the primary vaccination schedule is 
given during the first six months of life, the pattern of disease among infants can give 
an indication of the effectiveness of vaccination programs. In order to determine 
whether cases are due to vaccine failure or failure to vaccinate, it is important to know 
whether childhood cases of pertussis are vaccinated and, if so, how many doses of the 
vaccine they have received. Use of the vaccination status data is further developed in 
the vaccine effectiveness chapter. 
 
In order to interpret trends in pertussis notifications over time and to make 
comparisons with other countries, it is helpful to know the method of diagnosis of 
notified cases. A paper describing South Australian notification, hospitalisation and 
mortality data concluded that the increase in notifications from 1993–1996 
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represented increased serological testing rather than an increase in pertussis 
incidence.1 
 
This chapter uses the additional data fields to provide a more in-depth analysis of 
NSW notification data than was possible with the national notification data. It also 
aims to examine age-specific notification and hospitalisation rates, particularly in 
cases aged 0 to 23 months, to look for variation in rates between health areas and, 
using notification data, to examine differences in methods of diagnosis over time and 
between age groups. 
Methods 
Notifications 
All notified cases of pertussis with disease onset dates between 1 January 1993 and 31 
December 1999 were selected from the NDD in the Health Outcomes and Information 
Statistical Toolkit (HOIST), NSW Department of Health. These data were 
downloaded from HOIST in March 2000. SAS for Windows2 and Excel3 were used 
for the analyses. 
 
There are two fields pertaining to method of diagnosis in NDD. The first field, 
‘LABCONF’, relates to whether a case is laboratory confirmed (yes/no category) 
whilst a second field, ‘IDENMTHD’, contains information on the method of 
identification. The method of identification field has nine categories, only one of 
which may be selected. These categories are: serology, antigen detected, clinical, 
culture, histopathology, microscopy, radiologically active, unknown and, since 1999, 
polymerase chain reaction (PCR). For most analyses, the categories radiologically 
active, histopathology, antigen detected and microscopy were re-categorised as 
‘other’. Cases whose method of diagnosis was ‘unknown’ or missing and were 
recorded as not laboratory confirmed were assumed to have been identified on clinical 
grounds and re-categorised as such.  
 
Month of age was calculated by multiplying the NDD variable ‘AGE’, which gives 
year of age to 10 decimal places, by 12 and then specifying that the month of age 
variable is an integer to prevent rounding. 
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Hospitalisations 
Data on pertussis cases discharged from hospital from between July 1993 and June 
2000 were obtained from the NSW Department of Health Inpatient Statistics 
Collection Online System (ISCOS) by financial year of discharge and age in months 
on admission. For infants aged less than 12 months, data were also obtained by health 
area of residence. From 1993 to June 1998, the ICD-9/ICD-9-CM code 033 
(whooping cough) was used to identify hospitalisations and deaths (the same as for 
the national data). From July 1998 to June 2000 the ICD-10-AM code A37 was used. 
This code includes codes for Bordetella pertussis (A37.0), Bordetella parapertussis 
(A37.1) and whooping cough with no organism mentioned (A37.9). 
Calculations 
Rates were calculated using Australian Bureau of Statistics (ABS) mid-year estimated 
resident populations for NSW, downloaded from HOIST, for the years 1993–1999 by 
five-year age group and health area. Where population data were required in smaller 
age groups than those provided by the ABS, the broader age group was divided 
proportionally to the required age group. For example, to calculate the population by 
month of age, the population figure for the 0–4 year age group (0–59 months) was 
divided by 60. Rates are presented as annual rates or average annual rates per 100 000 
total population or population in age or geographic subgroups, as appropriate. 
Average annual rates were calculated by dividing the total number of cases for the 
period of investigation by the sum of each year’s population for the same period. For 
hospitalisation data, the mid year population estimate for the first half of the financial 
year was used as the denominator. 
Results  
Notifications 
Between January 1993 and December 1999, 13 456 cases of pertussis were notified to 
the NSW Health Department. Notifications peaked in the spring and summer months 
of 1993/1994 and again, with an even greater number of notifications, in 1997/1998 
(Figure 3.1). The average annual rate for the entire period was 31 notifications per 
100 000 population. Of the 13 456 cases, 563 (4%) were recorded as being admitted 
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to a hospital and 320 of the hospitalised cases (57%) were infants aged less than one 
year. Only one case was recorded as having died as a result of pertussis infection. 
 
Figure 3.1. Pertussis notifications by month of onset, NSW, 1993–1999 
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Age distribution 
Infants aged less than one year had the highest notification rate, followed by school 
aged children (Table 3.1 ). All age groups experienced an increase in notification rates 
during the epidemic year of 1997 (Figure 3.2). The adult (aged ³15 years) notification 
rate was higher in 1997–1999 than in 1993–1996. Following the introduction of the 
fifth dose of DTP for 4–5 year olds in 1995, the notification rate in 5 and 6 year olds 
fell below that for the 7–9 year olds, falling to the same rate as the 10–14 year olds in 
1996. Since 1996, the notification rate in 4–5 year olds has remained below that for 7–
14 year olds (Figure 3.3 ). In 1999, the notification rate in 7–9 year olds fell below the 
rates for 10–14 year olds who, in 1999, had a notification rate only just below that for 
infants aged less than 12 months. 
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Table 3.1. Pertussis notifications and average annual notification rates,  
by age group, NSW, 1993–1999 
Age group Notifications 
n                      %  
Average annual rate 
per 100 000 
<1 year 773 6 126 
1-4 years 1 105 8 45 
5-9 years 2 718 20 89 
10–14 years 2 225 17 74 
15+ years 6 632 49 19 
Total 13 453 100 31 
 
 
 
Figure 3.2. Pertussis notification rates by age group and year of onset, NSW, 1993–
1999  
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Figure 3.3. Pertussis notification rates for 5 –14 year olds by age group and year of 
onset, NSW, 1993–1999  
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Children aged under 2 years 
During the period 1993–1999, in children aged less than two years, there was an 
overall downward trend in average annual notification rates by month of age, although 
the rates did not always decrease with increasing age (Figure 3.4). When the average 
annual notification rate in five age groups corresponding with eligibility to receive 0, 
1, 2, 3 and 4 doses of the vaccine was examined the downward trend was clear, with 
infants aged less than 2 months having the highest rates and those aged 18–23 months 
having the lowest (Figure 3.5 ). There was a clear reduction in notification rate 
corresponding with eligibility to receive each dose of the vaccine, with the greatest 
incremental decrease corresponding with eligibility to receive the second dose of the 
vaccine (Figure 3.5). 
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Figure 3.4. Pertussis notification rates in children aged under 2 years, by month of 
age, NSW, 1993–1999 
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Figure 3.5. Pertussis notification rates in children aged under 2 years, by age group, 
NSW, 1993–1999 
0
50
100
150
200
250
300
0-1 2-3 4-5 6-17 18-23
Age group in months
A
ve
ra
ge
 a
nn
ua
l n
ot
ifi
ca
tio
n 
ra
te
 
pe
r 
10
0 
00
0 
po
pu
la
tio
n
 
 
Chapter 3. Pertussis notifications and hospitalisations in NSW  
 68
Children aged four months and over had a significantly lower risk of being notified 
with pertussis compared with infants aged less than two months. Risk decreased with 
increasing age (Table 3.2). 
 
Table 3.2. Relative risk of pertussis notification by age group in children aged under 
2 years, NSW, 1993–1999  
Age group 
(months) 
Doses 
eligible 
Notifications Estimated 
population 
Relative Risk 95% CI 
0-1 0 243 101 866 1.0 (referent) - 
2-3 1 214 101 866 0.88 0.73 to 1.06 
4-5 2 107 101 866 0.44 0.35 to 0.55 
6-17 3 351 611 196 0.24 0.20 to 0.28 
18-23 4 99 305 598 0.14 0.11 to 0.17 
 
The majority of cases aged less than two years, for whom information on the number 
of doses of a pertussis-containing vaccine was available, had not received any doses 
of a pertussis vaccine (Figure 3.6). 
 
Figure 3.6. Pertussis notification rates in children aged under 2 years, by age group 
and number of doses of pertussis vaccine received, NSW, 1993–1999 
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Method of diagnosis 
Of the 13 456 notifications, 78% were coded as laboratory confirmed, 15% were 
coded as not laboratory confirmed and 7% had missing data (the NDD field was 
called ‘LABCONF’ and was a yes/no category). The method of diagnosis (the other 
NDD field relating to method of diagnosis which was called ‘IDENMTHD’) was 
either missing or coded as unknown in 3764 (28%) of cases. When data pertaining to 
laboratory confirmation were compared with data about the method of diagnosis 
(Table 3.3), a few anomalies became apparent. Of the 550 cases who were coded as 
diagnosed by culture, 50 (9%) were coded as not being laboratory confirmed (Table 
3.3). Likewise, of the 7868 cases who were coded as diagnosed by serology, 330 (4%) 
were coded as not being laboratory confirmed.  
 
Table 3.3. The NDD pertussis identification fields, NSW, 1993–1999 
Laboratory confirmed (‘LABCONF’) Method of 
Identification 
(‘IDENMTHD’) 
missing (%) no (%) yes (%) Total 
missing 21 (2.3) 321 (35) 564 (62) 906 
unknown 772 (27) 661 (23) 1 425 (50)   2 858 
clinical 124 (17) 572 (79) 26 (3.6)      722 
serology 70 (0.9) 330 (4.2)    7 468 (95)   7 868 
culture 4 (0.7) 50 (9.1) 496 (90) 550 
PCR 0 (0.0) 1 (25) 3 (75) 4 
antigen detected 0 (0.0) 16 (3.1) 505 (97) 521 
microscopy 0 (0.0) 1 (4.3) 22 (96) 23 
histopathology 0 (0.0) 1 (33) 2 (67) 3 
radiologically active 0 (0.0) 0 (0.0) 1 (100) 1 
Total 991 (7.4) 1 953 (15) 10 512 (78) 13 456 
Note: The colours indicate the categories which were re-coded and correspond with the 
colours used in Table 3.4 and Figures 3.7, 3.11 & 3.12. 
 
After re-categorising the fields for method of diagnosis, 2782 (21%) of the cases had a 
missing or unknown method of diagnosis. Of the 10 674 cases for whom a method of 
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diagnosis was recorded, the majority (74%) were based on serology (Table 3.4). A 
further 16% of cases were diagnosed clinically, 5% based on culture results and the 
remaining 5% on ‘other’ methods. 
 
Table 3.4. Method of pertussis diagnosis, after re-categorising, NSW,  
1993–1999 
Method of identification n (%) % (of known) 
clinical   1 704 13 16 
serology   7 868 58 74 
culture 550 4 5 
PCR 4 0 0 
other 548 4 5 
Sub-total 10 674 79 100 
Missing 793 6  
Unknown   1 989 15  
Total 13 456 100  
The categories radiologically active, histopathology, antigen detected and microscopy were 
re-categorised as ‘other’, and cases whose method of diagnosis was ‘unknown’ or missing 
and were recorded as not laboratory confirmed were re-categorised as ‘clinical’. 
 
 
During peak periods of pertussis notifications there was a rise in cases diagnosed by 
all methods, although the rise in notifications based on positive serology is the most 
obvious (Figure 3.7). The proportion of cases where the method was unknown or 
missing was highest in 1993 (44%) but has remained fairly constant from 1994–1999, 
averaging 19%. The proportion based on a positive serology has not significantly 
increased since 1994 (Table 3.5  & Figure 3.8). 
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Figure 3.7. Pertussis notifications by method of diagnosis, for all ages, by month of 
onset, NSW, 1993–1999  
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Table 3.5. Number and proportion of pertussis notifications based on positive 
serology, by year of onset, NSW, 1993–1999 
Year Number diagnosed 
by serology 
Total (method of 
diagnosis known) 
% serology   95% CI 
1993 515 952 54 51 to 57 
1994 850 1128 75 73 to 78 
1995 869 1030 84 82 to 87 
1996 695 847 82 79 to 85 
1997 2604 3436 76 74 to 77 
1998 1380 2043 68 66 to 70 
1999 955 1238 77 75 to 79 
Total 7868 10674 74 73 to 75 
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Figure 3.8. Proportion of pertussis notifications based on positive serology, by month 
of onset, NSW, 1993–1999  
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Serology had a much smaller impact on notifications in children aged under 5 years 
(Figure 3.9) than on notifications in persons aged 5 years and over (Figure 3.10). 
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Figure 3.9. Method of pertussis diagnosis by month of onset, 0 –4 year olds, NSW, 
1993–1999 
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Figure 3.10. Method of pertussis diagnosis by month of onset, 5+ year olds, NSW, 
1993–1999 
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The proportion of notifications based on a positive culture result was greatest in 
infants aged less than one year, accounting for 25% of total notifications in this age 
group (including those whose method of diagnosis was unknown). This proportion 
decreased with increasing age, accounting for only 1% of cases aged 15 years or over. 
The proportion of notified cases aged less than one year who were hospitalised and 
diagnosed by culture was higher (34%) than all notified cases in this age group. 
Conversely, the proportion who were diagnosed by serology increased with age, 
ranging from 20% of cases aged less than one year to 66% of cases aged 15 and over 
(Figure 3.11). The proportion of notified hospitalised cases aged less than one year 
diagnosed by serology was slightly less than notifications overall (16%). 
 
Figure 3.11. Method of pertussis diagnosis by age group, NSW, 1993–1999 
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In children aged less than 24 months, the proportion diagnosed by culture was greatest 
among infants aged less than four months, with a trend for a decreasing proportion to 
be diagnosed by culture with increasing age (c 21 =40, p<0.001). The proportion 
diagnosed by serology was greatest in those aged 18 months and over. The proportion 
of children aged under two years diagnosed clinically was similar in each age group 
(Figure 3.12). 
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Figure 3.12. Method of pertussis diagnosis by age group in children aged less than 2 
years, NSW, 1993–1999  
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Geographic distribution 
There was considerable variation in notification rates between the health areas, with 
Northern Rivers having the highest average annual notification rate and the Central 
Coast having the lowest (Table 3.6). In 12 of the 17 health areas, the highest 
notification rate was in 1997. Northern Rivers health area had a notification rate far 
exceeding that for other areas in 1994 and 1995, yet still had a high notification rate in 
1997. In spite of being geographically adjacent to the Central Coast (Figure 6.1 ), 
since 1996 the Hunter region has had a much higher notification rate than this area. In 
1997 the notification rate in the Hunter was over four times greater than that in the 
Central Coast. 
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Table 3.6. Pertussis notification rate per 100 000 population by health area and year 
of onset, NSW, 1993–1999  
Area 1993 1994 1995 1996 1997 1998 1999 Average 
Metropolitan         
Central Sydney 17.6 7.9 6.6 8.6 63.6 20.2 17.4 20.3 
Northern Sydney 23.6 9.8 15.0 19.4 60.0 16.5 21.3 23.7 
Western Sydney 20.1 20.8 19.9 23.3 81.9 24.5 14.3 29.3 
Wentworth 26.7 22.6 40.7 22.5 99.0 61.7 17.9 41.9 
S. Western Sydney 31.5 15.6 12.9 10.1 71.7 26.2 17.7 26.6 
Central Coast 10.3 11.7 11.0 12.2 29.9 17.1 15.0 15.5 
Hunter 11.6 13.8 15.5 27.4 127.2 48.4 52.3 42.7 
Illawarra  17.1 24.5 29.9 10.2 56.3 65.1 16.8 31.6 
S. Eastern Sydney 43.4 20.7 14.0 15.6 70.1 31.0 20.8 30.8 
Total metropolitan 24.5 16.1 16.9 16.9 74.5 31.4 21.8 29.0 
Rural         
Northern Rivers  49.4 190.6 122.8 25.0 70.1 23.1 5.8 68.2 
Mid North Coast  24.3 26.8 23.4 21.7 46.9 43.2 18.2 29.3 
New England  19.2 10.5 2.8 33.0 55.8 34.7 10.3 23.7 
Macquarie  76.8 17.7 10.8 16.5 36.8 22.4 33.9 30.6 
Mid Western 36.0 16.4 15.1 9.0 50.4 40.3 41.4 29.9 
Far West 17.5 29.5 2.0 44.0 62.5 163.5 10.3 46.6 
Greater Murray 2.0 9.8 48.9 30.4 26.4 90.1 35.0 34.7 
Southern  4.1 17.2 25.5 14.5 52.8 41.0 26.9 26.2 
Total rural 26.2 46.4 40.1 23.3 49.4 49.0 22.6 36.7 
NSW total 25.5 23.2 22.3 18.5 69.2 35.4 22.0 31.0 
 
 
Notifications in infants aged less than 12 months were examined by health area and 
financial year of onset to allow comparison with hospitalisation data (Table 3.7).  
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Table 3.7. Number of notifications and average annual rates per 100 000 population 
for infants aged less than 12 months by health area and financial year of onset, NSW, 
July 1993–June 1999 
 93/94 94/95 95/96 96/97 97/98 98/99 Total Average 
annual 
rate 
Metropolitan         
Central Sydney 4 3 4 8 18 8 45 131 
Northern Sydney 10 4 2 9 15 1 41 79 
Western Sydney 15 10 13 14 27 7 86 144 
Wentworth 3 3 2 11 14 5 38 124 
S. Western Sydney 30 1 6 12 28 8 85 117 
Central Coast 11 1 0 3 2 2 19 78 
Hunter 15 6 16 11 26 7 81 181 
Illawarra 5 4 2 3 12 2 28 97 
S. Eastern Sydney 14 5 6 11 27 4 67 133 
Total metropolitan 107 37 51 82 169 44 490 123 
Rural         
Northern Rivers 28 20 11 0 13 2 74 364 
Mid North Coast 12 3 7 4 11 10 47 233 
New England 4 1 0 3 1 3 12 74 
Macquarie  12 0 1 3 1 2 19 179 
Mid Western 11 4 3 2 5 1 26 172 
Far West 2 0 1 4 0 6 13 270 
Greater Murray 0 5 5 4 2 4 20 82 
Southern 2 3 3 2 4 2 16 102 
Total rural 71 36 31 22 37 30 227 178 
NSW total 178 73 82 104 206 74 717 137 
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The proportion of notifications which were laboratory confirmed was slightly greater 
in rural areas (87%) than in metropolitan areas (83%) (Table 3.8). 
 
Table 3.8. Method of pertussis diagnosis by place of residence (rural versus 
metropolitan) and age group, NSW, 1993–1999  
Age 
group 
(years) 
Place Culture 
% 
Serology 
% 
Other 
% 
laboratory* 
% 
Clinical 
% 
Unknown 
% 
n 
0-4 Metro 22.8 38 2.9 64 36 22 1253 
 Rural 13.0 48 1.1 63 37 27 613 
5+ Metro 6.5 48 15.5 70 30 22 8442 
 Rural 9.5 51 2.6 63 37 16 3051 
Total Metro 5.6 71 6.8 83 17 22 9695 
 Rural 3.9 82 0.7 87 13 18 3664 
* culture + serology + other  
 
Hospitalisations 
From July 1993 to June 2000, there were 1619 persons hospitalised with pertussis, 
giving an average annual hospitalisation rate of 3.7 per 100 000. Hospitalisation rates 
declined steeply with increasing age (Table 3.9). Children aged less than one year 
accounted for 61% of the hospitalisations and persons aged 15 years and over 
comprised only 9%. From July 1993 to June 1999 there were 955 hospitalisations in 
infants aged less than one year. In the same time period there were only 718 
notifications in this age group, 291 of whom were recorded as being hospitalised. 
 
Table 3.9. Pertussis hospitalisations by age group, NSW, July 1993–June 2000 
Age group Hospitalisations 
n                              % 
Average annual 
rate per 100 000 
<1 year 990 61 162.0 
1-4 years 250 15 10.2 
5-9 years 156 10 5.1 
10–14 years 72 4 2.4 
15+ years 151 9 0.4 
Total 1619 100 3.7 
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Hospitalisation rates peaked in 1993/94 and again in 1997/98 (Figure 3.13). 
 
Figure 3.13. Pertussis hospitalisation rates by age group and financial year of 
discharge, NSW, July 1993–June 2000 
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Children aged under 2 years 
In children aged less than two years, hospitalisation rates were greatest in infants aged 
two months (Figure 3.14). In infants aged 3–7 months, there was a steep decline in 
hospitalisation rates with each month of increasing age. The greatest decrease was 
between infants aged two months and three months, followed closely by the decrease 
between infants aged three months and four months. From 7–23 months of age, 
hospitalisation rates remained at about the same level, decreasing slightly after 12 
months of age. When the average annual hospitalisation rate in five age groups 
(corresponding with eligibility to receive 0, 1, 2, 3 & 4 doses of the vaccine) was 
examined in the same way as the notification data, infants aged two and three months 
had the highest rates and those aged 18–23 months had the lowest (Figure 3.15). The 
greatest incremental decrease in hospitalisation rates corresponded with eligibility to 
receive the second dose of the vaccine. 
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Figure 3.14. Average annual hospitalisation rates for pertussis in children aged 
under 2 years, by month of age, NSW, July 1993–June 2000 
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Figure 3.15. Average annual hospitalisation rates for pertussis in children aged 
under 2 years, NSW, by age group, July 1993–June 2000 
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Children aged four months and over had a significantly lower risk of being 
hospitalised with pertussis compared with infants aged less than two months, and this 
risk decreased with increasing age (Table 3.10). 
 
Table 3.10. Relative risk of pertussis hospitalisation by age group in children aged 
under 2 years, NSW, July 1993–June 2000 
Age group 
(months) 
Doses 
eligible  
Hospitalisation Estimated 
population 
Relative Risk 95% CI 
0–1 0 276 101 866 1.0 (referent) - 
2–3 1 413 101 866 1.50 1.29 to 1.74 
4–5 2 153 101 866 0.55 0.46 to 0.68 
6–17 3 219 611 196 0.13 0.11 to 0.16 
18–23 4 45 305 598 0.05 0.04 to 0.07 
 
Geographic distribution 
Hospitalisation rates in infants aged less than 12 months varied between health areas 
(Table 3.11). Overall there were 949 hospitalisations between July 1993 and June 
1999. This compares with only 717 notifications in the same time period (Table 3.7). 
The overall notification to hospitalisation ratio for the six-year period was 1:1.3, but 
varied by health area from 1:0.9 in the Hunter, Northern Rivers, Mid North Coast and 
Mid Western areas to 1:2.2 in South Western Sydney. For each of the metropolitan 
areas, except the Hunter, the total number of hospitalisations in this age group was 
greater than the number of notifications. This was also the case in half the rural areas. 
Unlike notification rates, the Hunter and Central Coast areas had similar 
hospitalisation rates. 
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Table 3.11. Pertussis hospitalisations and average annual rates per 100 000 
population in infants aged less than 12 months by health area and financial year of 
separation, NSW, July 1993 – June 1999 
Area 93/94 94/95 95/96 96/97 97/98 98/99 Total Average 
annual 
rate 
N:H* 
ratio 
Metropolitan          
Central Sydney 15 5 7 9 14 6 56 163 1.2 
Northern Sydney 12 5 5 9 17 6 54 104 1.3 
Western Sydney 31 15 9 26 39 15 135 227 1.6 
Wentworth 6 2 4 13 12 6 43 140 1.1 
S. Western Sydney 52 17 19 34 51 14 187 258 2.2 
Central Coast 16 9 0 2 5 3 35 144 1.8 
Hunter 19 6 17 6 12 9 69 154 0.9 
Illawarra 8 14 6 7 15 2 52 179 1.9 
S. Eastern Sydney 13 9 5 10 24 6 67 133 1.0 
Total metropolitan 172 82 72 116 189 67 698 176 1.4 
Rural          
Northern Rivers 30 13 11 0 9 7 70 344 0.9 
Mid North Coast 10 1 10 5 13 5 44 218 0.9 
New England 3 0 0 4 7 2 16 98 1.3 
Macquarie  17 4 1 6 1 2 31 292 1.6 
Mid Western 8 8 3 1 3 1 24 159 0.9 
Far West 15 2 1 0 1 1 20 416 1.5 
Greater Murray 6 9 5 2 2 6 30 124 1.5 
Southern 2 1 4 1 7 1 16 102 1.0 
Total rural 91 38 35 19 43 25 251 197 1.1 
NSW total 263 120 107 135 232 92 949 181 1.3 
*Ratio of the total number of notifications to the total number of hospitalisations. 
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Discussion 
Hospitalisations represent those pertussis cases with severe disease. However, it is 
difficult to know what type of cases those notified represent. The extent of under-
notification is highlighted in the comparison of notification versus hospitalisation data 
in infants aged less than one year. The number of hospitalisations exceeded the 
number of notifications in this age group by 32%. This is the age group in which 
pertussis infection is the most severe and it is therefore targeted by pertussis control 
programs. In order to better control pertussis in this age group it would be useful to 
have a measure of incidence. Given that in this group the notification rate is even less 
than hospitalisation rate, it clearly underestimates incidence considerably. 
Hospitalisation data are less subject to variations in reporting practices than 
notification data (see Limitations of the data , Chapter 2) and may be more useful for 
monitoring trends in incidence in this age group than notification data.  
 
Although pertussis is notifiable by law, a study undertaken in New South Wales in 
1991 and 1992 (before and after the new Public Health Act 1991) found very little 
improvement in self-reported notification among general practitioners.4 A study 
undertaken in the Northern Rivers Health Area in 1996 found that only 18% of 
notified pertussis cases had been notified by general practitioners.5 A further study 
undertaken two years later, in 1998, in the South Eastern Sydney health area found 
that 40% of notified pertussis cases had been notified by general practitioners.6 
Although this is an improvement, it is still a low proportion. Reasons given by doctors 
for not notifying include the belief that the laboratory will notify, the extra time it 
takes to notify a case and poor knowledge of which diseases should be notified, of the 
notification process and of the role of the public health unit once the notification is 
received.5,6  
 
Only one of the five deaths recorded in the Australian Bureau of Statistics Causes of 
Death Collection (see Chapter 2) was recorded in the NDD. This may be because the 
notification was received prior to the death of the infant and the information was not 
updated. Alternatively, the cases who died are likely to have been hospitalised cases, 
who may be less likely to be notified. 
Chapter 3. Pertussis notifications and hospitalisations in NSW  
 84
Age distribution 
The age-specific notification rates for NSW follow a similar pattern to the national 
data (see Chapter 2). As NSW data are a large subset of the national data and there is 
a national vaccination schedule, this is to be expected.  
 
The prime advantage of examining NSW data over national data is that age in months 
was available. The reduction in notification rate by age group, corresponding with 
eligibility to receive each dose of the vaccine, is suggestive of an impact of 
vaccination. Although other factors may play a role in this general decline in 
notification rate with age, it is unlikely that other factors could account for the pattern 
of the decrease. Younger infants may suffer from a more severe form of the disease, 
which could increase their chances of notification. Also, one may argue that older age 
groups are more likely to have suffered previous pertussis infections and so will be 
immune. However, based on notification and hospitalisation data, the number of 
infants infected with pertussis is small relative to the population, even allowing for 
under-reporting. Also, within each age group there was not always a decline in 
notifications by month of age. Instead there was a decrease in a stepwise fashion 
corresponding with eligibility to receive another dose of the vaccine. The pattern of 
the decrease is strongly suggestive of an effect of vaccination, with the second dose of 
the vaccine at four months of age having the greatest impact.  
 
The percentage reduction in notification rates shown in Table 3.1  could be regarded as 
a crude estimate of the effectiveness of the vaccination program at preventing notified 
cases of pertussis. The number of doses of vaccine received by cases in this age group 
suggest that only a minority had been age-appropriately vaccinated. Even without 
formal vaccine effectiveness estimations, the data suggest that most of the 
notifications in children aged less than two years are a result of failure to vaccinate or 
of being too young to be vaccinated, rather than vaccine failure. Likewise, the 
percentage reduction in hospitalisation rates shown in Table 3.10 could be regarded as 
a crude estimate of the effectiveness of the vaccination program at preventing 
hospitalised cases of pertussis. Vaccine effectiveness is measured as one minus the 
relative risk, so the effectiveness of eligibility for the first two doses is 45% and for 
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three doses is 87%. Unfortunately the vaccination status of hospitalisations is not 
collected at the State level.  
 
A similar pattern was observed in both hospitalisations and notifications by month of 
age for children aged less than two years, although some differences were apparent. 
The hospitalisation rate peaked in two-month-olds, not one-month-olds as was the 
case with notifications. However, in both notification and hospitalisation rates, one 
and two month olds had rates which were not significantly different from one other. 
The difference may be due to the date of admission occurring later than the date of 
onset, as the child may be less likely to require hospitalisation in the early catarrhal 
phase of the disease. It generally takes seven to ten days for the illness to enter the 
paroxysmal stage7 where hospitalisation becomes more likely. There was a reduction 
in hospitalisation rate with each month of increasing age from two to seven months of 
age. Younger infants with pertussis are more likely to have severe disease which 
requires hospitalisation than are those who are older. However, the pattern of 
hospitalisations is still suggestive of an effect of vaccination, with the greatest impact 
coming from the second dose and a further significant reduction resulting from the 
third dose. Authors of a paper describing New Zealand surveillance data during an 
epidemic detected a similar pattern with the peak age-specific notification and 
hospitalisation rates in the six-week to two-month age group.8 
 
Infants aged less than one month of age had significantly lower notification and 
hospitalisation rates than infants aged one month. This may be due to newborn infants 
having less exposure, having some protection from maternal antibodies or a 
combination of the two. Transplacental pertussis IgG antibody concentrations in 
newborns have been found to be comparable  to maternal concentrations and to decline 
with a half-life of about six weeks.9 However, the absolute quantities of antibodies 
were much lower than the concentrations seen after primary or booster pertussis 
vaccination.9 The reason for a rise in notification rate in 11-month-olds is not clear. 
No similar rise was apparent in the hospitalisation rates, suggesting the result may be 
spurious or artefactual. 
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Method of diagnosis 
Information on method of diagnosis was poorly collected over this time period. The 
reason that some of the notifications which were clearly based on a positive laboratory 
result were coded as ‘not laboratory confirmed’ is not clear. It may be that laboratory 
confirmation became available after the case had been notified, and the laboratory 
confirmation field was not updated. As laboratory confirmation can be derived from 
the method of identification field (assuming ‘clinical’ means clinical only), the other 
field seems to be redundant. The validity of the method of diagnosis data is not 
known. The category ‘radiologically active’ is presumably a data entry error and 
accounted for only one case. The assumption that cases whose method of diagnosis 
was ‘unknown’ or missing and  were recorded as not laboratory confirmed were 
identified on clinical grounds may have resulted in some misclassification.  
 
Culture was of most importance in infants aged less than one year and of least 
importance in adults. Culture of the organism from a nasopharyngeal swab or aspirate 
is the ‘gold standard’ for the diagnosis of pertussis. One study found that cultures 
gave positive results for the presence of B. pertussis in 75% of cases during the early 
coryzal stage of the disease.10 However, during this early phase pertussis is less likely 
to be suspected and as the disease progresses it becomes increasingly difficult to 
culture the bacteria and by the whooping cough stage it is often not possible.11 In most 
clinical situations the isolation rates are much lower.12 A study in the Netherlands 
which used serology as the reference standard found the overall sensitivity of culture 
to be 7%, but that it varied considerably with the duration of disease at the time of 
diagnosis and with vaccination status.11 The same study estimated the sensitivity of 
PCR as 21% but found that it declined with increasing age and increasing duration of 
disease.11 Although only four notified cases were based on a positive PCR result, 
these were all in 1999 and the proportion may well increase in future years. 
 
Overall, and particularly amongst persons aged more than 12 months, the majority of 
notifications were based on a positive serological result. This must be kept in mind 
when making international comparisons with countries such as the United States, 
whose case definitions do not include diagnosis by serology. As mentioned in the 
previous chapter, a study undertaken in western Sydney found that cases notified on 
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the basis of a widely used commercially available ELISA for IgA against whole -cell 
B. pertussis reported clinically consistent pertussis almost uniformly, suggesting that 
notifications based on positive serology underestimate, rather than overestimate, the 
true incidence of pertussis.13 Authors of one review commented that, in symptomatic 
adolescents and adults, serology may be the most important diagnostic tool, since 
pertussis in these individuals is usually diagnosed late in the course of their disease 
and they are thus frequently culture negative.14 There is no evidence from the 
notification data that the proportion of notifications based on serological tests has 
increased since 1994. However, it did increase from 1993 to 1994 and in South 
Australia the proportion of cases based on serology rose from 15% in 1985 to 90% in 
1996.1 
 
The proportion of notifications based on serology increased with age and the impact 
of serology on notifications was far greater in persons aged five years and over than it 
was in children aged less than five. This finding is not surprising, as infants aged less 
than one year have a less reliable IgA antibody response to B. pertussis9 and the 
organism is more likely to be isolated from younger children.  
 
The proportion of cases diagnosed clinically decreased with age. The case definition 
includes the presence of at least one typical pertussis symptom (paroxysms of 
coughing, inspiratory ‘whoop’ without other apparent causes or post-tussive 
vomiting) or is epidemiologically linked to a laboratory confirmed case. The decrease 
in clinically diagnosed cases with age is most likely due to the decline in typical 
pertussis symptoms with age and the increasing use of serology in older age groups. 
One study estimated that a clinical case definition of an acute cough lasting for 14 or 
more days had a sensitivity of between 84% and 92% and a specificity between 63% 
and 90% when used in an outbreak setting. 15 However, this case definition is of 
limited value in non-outbreak settings or when a case is not linked to a laboratory 
confirmed case. Some doctors are reluctant to notify a pertussis case without 
laboratory confirmation.6 
 
When children aged less than two years were grouped according to eligibility to 
receive another dose of the vaccine, there was very little change in the proportions 
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notified with different diagnostic tests between age groups. This suggests that the 
decrease in notification rates with increasing age in children aged less than two years 
is unrelated to diagnostic testing. 
Geographic distribution 
The extent to which the differences in notification rates between areas reflect 
differences in incidence versus differences in diagnostic and notification practices is 
difficult to determine using notification data alone. However, the comparison of 
notifications and hospitalisations in the under-12-month age group in each area over 
the same time period provides some insights. The health area with the highest average 
annual notification rate, for all ages and for infants aged less than 12 months, was 
Northern Rivers. Northern Rivers also had the second highest hospitalisation rate (the 
highest was the Far West but this was calculated on very few cases) suggesting that 
pertussis incidence in this area is higher than in other areas. This is likely to be related 
to vaccination coverage. Northern Rivers has the lowest pertussis vaccination 
coverage of any NSW health area, with only 81% of children aged 12 months being 
recorded on the Australian Childhood Immunisation Register as having received three 
doses of a pertussis-containing vaccine in 1999 (see Chapter 4).  
 
The Hunter had a much higher notification rate than the geographically adjacent 
Central Coast, with the average annual notification rate in infants aged less than 12 
months in the Hunter being 230% higher than that in the Central Coast. In contrast, 
the average annual hospitalisation rate in this age group was only 7% higher in the 
Hunter. The most likely explanation for this is that the degree of under-reporting is 
greater in the Central Coast than in the Hunter. The ratios of notifications to 
hospitalisations for the health areas give an indication of the relative extent of under-
reporting in each health area. Some health areas may more actively seek cases, 
particularly if they are experiencing an outbreak. Some of the differences in ratios 
may be due to doctors and/or laboratories in the area being more or less willing to 
notify. This may have more of an influence on notification rates in less densely 
populated areas where there are fewer doctors or laboratories.  
 
Alternatively, it is possible that some areas with relatively low notification rates could 
have had relatively high hospitalisation rates if a greater proportion of disadvantaged 
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persons resided in that area. Perhaps infants who are malnourished or disadvantaged 
in some other way may be at greater risk of experiencing more severe disease than a 
well nourished, well cared for infant who is also infected with pertussis. This is 
speculation only and further studies would be required to determine whether this 
could be a plausible explanation. 
 
The 1997/1998 pertussis epidemic affected most health areas and only two of the 
areas (Northern Rivers and Macquarie) had higher notification rates in years other 
than 1997 or 1998. Four of the five deaths recorded in the study period in NSW were 
in 1997,16 suggesting that this increase in notification rate represents a true increase in 
pertussis incidence. 
Conclusion 
Even allowing for the limitations of data collected from a passive surveillance system, 
notification and hospitalisation data can provide much valuable information about the 
epidemiology of pertussis and the impact of vaccination programs. The hospitalisation 
data provide particularly useful information about pertussis in infants aged less than 
12 months but less useful information about pertussis in older persons, amongst 
whom hospitalisation with pertussis is rare. Comparison of area-specific notification 
and hospitalisation data from the same time period can provide insights into the extent 
to which differences in notification data may reflect differences in pertussis incidence. 
 
Pertussis remains an important public health problem in NSW with infants too young 
to be vaccinated having the greatest risk of death, hospitalisation and notification due 
to pertussis. The analysis of notification and hospitalisation rates by month of age 
shows a clear effect of  vaccination, with infants eligible for two or more doses of 
pertussis-containing vaccine having a significantly reduced risk of being notified 
and/or hospitalised with pertussis. This risk is further reduced significantly with 
eligibility to receive the third and fourth dose of pertussis-containing vaccine. The 
reduction in notification rates over the time period amongst 5-9 year olds, together 
with the pattern of reduction within this age group, is strongly suggestive of an impact 
from the introduction of the fifth dose of DTP vaccine in late 1994. Overall, the 
results suggest that the vaccination program is effective for children aged less than 10 
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years. The effectiveness of the vaccination program is more formally assessed in 
Chapter 6.  
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Background 
A description of the epidemiology of any disease for which a vaccination program is 
in place requires a discussion of vaccination coverage. The Australian Childhood 
Immunisation Register (ACIR) is unique and its introduction in Australia in 1996 was 
the subject of much discussion, as well as criticism. This chapter provides a 
background to the development of the ACIR and then uses data from the ACIR to 
examine pertussis vaccine coverage and the number and type of vaccines 
administered, at both a national level and a State level for NSW. Some of the NSW 
vaccine coverage data presented in this chapter are used in the vaccine effectiveness 
estimations (Chapter 6).  
 
The ACIR data were kindly provided by Brynley Hull. The DTP coverage figures for 
Australia and NSW at 12 and 24 months of ages (Figures 4.2, 4.3, 4.12 & 4.13) are 
those published quarterly in Communicable Diseases Intelligence. 
Immunisation registers and development of the Australian 
Childhood Immunisation Register (ACIR) 
Public health registers 
Last1 defines a register as a file of data concerning all cases of a particular disease or 
other health-related condition in a defined population such that the cases can be 
related to a population base. The register is the actual document, and the registry is the 
system of ongoing registration.1 For epidemiologic purposes population-based 
registers are generally considered to be the most useful.1,2 For example, in cases where 
the register records disease, incidence rates may be calculated. Similarly, where the 
register records immunisations, coverage rates may be calculated. Public health 
registers are population based rather than hospital or clinic based.  
 
Public health registers may be based on the collection of cases of disease or events, or 
on persons.3 Registers which are based on cases or events require population census 
data in order to calculate rates whereas those which are person based hold their own 
denominator data.3 Person-based registries are less common than disease registries.3 
Reasons for this include concerns about privacy and confidentiality, the difficulty of 
Chapter 4. The ACIR and pertussis vaccination   
 94
handling such large data sets and the comparatively recent recognition of the need for 
such registers.3 
 
The most successful registries are those in which purposes are explicit and realistic, 
the data collected are accurate and are limited to essential information, and the 
registry meets needs that cannot be accommodated using simpler, less expensive 
methods. The complexity of the data-collection process limits the extent to which data 
can be made rapidly available.2 
Immunisation registers 
General characteristics of an ideal immunisation register include: being population 
based; the inclusion of all children regardless of nationality and residency status, or 
any other characteristic; the ability to produce aggregate statistics and individual 
information in a timely manner; a high level of accuracy and completeness; a core 
data set including a unique personal identifier; the capacity to deliver both aggregate 
data on immunisation coverage and individual immunisation status information, 
including a recall/reminder service at parental and health service levels; the capacity 
to deliver profiles of immunisation providers, classes of providers, and vaccine 
consumption by region and trends over time; and financial and organisational 
efficiency. 3,4 Specific characteristics of an ideal register include the provision of: 
regular and accurate immunisation coverage data for particular ages by vaccine type 
and area of residence; timely recall/reminder notices to parents; accurate information 
for parents on the immunisation status of their child, including official certification; 
accurate information to providers on the immunisation status of particular children 
who attend for immunisation, including opportunistic immunisation; accurate 
information on unimmunised or incompletely immunised children to health 
departments and providers; profiles of immunisation providers by region, and trends 
over time; vaccine consumption by type for different regions and trends over time.3 In 
addition, an ideal register might be able to be linked with infectious disease 
notifications or adverse events for the purpose of estimating vaccine efficacy and 
increasing information on vaccine side effects.3 The recording of a batch number may 
allow the estimation of vaccine efficacy and the collection of side effect information 
by vaccine batch. 3 If demographic information such as ethnic group is collected then 
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this allows the reporting of immunisation coverage by group.3 Otherwise demographic 
categories must be inferred from area of residence by proxy variables. 
 
Prior to the advent of the Australian Childhood Immunisation Register (ACIR) there 
were two types of population-based immunisation registers in Australia, those 
operated by municipal councils, especially in Victoria, and the reminder system 
operated in the Australian Capital Territory (ACT).3 The Support and Evaluation 
Resource Unit 5 describes the operation of such population based registries as patchy 
and as varying across States and Territories. Problems with local registers are mainly 
related to incomplete information on all children, as families move in and out of areas. 
 
In addition, there are provider-based reminder systems operated by many general 
practitioners throughout Australia.3 The main limitations of these are that they are 
generally not population based and as such cannot provide coverage data. Few general 
practitioners have formal reminder systems.3,5 
 
Queensland has continued to operate a separate register, the Vaccine Information and 
Vaccine Administration Service (VIVAS), which commenced before the ACIR. 
VIVAS, a centralised system of vaccine supply which includes delivery coupled with 
reporting,3 has the potential to link communicable disease notifications and adverse 
events reports to the immunisation record of individual children and particular vaccine 
batches. This would be ideal for estimation of vaccine effectiveness.3 The system in 
the ACT is also one whereby general practitioners are given free vaccines in exchange 
for provision of vaccination data to ACT Health. 6  
The ACIR 
Overseas experience has shown that registers help to improve immunisation rates by 
reminding parents and providers and by providing information on immunisation 
coverage to help public health managers target programs.4 As a result of the 
inadequacies with existing registries, difficulty in coordination across jurisdictional 
boundaries and the success of population-based immunisation registers in 
immunisation programs in other developed countries,3 the ACIR was developed. 
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The ACIR is one element of a national strategy to improve and maintain high 
immunisation coverage in Australian children under the age of seven years.3 The 
broad objectives of the ACIR were: 
· to form the basis for a recall/reminder scheme which will inform parents when 
their child’s next vaccination is due; 
· to enable parents and immunisation providers to check on the immunisation status 
of an individual child regardless of where the child was immunised; and 
· to provide a measure of immunisation coverage data at national, State/Territory 
and local levels.7 
 
The ACIR is administered by the Health Insurance Commission (HIC) as part of the 
National Childhood Immunisation Program.3 The ACIR commenced on January 1, 
1996. On this day, all children of eligible age for the register (ie, less than seven years 
of age) had their details copied from Medicare (Australia's universal health insurance 
scheme) to the ACIR. The Medicare database constitutes an almost complete 
population denominator, as approximately 98% of children are estimated to be 
registered with Medicare by 12 months of age.8 All children on the ACIR have an end 
date which coincides with their seventh birthday. All children born since 1 January 
1996, who are enrolled with Medicare, are recorded on the ACIR by way of daily 
transfers from Medicare files.3 In addition, if a child is not enrolled in Medicare, he or 
she can be added to the ACIR when details of an immunisation are supplied by a 
provider. Children who have died, moved abroad or been removed from Medicare are 
allocated an end date which coincides with their death or departure. Only 
immunisations given since 1 January 1996 have been entered onto the ACIR. As a 
result, ACIR data are less complete for children with birth dates prior to 1 January 
1996. Monetary incentives for notification of immunisation encounters to the register 
are used to encourage provider participation.5 
Information  
Immunisations are notified to the HIC by either electronic means or by paper ACIR 
notification forms, which are scanned electronically and checked in Perth before 
transmission to the HIC central office in Canberra.8 Notifications which are not in 
accordance with the National Health and Medical Research Council (NHMRC) 
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guidelines, or are duplicates, are queried with the provider and if their validity cannot 
be established they are rejected. 8 
 
The following information is collected by the ACIR. 
Child 
Child information may include: parent/guardian name, child surname, given name, 
address, date of birth, gender, aboriginality, Medicare number, vaccines administered 
by type and dose, date of service and service provider details.9 
Provider 
Service provider information may include: surname, given name, initial, address, 
phone number, provider/registration number, date of birth, bank account details, 
payment details and immunisation services provided.9 
Vaccines  
The vaccines recorded on the ACIR are those on the NHMRC’s schedule for children 
from birth to six years of age.9 
 
The flow of information to and from the ACIR is summarised in Figure 4.1. 
 
Figure 4.1. Flow of information to and from the ACIR 
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Calculating population vaccination coverage data 
Population coverage figures are calculated from the ACIR data using the cohort 
method. A three month cohort of children is defined by date of birth, the first cohort 
being born between 1 January 1996 and 31 March 1996.8 At the 12-month assessment 
date of 31 March 1997, this cohort was aged 12 months to less than 15 months, 
although only vaccinations given on or before the child’s first birthday were 
considered. 10 If a record indicates that a child has received the third dose of a vaccine, 
then they are assumed to have received the two earlier doses, even if records of the 
previous doses are missing. 11 The immunisation status of members of each cohort at 
12 and 24 months of age is published quarterly in Communicable Diseases 
Intelligence. Reports include the percentage of all children registered on the ACIR 
who are immunised according to the schedule for each disease at the time of 
assessment. The cohort method is also used to assess immunisation coverage in the 
United Kingdom and by countries reporting to the World Health Organization 
(WHO), thus allowing for international comparisons.8 
Data quality 
The data quality of any large database has three main components — currency, 
accuracy and comprehensiveness.3 The data currency of the ACIR has improved 
progressively since its commencement3 and it is expected that all aspects of data 
quality will improve with time. Major factors leading to poor data quality are related 
to vaccine providers either not reporting to the ACIR or reporting encounters in a non-
timely fashion. A re-evaluation of the ACIR coverage estimates for three of the early 
birth cohorts using 1999 data found that the earlier coverage estimates had 
underestimated ‘true’ coverage by at least 2-4%.12  
 
In July 1998, several schemes were introduced to improve the completeness and 
timeliness of reporting immunisation encounters to the register. These included the 
General Practice Immunisation Incentives (GPII) Scheme, whereby general 
practitioners received a service incentive payment of $18.50 for each encounter form 
received by the HIC, plus an outcome bonus payment if they reached target levels of 
immunisation coverage.13 This was in addition to the standard $6 received by all 
immunisation providers for receipt of an immunisation encounter form. Parental 
incentives were also introduced and were linked with maternity allowance, childcare 
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assistance and childcare rebate.13 Full payment of these allowances to parents was 
dependent upon their child being recorded as fully immunised on the ACIR or their 
having signed a form to state that they were conscientious objectors to immunisation. 
A second evaluation of the ACIR, undertaken in late 1999, concluded that the ACIR 
data quality had improved considerably since the first evaluation of the Register in 
1997, and that the immunisation incentives offered to general practitioners under the 
GPII Scheme had had a positive influence on reporting behaviour and subsequent data 
quality.14 However, it is believed that immunisation coverage estimates from the 
ACIR still under-estimate the ‘true’ level of coverage. A study aiming to measure the 
difference in immunisation rates reported by parents compared with that documented 
in the ACIR and to assess the level of under-reporting to the ACIR by providers, will 
be undertaken by staff at the National Centre for Immunisation Research in the second 
half of 2001. 
 
The remainder of this chapter uses data from the ACIR to describe pertussis vaccine 
coverage and trends in the types of vaccine used.  
Using data from the ACIR: Pertussis vaccination in Australia 
Coverage 
Changes in pertussis vaccine coverage can have a dramatic effect on pertussis 
notifications (see Chapter 1). It is important to be able to measure coverage as part of 
a disease control strategy. Prior to the implementation of the ACIR, vaccination 
coverage estimates were derived from a variety of sources.15 The only national 
surveys that can be generalised to the whole population are the Australian Bureau of 
Statistics (ABS) household surveys, the most recent of which was conducted in 
1995.16 The ABS survey results are derived from a cross-sectional sample of children 
aged 12-23 months, hence these rates are not directly comparable with those from the 
ACIR.16 
 
The proportion of children aged 12 months recorded on the ACIR as having received 
3 doses of DTP ranged from 77% in March 1997 (the first birth cohort) to 92% by 
December 2000 (Figure 4.2 ). From December 1999 to December 2000, coverage 
remained at around 90%. This increase is probably due more to increased notification 
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to the ACIR than to any increase in vaccination coverage over this period.17 The ABS 
1995 survey estimated coverage at 86%.16 
 
The proportion of children aged 24 months recorded on the ACIR as having received 
4 doses of a diphtheria -tetanus-pertussis vaccine (DTP) was only marginally lower 
and ranged from 76% in March 1998 (the first birth cohort) to 90% by December 
2000 (Figure 4.3 ). This suggests that most children who receive the first three doses 
will also receive the fourth dose. 
 
Figure 4.2. DTP coverage (dose 3) at 12 months of age, by birth cohort, Australia, 
March 1997–December 2000 
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Figure 4.3. DTP co verage (dose 4) at 24 months of age, by birth cohort, Australia, 
March 1998–December 2000 
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Trends in pertussis vaccine use 
Where more than one type of vaccine is licensed, the ACIR records the vaccine type. 
Such is the case with pertussis vaccines since an acellular pertussis vaccine (DTPa) 
was licensed for use in Australia in 1997. In this section, data from the ACIR were 
used to track changes in pertussis vaccine use at a national level. This is the first time 
that data from the ACIR have been used for this purpose. 
 
Since early 1997 the use of the acellular pertussis vaccine (DTPa) increased, with a 
corresponding decrease in the use of whole-cell vaccine (DTPw) (Figures 4.4 –4.6). 
There was a steep increase in the use of DTPa in the primary course during 1999, and 
by April 1999 the number of DTPa vaccines given in the first three doses exceeded 
the number of DTPw vaccines (Figure 4.4). Prior to 1999, DTPa was available free of 
charge for the first three doses only in South Australia and the Northern Territory. In 
1999, DTPa became available free of charge in all States and Territories. By August 
2000, only 3% of DTP vaccines given as part of the primary course were recorded as 
whole-cell vaccines.  
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Figure 4.4. Number of doses of DTPw and DTPa (doses 1 -3) administered each 
month, Australia, January 1996–August 2000 
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The number of acellular vaccines given as a fourth or fifth dose exceeded the number 
of whole-cell vaccines given for these doses since March 1998 (Figure 4.5). DTPa has 
been funded at the national level for the fourth (18 month) and fifth (preschool) 
boosters since 1997. The number of DTP vaccines given as a fourth or fifth dose 
peaked in January each year, coinciding with the timing of the preschool fifth dose. 
By August 2000, only 3% of DTP vaccines given as booster doses were whole -cell 
vaccines. 
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Figure 4.5. Number of doses of DTPw and DTPa (doses 4 –5) administered each 
month, Australia, January 1996–August 2000 
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Combined diphtheria-tetanus vaccine (CDT) has not been a part of the routine 
immunisation schedule since 1994, when it was replaced by the preschool booster 
dose of DTP. It is only recommended where DTP is contraindicated. The number of 
doses of CDT vaccines administered is negligible compared with the number of DTP 
vaccines (Figure 4.6). Since acellular vaccines became available, the number of CDT 
vaccines used was greatly reduced (Figure 4.7). Of all the CDT vaccines administered 
in the time period examined, 30% were given as a preschool booster dose. The 
reduction in the number of CDT vaccines given each year in January, particularly 
CDT5, suggest that, although CDT use as the preschool booster continued well 
beyond 1994, its use decreased each year. By January 2000, only 173 doses of CDT5 
were recorded. The decrease in CDT use could be at least partly due to parents and 
providers who were concerned about vaccine side effects being more willing to have 
their child vaccinated with an acellular vaccine. Since March 2000, fewer than 100 
CDT vaccines per month were recorded on the ACIR as having been given, 
suggesting that this vaccine is not being inappropriately used. 
 
Chapter 4. The ACIR and pertussis vaccination   
 104 
Figure 4.6. Number of doses of DTPw, DTPa and CDT (doses 1 –5) administered by 
month, Australia, January 1996–August 2000 
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Figure 4.7. Number of doses of CDT (doses 1–5) administered by month, Australia, 
January 1996–August 2000 
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Using data from the ACIR:  
pertussis vaccination in New South Wales 
Trends in pertussis vaccine use 
In this section, trends in vaccine use are examined in the same way as the national 
data in order to assist with interpretation of NSW notification data. Patterns of use of 
whole-cell and acellular vaccines for the first three doses were very similar to the 
national trends, with the number of acellular vaccines administered exceeding the 
number of whole-cell vaccines since May 1999 (Figure 4.8). Widespread use of 
acellular vaccines for the fourth and fifth doses occurred slightly later in NSW 
compared with the national pattern, with the number of acellular vaccines not 
exceeding the number of whole-cell vaccines until September 1998 (Figure 4.9).  
 
Figure 4.8. Number of doses of DTPw and DTPa (doses 1–3) administered by month, 
NSW, January 1996–August 2000 
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Figure 4.9. Number of doses of DTPw and DTPa (doses 4–5) administered by month, 
NSW, January 1996–August 2000 
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Of all the CDT vaccines administered in the time period examined, 46% were given 
as a preschool booster dose, a greater proportion than at the national level. 
 
Figure 4.10. Number of doses of DTPw, DTPa and CDT (doses 1–5) administered by 
month, NSW, January 1996–August 2000 
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Figure 4.11. Number of doses of CDT (doses 1–5) administered by month, NSW, 
January 1996–August 2000 
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Pertussis vaccine coverage 
The proportion of NSW children aged 12 months recorded on the ACIR as having 
received 3 doses of DTP ranged from 75% in March 1997 (the first birth cohort) to 
91% by December 2000 (Figure 4.12). From December 1999 to September 2000, 
coverage remained at around 88% and then rose to 91% in December 2000. Although 
the earlier figures were lower than the national figures, by December 2000, NSW 
coverage was similar to the national coverage. A 1997 study involving a random 
sample of 850 NSW children identified by the ACIR as 90 days overdue for at least 
one scheduled immunisation found that 85% of these children were in fact fully 
immunised.18 Hence the increase in coverage was probably due more to increased 
notification to the ACIR than to any increase in vaccination coverage over this period.  
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Figure 4.12. DTP coverage (doses 1 –3) at 12 months of age, by birth cohort, NSW, 
March 1997–December 2000 
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The proportion of children aged 24 months recorded on the ACIR as having received 
4 doses of a diphtheria -tetanus-pertussis vaccine (DTP) was only marginally lower 
and ranged from 76% in March 1998 (the first birth cohort) to 88% by December 
2000 (Figure 4.13). These figures are similar to the national ones and suggest that 
most NSW children who receive the first three doses will also receive the fourth dose. 
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Figure 4.13. DTP coverage (dose 4) at 24 months of age, by birth cohort, NSW, 
March 1998–December 2000 
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The remainder of this section examines differences in pertussis vaccine coverage in 
NSW by health area and age, in order to determine the most appropriate coverage 
figures to be used in the vaccine effectiveness estimations (Chapter 6). The proportion 
of the population vaccinated (PPV) is required for these calculations and is included 
here in the tables. PPV is calculated by dividing the proportion of fully vaccinated 
children by the proportion of fully vaccinated plus unvaccinated children. Partially 
vaccinated children are excluded from PPV calculations.  
Coverage by month of age for children aged less than 2 years 
A cohort of 135 825 children born between 1 March 1997 and 30 August 1998 was 
selected from the ACIR. Age was calculated as of 31 March 1999. The date of 
assessment was 30 June 1999, thus allowing a three-month grace period. 
 
The proportion of unvaccinated children aged 6–24 months remained constant 
between 5–8% (Table 4.1). The proportion fully vaccinated increased from six to ten 
months of age and then remained constant between 84–87%. The proportion partially 
vaccinated correspondingly decreased. This most likely reflects DTP3 being given 
later than six months of age in some children. From 7–18 months of age the PPV 
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values remained quite constant. This has important implications for VE estimations. 
Of the infants who have received three doses of the vaccine by 12 months, 60% have 
received the third dose by six months, 86% by seven months and 93% by eight 
months. The PPV values vary even less as infants in receipt of one or two doses are 
excluded. The mean PPV for 7–18 month olds is 0.936 compared with 0.933 for 6–18 
month olds. Taking the value at 12 months of age should be representative for infants 
older than seven months. 
 
Table 4.1. Immunisation coverage by month of age for children aged 6 –24 months, 
NSW, 1999 
Month of age % fully 
vaccinated* 
% partially 
vaccinated† 
% 
unvaccinated 
PPV 
(full/full+none) 
6 51 43 6 0.898 
7 74 21 5 0.936 
8 80 15 5 0.940 
9 82 13 5 0.939 
10 84 11 5 0.940 
11 85 10 5 0.942 
12 86 9 5 0.942 
13 85 9 6 0.931 
14 85 9 6 0.935 
15 85 9 6 0.935 
16 85 9 6 0.932 
17 85 9 6 0.930 
18 85 9 6 0.934 
19 85 8 6 0.932 
20 86 8 6 0.930 
21 87 7 7 0.928 
22 85 7 7 0.920 
23 85 7 8 0.918 
24 85 8 7 0.926 
*3 doses. 
†1 or 2 doses. 
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Coverage with the fourth dose increased from 32% at 18 months of age to 80% by 22 
months of age (Table 4.2). 
 
Table 4.2. Immunisation coverage (4 doses) by month of age for children aged  
15–24 months of age, NSW, 1999 
Month of age % fully 
vaccinated* 
% partially 
vaccinated† 
% unvaccinated PPV 
(full/full+none) 
15 1 94 5 0.088 
16 1 94 6 0.087 
17 2 92 6 0.271 
18 32 63 5 0.863 
19 62 34 5 0.931 
20 74 22 4 0.944 
21 78 17 4 0.947 
22 80 15 5 0.941 
23 80 15 5 0.942 
24 82 13 4 0.949 
*4 doses. 
†1-3 doses. 
 
Coverage by health area  
Health area was determined by postcode of residence. Postcodes may belong to more 
than one health area. This is the case with some postcodes in the Central Sydney and 
South Eastern Sydney health areas. As these areas had similar coverage rates and are 
geographically adjacent (for map see Figure 6.1 ) the two areas were combined.  
12 months of age 
A one-year cohort of 87 564 children born between 1 April 1997 and 31 March 1998 
was selected from the ACIR and vaccination status at 12 months of age assessed as of 
31 March 1999. The proportion of children recorded on the ACIR as having received 
all three doses of DTP ranged from 81% in the Northern Rivers health area to 90% in 
the New England health area (Table 4.3). 
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Table 4.3. Immunisation coverage (3 doses) by health area for children aged 12 
months, NSW, 1999 
Health area 
% fully 
vaccinated* 
% partially 
vaccinated† 
% 
unvaccinated 
PPV 
(full/full+none) 
Metropolitan      
Central & SE Sydney 82 8 10 0.893 
Northern Sydney 84 8 9 0.907 
Western Sydney  83 9 7 0.920 
Wentworth  87 7 6 0.939 
South Western Sydney 85 9 6 0.930 
Central Coast 89 8 3 0.966 
Hunter 92 5 3 0.967 
Illawarra 88 8 4 0.954 
Total metropolitan 85 8 7 0.926 
Rural     
Northern Rivers 81 10 10 0.893 
Mid North Coast 84 10 6 0.936 
New England  90 6 3 0.965 
Macquarie  88 9 3 0.965 
Mid Western 89 8 4 0.962 
Far West  86 10 4 0.955 
Greater Murray  89 8 4 0.959 
Southern  86 9 4 0.953 
Total rural 86 9 5 0.946 
Total 85 8 6 0.930 
*3 doses 
†1-2 doses 
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At 2 years of age 
A one-year cohort of 88 206 children born between 1 April 1996 and 31 March 1997 
was selected from the ACIR and vaccination status at 2 years of age assessed as of 31 
March 1999. The proportion of children recorded on the ACIR as having received all 
four doses of DTP ranged from 77% in the Northern Rivers health area to 89% in the 
Hunter health area (Table 4.4). 
 
At six years of age 
Children aged six years were born before the ACIR commenced so most would not 
have had DTP1–4 recorded as given. An estimation of coverage at six years of age 
was made by assuming that children recorded as having received DTP5 were fully 
immunised. As the proportion completely unvaccinated is not likely to be different 
from the cohort aged 24 months this figure was used and the percentage partially 
vaccinated was calculated by subtracting the sum of fully vaccinated and 
unvaccinated from 100. Using this method, the proportion of children aged six years 
who had received all five doses of DTP was estimated to range from 61% in Central 
and South Eastern Sydney to 79% in the Hunter health area (Table 4.5). 
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Table 4.4. Immunisation coverage by health area for children aged 24 months, NSW, 
1999   
Health area 
4 doses 
(%) 
3 doses 
(%) 
1 or 2 
doses (%) 
No doses 
(%) 
PPV 
(³3/³3 +0) 
PPV 
(4 /4+0) 
Metropolitan       
Central & SE Sydney  78 7 8 6 0.912 0.904 
Northern Sydney 80 7 8 5 0.918 0.912 
Western Sydney  80 8 7 6 0.930 0.924 
Wentworth 83 8 5 5 0.952 0.948 
South Western Sydney 81 8 6 5 0.941 0.935 
Central Coast  85 8 3 4 0.972 0.969 
Hunter  89 6 2 3 0.979 0.978 
Illawarra  84 8 3 5 0.971 0.968 
Total metropolitan 81 8 5 6 0.939 0.933 
Rural       
Northern Rivers 77 9 8 6 0.919 0.910 
Mid North Coast 81 9 5 6 0.951 0.946 
New England  88 6 3 3 0.966 0.964 
Macquarie  82 8 4 6 0.958 0.954 
Mid Western  82 9 3 6 0.965 0.962 
Far West  81 10 4 6 0.958 0.953 
Greater Murray  84 8 3 5 0.968 0.966 
Southern  83 8 4 5 0.962 0.959 
Total rural 82 8 5 4 0.955 0.951 
Total 81 8 6 5 0.942 0.937 
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Table 4.5. Estimated immunisation coverage (5 doses) by health area  
for children aged 6 years, NSW, 1999 
Health Area 
% fully 
vaccinated* 
% partially 
vaccinated† 
% 
unvaccinated 
Metropolitan    
Central & SE Sydney 61 31 9 
Northern Sydney 64 28 8 
Western Sydney  66 27 7 
Wentworth 70 25 5 
South Western Sydney 65 29 6 
Central Coast 75 22 3 
Hunter  79 18 2 
Illawarra 70 26 3 
Total metropolitan 73 21 6 
Rural    
Northern Rivers 67 25 8 
Mid North Coast 75 20 5 
New England  72 24 4 
Macquarie  75 20 4 
Mid Western 74 23 3 
Far West  75 21 5 
Greater Murray  77 20 3 
Southern  73 22 4 
Total rural 74 22 4 
Total  71 24 5 
*5 doses 
†1-4 doses 
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Conclusion 
Coverage with DTP vaccines among young children in Australia is currently quite 
high (approximately 90% for both three doses at 12 months of age and four doses at 
24 months of age). As ACIR data are believed to underestimate true coverage, 
coverage with DTP may be even higher. Most children are vaccinated in a timely 
fashion, with 93% of fully vaccinated children aged 12 months receiving their third 
dose by eight months of age. The introduction of DTPa in Australia may have helped 
to improve coverage, although several other immunisation initiatives were introduced 
around the same time, making the evaluation of any one initiative difficult. Within 
New South Wales there was considerable variation in vaccine coverage between 
areas. This variation also existed in other States/Territories, where there were low 
reported coverage estimates relative to the State/Territory average in various rural 
areas as well as inner urban areas of most capital cities.19 
 
Australia is unique in having a national immunisation register. Although the data have 
limitations, especially with respect to completeness, they have improved considerably 
since the ACIR commenced operation in 1996. The ACIR is a valuable epidemiologic 
tool in the study of vaccine preventable diseases — the vaccine effectiveness study 
presented in Chapter 6 would not have been possible without the ACIR data.  
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Introduction 
Vaccine efficacy is the percentage reduction of disease incidence in a vaccinated 
group compared with an unvaccinated group, under ideal conditions. Vaccine efficacy 
studies are typically undertaken before licensure using double-blind randomised 
controlled trials, with all participants initially susceptible to the disease.1 Once a 
vaccine has been shown to be efficacious and is licensed, the use of a placebo is 
unethical. Therefore an experimental design cannot be used for vaccines on the 
vaccination schedule, so observational methods must be employed. Furthermore, 
efficacy measured in clinical trials under ideal conditions may differ from 
effectiveness in the field under non-ideal conditions and in different populations.2  
 
Vaccine effectiveness depends upon vaccine efficacy but is also affected by other 
factors such as transportation and storage at appropriate temperatures (‘cold chain’) 
and proper administration and timing of doses. The terms ‘vaccine effectiveness’ and 
‘vaccine efficacy’ are often used interchangeably and the abbreviation VE is used for 
both vaccine efficacy and effectiveness.3 In this review, VE is used as an abbreviation 
for vaccine effectiveness. 
 
The Australian vaccination schedule is constantly changing as new vaccines are 
introduced, booster doses are added and the timing of doses is changed. 4 To maintain 
public and provider confidence in vaccination programs, it is essential that the 
effectiveness of new vaccines and changes to the schedule of existing vaccines be 
evaluated. The evaluation of current vaccines/schedules should also be monitored to 
enable detection of variations in effectiveness over time which may result from 
changes in the target population or in the epidemiology of the disease. In the case of 
new vaccines these effectiveness studies may be a component of post-licensure 
surveillance. In addition to post-licensure surveillance, observational vaccine 
effectiveness studies are particularly important when disease incidence does not 
predictably decrease with increased vaccine coverage, when high proportions of 
vaccine failure among reported cases suggest a problem with the vaccine or when 
issues arise that were not predicted in pre-licensure evaluations.2  
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A number of observational methodologies can be used to assess vaccine effectiveness, 
some of which may be incorporated into routine surveillance of vaccine preventable 
diseases. This paper discusses the potential biases and limitations of observational VE 
studies, outlines six commonly used study types and provides examples from the 
literature.  
Calculating VE 
All VE studies involve comparison of the relative risks of disease in the vaccinated 
group(s) with the unvaccinated group(s), hence any study type from which relative 
risk can be estimated can be used to calculate VE.2 The standard equation for 
calculating VE as a percentage is:2 
100
ARU
ARVARU
(%) VE ´÷
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ç
è
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where ARU is the attack rate in the unvaccinated group and ARV is the attack rate in 
the vaccinated group. Rearranging the formula gives the following:2 
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where 
ARU
ARV  is equivalent to the relative risk. In case-control studies the relative risk 
is approximated by the odds ratio where the disease is rare. 
Protection against what? Defining the study question 
Immunisation may produce more than one effect, both at the individual and the 
population level.3 Individual effects include the production of an immunologic 
response, protection against infection or in some cases only against disease or severe 
disease, a reduction in the degree or duration of infectivity, or even behavioural 
effects such as changes in the rate of contact with potentially infectious sources.3 
Population effects include a reduction in transmission of disease and/or infection. 
Halloran et al3 distinguish between indirect (the population-level effects of 
vaccination in unvaccinated persons), total (the population-level effects of vaccination 
in both vaccinated and unvaccinated persons) and the overall public health effects of 
the vaccination program (the weighted average of the indirect effect on unvaccinated 
persons and the total effect on individuals receiving the vaccination). When designing 
a study to estimate VE, it is important to clearly define the question of interest, in 
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particular whether individual and/or population effects are of interest, as this 
determines the appropriate choice of unit of observation, comparison group, 
parameter of effect, and level of information required.3  
 
The question of interest is dependent upon the objective of the control program. If the 
objective of a control program is to reduce morbidity then high coverage with a 
vaccine protecting only against disease, or even severe disease, may be satisfactory.5 
In contrast, if herd immunity or eradication is the goal, the vaccine must clearly 
protect against infection. 5 
Potential biases in all study types 
Any factor which differentially raises or lowers the apparent attack rate in either the 
vaccinated or unvaccinated group will bias the VE estimate. In observational VE 
studies there are many potential biases that need to be minimised in either the design 
or analysis phase of a study. In addition, the results should be presented in a way that 
enables the reader to judge the extent to which potential biases have operated and to 
estimate their impact on the estimation of VE.2  
Case definition 
Ideally, case definitions should be sensitive and specific. Whilst a high sensitivity 
gives a more precise estimate of VE, the point estimate is not unduly affected by a 
low sensitivity as long as the case definition has equal sensitivity in the vaccinated 
and unvaccinated groups.2 This is a problem with pertussis, as vaccinated persons 
often experience a milder form of the disease which is less likely to fit a clinical case 
definition. In these situations, it is the effectiveness of the vaccine against more 
serious disease, rather than against all disease or infection, that is being estimated.  
 
For VE estimation the specificity of a case definition is generally more crucial than its 
sensitivity, as the misclassification of other illness as cases would equalise the attack 
rates in the two groups resulting in a falsely low VE estimate.2 The rarer the disease, 
and the greater the incidence of misclassified illness, the greater the bias toward low 
VE.2 This bias is even greater when the case definition has low sensitivity.2 
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Point estimates of pertussis VE increase with increasing specificity of clinical case 
definitions2 or when based on clinically severe or bacteriologically positive cases.5 
The same phenomenon has been observed in pertussis vaccine trials, where the greater 
the clinical severity of cases accepted as pertussis, the higher the VE estimates.6 
However, although laboratory confirmation increases specificity, it may lead to other 
biases as a result of problems with case ascertainment.2 
Case ascertainment 
In a pre-licensure trial, bias in case ascertainment is minimised by randomisation and 
by blinding the observer to vaccination status, neither of which is generally possible 
in an observational study. In observational studies, vaccinated and unvaccinated 
persons are self-selected groups who may not have equal access to health care 
services, hence equal case detection cannot be assured.2  
 
Studies using passively notified cases are particularly prone to bias in case 
ascertainment, as individuals with disease may not all have an equal probability of 
being notified. If notifications correlate with good public health practice and easy 
access to medical services, and hence are associated with high vaccine uptake, then 
vaccinated individuals may be preferentially notified, resulting in an underestimate of 
VE.5 Or if, as is the case with pertussis,6,7 the vaccine gives greater protection against 
more severe disease and there is a correlation between clinical severity and the 
probability of a physician recognising and then notifying a case, VE will be 
overestimated.5 A more serious problem occurs if, independently of disease severity, 
unvaccinated cases are more (or less) likely to be recognised and/or notified than 
vaccinated cases. For example, a physician’s knowledge that a child is fully 
vaccinated against pertussis could reduce the index of suspicion that an illness is in 
fact pertussis, resulting in an overestimate of VE.5 The extent of this bias is difficult to 
estimate.  
 
A pertussis outbreak investigation in the United Kingdom in 1987 found that only 31 
of 90 children with bouts of coughing lasting for two or more weeks followed by 
whooping, vomiting or choking/turning blue (probable cases) were notified.8 Using 
notified cases only the VE estimate was 88%. This fell to 75% when probable cases 
were included and 68% when the case definition included all children with bouts of 
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coughing lasting at least two weeks.8 The author found that notified children were 
younger and less likely to be vaccinated, suggesting that children were less likely to 
be diagnosed and notified as pertussis if they were known to have been vaccinated.  
Ascertainment of vaccination status  
Classification errors in vaccination status reduce VE estimates unless there is a bias 
towards misrepresenting vaccinated cases as unvaccinated.5 Studies relying on 
parental recall of a child’s vaccination status tend to overestimate vaccination 
coverage, whereas studies which require verification with written records may 
underestimate vaccination coverage.9  
 
VE estimation for diseases against which more than one dose of vaccine is necessary 
for full protection require information on the number of doses of vaccine given. If 
partial vaccination affords some protection against disease, then the way partially 
vaccinated cases are handled in the analysis can affect the VE estimate. If partially 
vaccinated cases are classified as unvaccinated but still receive some protection, the 
attack rate in the unvaccinated is lowered, whereas classifying partially vaccinated 
cases as fully vaccinated will raise the attack rate in the vaccinated. If the 
effectiveness of the full course of vaccination is being measured, then cases who are 
partially vaccinated should be excluded from the analysis wherever possible.2 
Comparability of vaccinated and unvaccinated groups — potential 
confounding 
In randomised controlled trials potentially confounding variables are randomly 
distributed among the experimental and control groups. In observational studies the 
groups may differ in many ways, only some of which may be recognised by the 
investigator.2 Unrecognised or unmeasurable differences between the experimental 
and control groups, such as increased susceptibility due to poor nutrition in 
unvaccinated marginalised groups, may pose serious threats to validity. However, the 
most important potential confounder in VE studies is exposure to disease. VE 
calculations generally assume equal exposure to infection in vaccinated and 
unvaccinated individuals or groups. Exposure to infection may in turn be associated 
with variables such as age and place of residence.  
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For a variable to be considered as a confounder it must be independently related to 
both the risk of disease and vaccination status. Not all variables which differ in 
frequency between vaccinated and unvaccinated groups fulfil this requirement. 
Orenstein et al2 give the example of a case-control study whereby cases, by definition, 
will have been more exposed to disease than controls but this difference in exposure 
does not bias the VE estimate unless the probability of exposure is also related to the 
probability of being vaccinated. If groups who have a greater risk of exposure (eg, 
children who attend day care) are more likely to be vaccinated, then VE will be 
underestimated.  
 
The indirect effects of vaccination can affect the probability of exposure in both 
vaccinated and unvaccinated groups, but not necessarily to an equal extent. If VE is 
estimated at a population level, where the study group comprises exposed and 
unexposed individuals, then whether or not the vaccine has been administered 
randomly will have a significant effect on the estimate.10 If groups with high vaccine 
coverage are at low risk of exposure to infection, for example because of herd 
immunity, and VE is viewed as the degree of protection afforded to an individual who 
has been exposed to the disease, then clustering of vaccine status in the population 
may produce falsely high VE estimates.5,10 Similarly, groups with low vaccine 
coverage may have greater exposure to infection resulting in falsely low VE 
estimates.2 However, if the overall effectiveness of the vaccination program is being 
studied, then it is appropriate to include the indirect protection of vaccination in the 
calculation.  
Age  
Age may be associated with both the probability of vaccination and the probability of 
having had prior exposure to the disease. Where immunity from disease and/or 
vaccination is acquired at a young age and diminishes with time, age may be a proxy 
measure for time since vaccination. Data should be analysed separately for narrow age 
groups or otherwise standardised for age.5 
Prior disease 
If prior disease is not associated with vaccination status then VE estimates will be 
unbiased.2 However, vaccinated and unvaccinated groups may differ with respect to 
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prior disease, in which case ignoring previous histories may bias the VE estimate.2 
However, the effect of this bias must be weighed against the problem of obtaining 
valid histories, which for some diseases may not be feasible. 
Observational study types 
A variety of observational methods may be used to estimate VE including the well 
established cohort and case-control design. In addition, household contact studies, the 
screening method, case cohort studies and coverage surveys are commonly used. Each 
methodology has its advantages and disadvantages and methodological problems have 
been identified for all study types. In order to identify observational studies evaluating 
VE in Australia and New Zealand, the Medline database from May 1987 to May 2000 
was searched for the textwords ‘vaccine efficacy’ or ‘vaccine effectiveness’ and 
‘Australia’ or ‘New Zealand’. Only ten studies were identified (Table 5.1). 
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Table 5.1. Observational studies evaluating VE in Australia and New Zealand 
Authors Study type Disease Setting 
Herceg A.11 Cohort Pertussis ACT school 
Gidding HF, Hills S, Selvey L, 
Roberts LA, Johnston S. 12 
Cohort Measles 
Rural 
Queensland 
town 
Jeremijenko AM, Kelly H, 
Patel M.13 Cohort Measles 
Western 
Australian town 
Patel MS, Lush D.14 Cohort Measles Central Australia  
Cheah D, Lane JM,  
Passaris, I.15 
Cohort Measles Canberra 
McDonnell LF, Jorm L,  
Patel MS.16 
Matched 
case-control Measles Western Sydney 
Bower C, Condon R, Payne J, 
Burton P, Watson C, Wild B.17 
Case-
control 
Haemophilus 
influenzae type b 
Western 
Australia  
Herceg A.18 Screening Haemophilus influenzae type b Australia 
Blakely T, Mansoor O,  
Baker M.19 
Screening Pertussis New Zealand 
Harrison GP, Durham, GA. 20 Screening* Measles New Zealand 
*Described by the authors as ‘outbreak investigation using attack rates’ but the methodology 
most closely resembles the screening method.  
 
Cohort studies 
A cohort design is most appropriate when a discrete population at risk can be 
defined.21 Most cohort studies of VE have been retrospective and have generally been 
undertaken as part of an outbreak investigation. The cohort, often based in a school, 
childcare centre or geographically defined area, is defined and the vaccination status 
of all members of the cohort is ascertained. The relative risk of disease in the 
vaccinated compared with the unvaccinated group is then calculated thus enabling the 
calculation of VE. Examples of disease outbreaks in Australia where VE has been 
measured using a cohort study design include a pertussis outbreak in an Australian 
Capital Territory school11 and measles outbreaks in Bunbury, Western Australia,13 
Canberra,15 Central Australia14 and rural Queensland.12  
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Orenstein et al1 list five criteria which minimise bias in cohort studies which are part 
of an outbreak investigation:  
1) absence of substantial prior disease activity in the studied age group  
2) both vaccinated and unvaccinated individuals are included in the study 
population  
3) adequate numbers in the population in the age group to be studied  
4) high overall attack rate and  
5) good vaccination records available.  
 
Retrospective cohort studies have also been used to estimate pertussis VE in non-
outbreak situations. An example is in child-care centres and schools in Quebec, 
Canada.22 
 
The classification of study types is not always as simple as it may first appear. One 
study in the literature identified vaccinated and unvaccinated cases by an enhanced 
notification system and used the results of a previous coverage survey to construct a 
theoretical cohort of vaccinated and unvaccinated children of a specific age group. 23 
Although the authors called this a retrospective cohort study, the design did not fulfil 
the criteria for a cohort study, in that subjects were not selected on the basis of 
exposure (vaccination) but on the outcome of interest (being notified as having 
pertussis). Cases were then compared with population controls. The theoretical cohort 
of unvaccinated children was not followed up to ascertain whether the children 
developed pertussis. More appropriate study designs would have been either the 
screening method or the case-cohort method. However, the cohort and screening 
methodologies yield very similar VE estimates: 76% using the cohort method23 and 
74% using the screening method. This is not surprising, as the screening method VE 
equation is derived from the cohort method. A New Zealand study of measles 
notifications used similar methodology, referring to the study design as ‘outbreak 
investigations using attack rates.’20 
Household contact studies 
Household contact studies are used to measure the secondary attack rate of disease in 
household contacts of index cases. VE is calculated by combining the total population 
of the households under study, excluding the primary and co-primary cases, to form 
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vaccinated and unvaccinated cohorts.2 The methodology corrects for potential 
differences in exposure between vaccinees and non-vaccinees, thus reducing the bias 
that may result from differential exposure.1 Orenstein et al1 comment that next to 
outbreak investigations, this technique has been evaluated most and is an acceptable 
alternative to outbreak investigations. However, Fine and Clarkson5 point out that the 
relative simplicity of the household secondary attack method should not be taken as 
license for its uncritical application and interpretation. No Australian or New Zealand 
household contact studies were identified in the literature. 
 
Pertussis VE estimates derived from household secondary attack rates are generally 
lower than those obtained by other methods, regardless of diagnostic criteria used for 
case ascertainment.24 One possible bias in these study types, which relates to pertussis 
vaccines and level of exposure, is the assumption that these vaccines are less effective 
under conditions of heavy exposure such as those within households.5 The study of 
family contacts of ascertained cases, which are highly selected populations, may 
introduce bias. If vaccine uptake is non-random, then most or all of the vaccinated 
individuals in the study will be included because of a prior vaccine failure in the 
household (ie, the index case). Possible risk factors for vaccine failure are likely to be 
shared by members of the household, thus introducing a bias against the vaccine. 
 
Again assuming non-random vaccine uptake and the likelihood that household 
contacts share the same vaccination status of the primary case, studies of situations in 
which pertussis is introduced to a household by a vaccinated case may be biased in 
favour of the vaccine.5 This arises from the reduced severity of disease in vaccinated 
persons which may result in close contacts being exposed to fewer bacilli than the 
contacts of unvaccinated individuals, thus reducing the risk of infection preferentially 
among vaccinated contacts and raising VE estimates.  
 
Households with larger rather than smaller numbers of cases are more likely to be 
identified and included in a study.5 This ascertainment bias is likely to lower vaccine 
effectiveness as households in which the vaccine is working best would be selectively 
excluded from the study. 5 
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Secondary attack rates in clusters 
This is a modified form of household contact studies that has been used in urban and 
semi-urban settings.1 This method is less rigorous than household contact studies due 
to the more questionable comparability of exposure of vaccinees and non-vaccinees, 
but is logistically easier to carry out than a household contact study.1 Orenstein et al1 
suggest that further evaluation of this method is needed. 
Case-control studies  
In a case-control study, cases are selected on the basis of having the disease of 
interest, and controls on the basis of being comparable to cases but without having the 
disease, so that the odds ratio of vaccination can be calculated. The traditional VE 
equation cannot be used in case-control studies1 as cases represent one sampling 
fraction of all cases and the controls represent a different sampling fraction of the 
population that is not ill.25 As the sampling fraction is unknown, the total populations 
of vaccinated and unvaccinated people cannot be calculated and therefore neither can 
attack rates.1 However, for rare diseases, the odds ratio approximates relative risk and 
so can be used to estimate VE. Although the VE estimate will be erroneously high 
when the attack rate in vaccinated persons is greater than 10%,1 this is usually not the 
case and therefore the  error will not be of an important magnitude.1 In Australia case-
control studies have been used to estimate VE for measles in Western Sydney16 and 
for Haemophilus influenzae type b infection in Aboriginal children in Western 
Australia.17 
Screening method 
Using the screening method, VE is estimated by comparing the proportion of cases 
who are vaccinated (PCV) with the proportion of a comparable group in the 
population who are vaccinated (PPV). The screening method equation is:26 
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Figure 5.1 shows the curves generated from this equation. As can be seen from 
Figure 5.1, an overestimate in PPV will result in an overestimate of VE. The error is 
particularly marked when vaccine coverage is greater than 80%.1 
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Figure 5.1. Relationship between the proportion of cases vaccinated (PCV) and the 
proportion of population vaccinated (PPV) for eight values of vaccine effectiveness 
(VE) 
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Source: Orenstein et al.1 
 
 
The screening method is a relatively rapid way of estimating VE which has been used 
to estimate pertussis VE in the Netherlands,27 the United States,28 Nova Scotia,29 the 
United Kingdom 30 and New Zealand. 19 In Australia it has been used to estimate the 
VE of Haemophilus influenzae type b18 but has not previously been used to estimate 
the VE of pertussis. The screening method is particularly useful for routine 
monitoring of VE or in circumstances where data on the vaccination status of cases 
only are available. Provided that any biases remain reasonably constant, the screening 
method may be used for monitoring changes in VE over time. It should not be relied 
upon for precise VE estimates.1 An overestimate in PPV will result in an overestimate 
of VE and this error is particularly noticeable when vaccine coverage is greater than 
80%.1 
 
Care must be taken to stratify the data by possible confounding variables such as age 
and location. If different population groups have different coverage figures then the 
groups should be analysed individually. Farrington26 illustrates the effect of pooling 
PCV = PPV - (PPV * VE)
  1 - (PPV * VE)
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population coverage figures in an example of two cohorts, A and B, of equal size. In 
cohort A there are 100 cases, 50 of whom are vaccinated and the PPV is 0.9. In cohort 
B there are 10 cases, one of whom is vaccinated and PPV is 0.5. The screening 
method VE estimate is 89% in each cohort. However, if the cohorts are combined, 
then there are 110 cases, 51 of whom are vaccinated, while the combined value of 
PPV is 0.7 which produces a VE estimate of only 63%.26 
Case-cohort 
This study type is also known as case-base and is similar to the screening method 
except that vaccination status is sampled in population controls rather than using an 
assumed true value of PPV.26 
Coverage surveys 
Where disease is common, a cross-sectional survey may be undertaken in a 
geographically defined area.2 This approach is conceptually similar to an outbreak 
investigation in which study subjects are categorised retrospectively according to their 
vaccination status. The relative risk of disease in the unvaccinated group compared 
with the risk in the vaccinated group can be calculated (except that the risk period in a 
coverage survey is generally longer than in an outbreak investigation).2 Study 
participants must be old enough to have lived through a sufficient period of risk of 
disease and those who receive vaccination after the period of observation begins 
should be excluded from the analysis, leaving a cohort of vaccinated and unvaccinated 
members.2 Persons whose vaccination status or disease history is uncertain must also 
be excluded from the analysis.1 There has been only limited use of this approach and 
modifications may be required as experience with the technique accumulates.1 
Conclusion 
There are a variety of observational methods which can be used to estimate VE, none 
of which is perfect. The screening method is the cheapest and most rapid means of 
determining whether there is a major problem with the vaccine, as all that is required 
is a reliable estimate of the proportion of cases who are vaccinated and an estimate of 
the vaccine coverage in the population at risk.1 The great advantage of this method is 
that it allows for ongoing monitoring of VE where these data are available. If the 
screening method results suggest that VE is lower than expected, this should be 
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confirmed by more rigorous methods. Of the more accurate observational methods 
available, cohort studies undertaken during an outbreak investigation offer the 
simplest means of VE estimation and are the preferred study design where the 
situation permits.1 The most appropriate study design will depend upon the specifics 
of the particular situation such as availability of resources, access to records, the 
number and distribution of cases and the availability of population coverage data. 
 
Whilst results obtained using observational methods may be distorted due to 
unavoidable bias, it may still be possible to calculate a sufficiently good estimate of 
VE for operational purposes.31 Potential biases should be considered in the design 
phase of a VE study and steps taken to minimise them if possible. All reports of VE 
studies should include a discussion of the biases which may have been operating and 
their possible effects on VE estimates. Provided that these steps are taken, 
observational methods provide valuable tools for the evaluation of vaccination 
programs. To date, few observational VE studies have been undertaken in Australia 
and New Zealand, suggesting the under-utilisation of these methods. 
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Part A: Effectiveness of pertussis vaccination in NSW children, 
1993 to 1998 
Introduction 
As demonstrated in Chapters 2 and 3, notification data can provide much useful 
information about the epidemiology of pertussis. In addition to the analysis and 
interpretation of disease surveillance and vaccination coverage data, there is a need for a 
system capable of detecting major shifts in the effectiveness of the pertussis vaccination 
program. Further indications for monitoring pertussis vaccine effectiveness (VE) in 
Australia include evidence of a major change in VE elsewhere,1 a lack of effectiveness data 
on the whole-cell vaccine used in Australia and the recent introduction of acellular 
vaccines. 
 
This chapter combines New South Wales (NSW) notification data (Chapter 3) with vaccine 
coverage data from the ACIR (Chapter 4). It aims to estimate the effectiveness of the 
primary course (doses 1-3 due at 2, 4 & 6 months of age) of the pertussis vaccination 
program in NSW children using the screening method. The screening method compares the 
proportion of cases who are vaccinated (PCV) with the proportion of a comparable group 
in the population who are vaccinated (PPV). It is a relatively inexpensive and rapid method 
which has been used to estimate pertussis VE in Nova Scotia,2 the United Kingdom,3 the 
United States,4 New Zealand5 and the Netherlands.1 In Australia it has been used to 
estimate the VE of Haemophilus influenzae type b6 but not pertussis vaccines. This study 
also aims to evaluate the usefulness of applying the screening method to surveillance data, 
using coverage data from the Australian Childhood Immunisation Register (ACIR), and to 
consider the application of this method for future VE estimations. 
Methods 
Study Subjects  
All notified cases of pertussis aged eight months to 14 years with disease onset dates 
between January 1993 and December 1998 were selected from the Notifiable Diseases 
Database (NDD) using the Health Outcomes and Information Statistical Toolkit (HOIST), 
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NSW Department of Health. Cases aged less than eight months were excluded, to allow 
time for infants to complete the primary vaccination schedule for pertussis. 
 
The NDD includes information on whether a case was vaccinated 
(yes/no/unknown/missing) and how many doses of vaccine the case had received. 
Vaccination status was calculated based on the number of doses of pertussis vaccine 
recorded and the child’s age. The NDD does not contain information on date of vaccination 
nor on the type of vaccine administered (whole-cell or acellular). Except where stated 
otherwise, fully vaccinated means having received at least 3 doses of a pertussis-containing 
vaccine. Incompletely vaccinated children were excluded from VE analyses, which were 
comparisons of fully vaccinated with unvaccinated groups, the approach recommended by 
Orenstein. 7  
 
NSW is divided into 17 area health services, eight of which are rural (Figure 6.1 ). Health 
areas in which vaccination status was unknown for more than 25% of cases were excluded. 
Residents of New England Area Health Service were excluded due to small numbers. As 
Southern Area Health Service had very small numbers of cases and is geographically 
adjacent to Greater Murray Area Health Service, these two areas were combined, as were 
Central Sydney and South Eastern Sydney. The areas studied include four metropolitan 
areas (Central Sydney, South Eastern Sydney, Western Sydney and Wentworth) and three 
rural areas (Southern, Greater Murray and Northern Rivers). These areas comprise 46% of 
the NSW population.  
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Figure 6.1. Health Areas of NSW 
 
 
Source: NSW Health Website —  www.health.nsw.gov.au/iasd/areas/  
Metropolitan Area Health Services
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Population estimates 
Population coverage estimates were taken from the Australian Childhood Immunisation 
Register (ACIR). The ACIR contains information on the vaccination status of children born 
since 1 January 1996, who are either registered with Medicare or have had a vaccination 
encounter reported to the ACIR. A 12-month cohort of 87 564 children born between 
01/04/97 and 31/03/98 was selected from the ACIR. Vaccination status at 12 months of 
age, using the third-dose assumption, was assessed as of 31/03/99. The third-dose 
assumption classifies a child as fully vaccinated as long as the third dose is recorded, 
irrespective of recording of the previous two doses.8 Health area was determined by 
postcode of residence. Incompletely vaccinated children were excluded and the proportion 
of the population vaccinated (PPV) for each area was calculated by dividing the number of 
children fully vaccinated by the sum of the number of children fully vaccinated and 
unvaccinated. It was assumed that PPV did not change over the study time period. The 
effect of using a pooled PPV value (ie, not stratified by health area) was examined. In 
addition, a sensitivity analysis was undertaken where it was assumed that two thirds of 
children recorded on the ACIR as having received one or two doses of vaccine had in fact 
received three, and one-third of the children recorded as having received no doses of 
vaccine had in fact received all three doses. 
VE estimation 
VE was estimated by fitting a logistic regression model using the method described by 
Farrington, whereby the number of vaccinated cases is regarded as from a binomial 
distribution with PCV as the parameter and number of cases (N) as the index. 9 Proc 
Genmod in the software package SAS10 was used for modelling. Logit PPV was specified 
as an offset in the model, and the variables age group, health area of residence and year of 
disease onset were included as potential confounders, giving the equation:  
logit (PCV) = logit (PPV)+ a+ b1x1+ b2x2+ b3x3 
where PCV = the proportion of cases vaccinated, x1-3 are the potentially confounding 
variables and b1-3 are the parameter estimates of those variables.  
 
The base model containing the three potentially confounding variables was fitted and the 
significance of each one was tested (using the type3 option in SAS). The effects of all 2-
way interactions were tested for statistical significance (p<0.05) by adding them in turn to 
the base model. VE was calculated for each combination of age group, area and year by 
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subtracting the exponentiation of the estimated linear predictor (XBETA in SAS) from one. 
Confidence intervals were calculated in a similar way using the standard error of the linear 
predictor (STD in SAS).  
 
The effect of including year of age as an explanatory variable was examined and the 
decision to include four age groups (8-23 months, 2-4 years, 5–8 years and 9-13 years) was 
based on these results. The first three age groups correspond with eligibility to receive 
three, four and five doses of a pertussis-containing vaccine respectively.  
 
In order to obtain overall estimates by area and age group, the average of the relevant 
parameter estimates for year, including the interaction terms, was calculated. To obtain 
overall estimates by year and age group, the parameter estimates for area, including the 
interaction terms, were weighted by population. The adjusted estimates of year and area 
were used to calculate VE for each age group, adjusted for year and area. The variances of 
these adjusted parameter estimates were calculated from the covariance matrix using 
Excel.11 Confidence intervals were calculated using these estimates.  
Variations on the model 
The effects of the following were examined: 
· Grouping years with a high number of notifications (the ‘epidemic years’ 1993 and 
1997) and years with a lower number of notifications (‘non-epidemic years’) 
· Grouping metropolitan health areas together and rural health areas together 
· Using only one value for PPV (ie, not one for each health area) 
· Increasing PPV — assuming that two-thirds of children recorded as having received 
one or two doses of vaccine had in fact received three, and one-third of the children 
recorded as having received no doses had received all three doses 
· Requiring cases aged over 18 months to have received four doses of a pertussis 
containing vaccine in order to be classified as fully vaccinated (ie, classifying cases 
aged over 18 months who had only received three doses as partially vaccinated and 
excluding them from analyses) 
· Classifying partially vaccinated children as unvaccinated 
· Including only cases who were laboratory confirmed (by culture or serology). 
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Results  
Pertussis cases 
In NSW from 1993 to 1998, 5447 cases of pertussis in children aged 8 months to 13 years 
from a known health area were notified. Of these, 2795 cases (51%) were resident in areas 
eligible for inclusion in VE analyses. There was considerable variation among health areas, 
in both notification rate and the vaccination status of cases (Table 6.1 ). After excluding the 
348 cases whose vaccination status was unknown and the 121 cases who had received only 
one or two doses of the vaccine, there were 2326 cases eligible for the VE analyses.  
Vaccination status of notified cases 
Of the 2326 cases eligible for inclusion in the study, 1227 (53%) had received at least three 
doses of a pertussis-containing vaccine. Most (90%) of the vaccinated cases aged two years 
or older had received a fourth dose, while 29% of vaccinated 5–8 year olds and 15% of 
vaccinated 9–13 year olds had also received a fifth dose of vaccine. 
 
Table 6.1. Number of notifications and average annual notification rates by health area 
and vaccination status in children aged 8 months to 13 years, NSW, 1993–1998  
Area full % partial % none % unk*  % Total Rate† 
Central Sydney 63 28 5 2 109 49 45 20 222 54 
Western Sydney 307 54 22 4 148 26 94 16 571 74 
Wentworth 291 64 19 4 106 23 38 8 454 111 
Sth Eastern Sydney  244 47 23 4 158 31 93 18 518 80 
Northern Rivers 124 19 24 4 450 70 47 7 645 218 
Greater Murray  165 60 22 8 70 26 16 6 273 84 
Southern 33 29 6 5 58 52 15 13 112 52 
Total 1227 44 121 4 1099 39 348 12 2795 91 
*unk=unknown 
†Average annual notification rate per 100 000 population aged 8 months to 13 years. 
Vaccination status variations 
The oldest age group had the highest proportion of both vaccinated cases and cases whose 
vaccination status was unknown (Table 6.2). 
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Table 6.2. Vaccination status of notified cases and average annual notification rates by age 
group, NSW, 1993–1998 
Age 
group 
Fully 
vaccinated* 
n  (%) 
Partially 
vaccinated† 
n (%) 
Un-
vaccinated 
n (%) 
Unknown 
n (%) 
Total 
n 
PCV 
(%) 
Rate‡ 
8-23 mth  62  (31) 16 (8) 103  (51) 20  (10) 201 37.6 64 
2-4 yrs 191  (45) 16 (4) 179  (42) 38  (9) 424 51.6 60 
5–8 yrs 408  (41) 51 (5) 441  (44) 105  (10) 1,005 48.1 109 
9-13 yrs 566  (49) 38 (3) 376  (32) 185 (16) 1,165 60.1 102 
Total 1,227 (44) 121 (4) 1,099 (39) 348 (12) 2,795 52.8 91 
*3 doses 
†1-2 doses 
‡Average annual notification rate per 100 000 population. 
 
The vaccination status of children in areas where at least 75% of notifications had a known 
vaccination status was compared with that in the other areas. In health areas where at least 
75% of notifications had a known vaccination status, PCV was 0.583 compared with only 
0.280 in areas where less than 75% of notifications had a known vaccination status. This 
difference was statistically significant (c 21 =152, p<0.001). 
Population estimates 
Northern Rivers had the lowest proportion of fully vaccinated children and 
Southern/Greater Murray had the highest (Table 6.3). The population values used in the 
sensitivity analysis are shown in Table 6.4. 
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Table 6.3. Vaccination coverage by health area for children aged 12 months,  
NSW, 1993–1998 
Health area 
% fully 
vaccinated* 
% partially 
vaccinated † 
% 
unvaccinated‡ 
PPV 
(full/full+none) 
Central & SE Sydney 82 8 10 0.893 
Western Sydney  83 9 7 0.920 
Wentworth  87 7 6 0.939 
Northern Rivers 81 10 10 0.893 
Southern & Greater Murray  88 8 4 0.957 
Total 85 8 6 0.930 
*3 doses, †1-2 doses, ‡0 doses. 
 
Table 6.4. Increased vaccination coverage used in sensitivity analysis by health area for 
children aged 12 months, NSW, 1993-1998  
Health area 
% fully 
vaccinated* 
% partially 
vaccinated† 
% 
unvaccinated‡ 
PPV 
(full/full+none) 
Central & SE Sydney 91 3 7 0.933 
Western Sydney  92 3 5 0.950 
Wentworth  94 2 4 0.961 
Northern Rivers 90 3 6 0.933 
Southern & Greater Murray  95 3 3 0.973 
Total 92 3 5 0.950 
*3 doses, †1-2 doses, ‡0 doses. 
 
Year of age 
In order to determine the effect of age on VE, a model was fitted using year of age as the 
only explanatory variable. This model had a poor fit (deviance = 814 with 372 degrees of 
freedom). The parameter estimates for 2–4 and 6–12 year old children were not 
significantly different from 13 year olds (the reference group). VE was highest in infants 
aged less than 12 months and lowest in 9 year olds (Figure 6.2). The decrease in VE with 
increasing age was not linear, hence including age as a continuous variable in the model 
would have been inappropriate, and in further analyses four age groups were used. 
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Figure 6.2. Estimated VE for each year of age, with age as the only explanatory variable, 
1993–1998 
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Fitting the model 
The model with no explanatory variables was a poor fit (deviance=538 with 119 df). VE, 
calculated from this base model, was 90.1% (95% CI 88.2 to 91.7%). The addition of each 
explanatory variable by itself significantly improved the fit of the model (Table 6.5 ). 
Health area was the most significant explanatory variable. All variables remained 
significant in the model in which all three were included (p<0.0001). Excluding cases 
which were not laboratory confirmed improved the fit of the model even further. 
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Table 6.5. Summary of models, 1993–1998  
Explanatory variable(s) Dev*/ df† c 2 df p-value 
None 4.52    
Age  4.30 40 3 <0.0001 
Year 3.88 96 5 <0.0001 
Area  2.67 232 4 <0.0001 
Age + year + area 1.98    
Age + year + area + year*area 1.32    
Age + year + area + year*area 
(for lab confirmed cases only) 
1.19    
*Dev=deviance 
†df=degrees of freedom. 
 
The final model included age group, year of onset and area (the base model), plus the 
interaction between area and year. This model had a deviance of 114 on 87 degrees of 
freedom, suggesting that the model was slightly over-dispersed (p=0.03). When the model 
was re-scaled by dividing the deviance by the degrees of freedom to incorporate the extra 
variability, as recommended by Farrington,9 the width of the 95% confidence intervals of 
the VE estimates increased. In the final model all variables were significant (p<0.001).  
VE Estimates 
VE estimates from the final model for each of the four age groups, stratified by health area 
and year, were calculated (Tables 6.6 to 6.9 ). 
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Table 6.6. Number of vaccinated cases (CV), total number of cases (n) and VE  
estimates for children aged 8–23 months by NSW health area, 1993–1998  
Health area year CV n VE (%) 95% CI (%) 
Central & SE Sydney 1993 1 3 88.6 79.4 to 93.7 
 1994 6 6 85.8 71.2 to 93.0 
 1995 2 3 89.9 73.0 to 96.2 
 1996 1 4 93.8 86.4 to 97.2 
 1997 4 13 94.9 91.7 to 96.8 
 1998 0 3 93.3 83.9 to 97.2 
Northern Rivers 1993 0 6 97.7 94.6 to 99.0 
 1994 3 16 98.5 97.4 to 99.2 
 1995 1 10 98.2 96.7 to 99.0 
 1996 1 2 97.7 93.0 to 99.3 
 1997 3 11 98.3 96.8 to 99.1 
 1998 2 2 92.2 70.9 to 97.9 
Western Sydney 1993 2 3 94.9 89.2 to 97.6 
 1994 4 8 90.4 80.7 to 95.2 
 1995 1 2 83.0 60.8 to 92.6 
 1996 1 6 92.9 85.5 to 96.5 
 1997 8 12 89.6 82.3 to 93.8 
 1998 4 6 83.4 58.3 to 93.4 
Wentworth 1993 0 4 97.0 93.4 to 98.7 
 1994 0 1 96.9 92.9 to 98.6 
 1995 1 4 90.9 80.6 to 95.7 
 1996 2 4 84.8 50.6 to 95.3 
 1997 7 10 87.0 76.4 to 92.8 
 1998 0 1 76.1 41.4 to 90.3 
Southern & Greater Murray 1993 1 3 99.4 92.5 to 99.9 
 1994 1 2 99.2 97.5 to 99.7 
 1995 0 6 97.4 95.1 to 98.7 
 1996 0 3 99.1 97.7 to 99.6 
 1997 4 8 96.8 93.8 to 98.4 
 1998 2 3 80.1 55.9 to 91.0 
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Table 6.7. Number of vaccinated cases (CV), total number of cases (n) and VE  
estimates for children aged 2–4 years by NSW health area, 1993–1998 
Health area year CV n VE (%) 95% CI (%) 
Central & SE Sydney 1993 10 19 77.8 63.6 to 86.4 
 1994 9 14 72.4 47.3 to 85.5 
 1995 4 5 80.3 49.4 to 92.4 
 1996 1 2 87.9 74.6 to 94.3 
 1997 21 47 90.0 85.6 to 93.0 
 1998 2 4 87.0 70.1 to 94.3 
Northern Rivers 1993 2 7 95.5 90.1 to 98.0 
 1994 12 39 97.1 95.4 to 98.2 
 1995 7 26 96.4 94.1 to 97.8 
 1996 3 9 95.6 87.1 to 98.5 
 1997 5 19 96.8 94.3 to 98.2 
 1998 2 4 84.7 45.1 to 95.8 
Western Sydney 1993 3 9 90.1 80.4 to 95.0 
 1994 5 9 81.3 64.2 to 90.2 
 1995 8 8 66.8 27.9 to 84.7 
 1996 8 14 86.1 73.4 to 92.8 
 1997 20 32 79.6 68.7 to 86.7 
 1998 5 6 67.7 20.7 to 86.8 
Wentworth 1993 4 8 94.2 87.9 to 97.2 
 1994 5 11 93.9 87.1 to 97.1 
 1995 11 15 82.2 64.8 to 91.0 
 1996 1 2 70.2 5.0 to 90.7 
 1997 10 15 74.5 57.0 to 84.9 
 1998 12 13 53.4 -7.3 to 79.8 
Southern & Greater Murray 1993 0 1 98.8 85.4 to 99.9 
 1994 1 3 98.4 95.3 to 99.5 
 1995 4 4 95.0 91.0 to 97.2 
 1996 1 5 98.2 95.7 to 99.2 
 1997 7 11 93.8 88.5 to 96.7 
 1998 8 9 61.2 18.9 to 81.4 
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Table 6.8. Number of vaccinated cases (CV), total number of cases (n) and VE  
estimates for children aged 5–8 years by NSW health area, 1993–1998 
Health area year CV n VE (%)     95% CI (%) 
Central & SE Sydney 1993 34 47 81.4 70.8 to 88.1 
 1994 20 31 76.8 57.2 to 87.5 
 1995 4 5 83.5 58.1 to 93.5 
 1996 8 18 89.9 79.6 to 95.0 
 1997 37 86 91.6 88.5 to 93.8 
 1998 6 10 89.1 75.6 to 95.1 
Northern Rivers 1993 5 15 96.3 91.9 to 98.3 
 1994 15 90 97.6 96.3 to 98.4 
 1995 11 67 97.0 95.3 to 98.1 
 1996 2 10 96.3 89.2 to 98.7 
 1997 7 56 97.3 95.4 to 98.4 
 1998 1 3 87.2 54.2 to 96.4 
Western Sydney 1993 11 21 91.7 84.0 to 95.7 
 1994 22 32 84.3 71.2 to 91.5 
 1995 20 24 72.2 41.5 to 86.8 
 1996 11 19 88.4 78.2 to 93.8 
 1997 45 63 82.9 74.9 to 88.4 
 1998 9 12 72.9 34.9 to 88.7 
Wentworth 1993 7 17 95.2 90.1 to 97.6 
 1994 5 17 94.9 89.4 to 97.5 
 1995 16 22 85.1 71.1 to 92.3 
 1996 6 7 75.1 22.0 to 92.0 
 1997 37 47 78.7 65.5 to 86.8 
 1998 8 14 60.9 11.5 to 82.8 
Southern & Greater Murray 1993 0 1 99.0 87.8 to 99.9 
 1994 1 10 98.7 96.2 to 99.6 
 1995 14 29 95.8 92.8 to 97.5 
 1996 3 16 98.5 96.5 to 99.3 
 1997 9 19 94.8 90.7 to 97.1 
 1998 34 41 67.5 34.5 to 83.8 
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Table 6.9. Number of vaccinated cases (CV), total number of cases (n) and VE  
estimates for children aged 9–13 years by NSW health area, 1993–1998  
Health area year CV n VE (%)   95% CI (%) 
Central & SE Sydney 1993 34 53 73.3 58.2 to 82.9 
 1994 8 13 66.8 37.8 to 82.3 
 1995 6 13 76.4 40.5 to 90.6 
 1996 11 19 85.5 70.7 to 92.8 
 1997 69 140 87.9 83.9 to 91.0 
 1998 9 16 84.3 65.2 to 92.9 
Northern Rivers 1993 5 18 94.6 88.4 to 97.5 
 1994 10 69 96.5 94.7 to 97.7 
 1995 16 54 95.7 93.2 to 97.3 
 1996 0 3 94.7 84.4 to 98.2 
 1997 9 34 96.1 93.4 to 97.7 
 1998 2 4 81.7 34.5 to 94.9 
Western Sydney 1993 10 17 88.1 77.0 to 93.8 
 1994 10 14 77.6 58.1 to 88.0 
 1995 15 22 60.2 15.7 to 81.2 
 1996 14 18 83.3 68.7 to 91.1 
 1997 59 83 75.5 64.2 to 83.2 
 1998 12 15 61.2 6.8 to 83.8 
Wentworth 1993 8 13 93.1 85.8 to 96.6 
 1994 9 11 92.7 84.7 to 96.5 
 1995 16 20 78.6 58.4 to 89.0 
 1996 12 13 64.3 -11.4 to 88.5 
 1997 65 78 69.4 51.0 to 80.9 
 1998 49 50 44.0 -25.0 to 74.9 
Southern & Greater Murray 1993 0 1 98.6 82.5 to 99.9 
 1994 3 9 98.1 94.5 to 99.4 
 1995 22 38 94.0 89.8 to 96.5 
 1996 7 15 97.8 95.0 to 99.0 
 1997 16 26 92.6 86.7 to 95.9 
 1998 60 63 53.4 6.4 to 76.8 
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Age group 
Age group was highly significant in the base model (c 23 =12.7, p=0.005). The 8-23 month 
age group had the lowest parameter estimate (corresponding to the highest VE estimate). 
The VE estimate, after adjustment for area and year, was highest in the 8–23 month age 
group and lowest in the 9–13 year group (Table 6.10).  
 
Table 6.10. VE estimates by age group, adjusted for year and NSW health area,  
1993–1998 
Age group Vaccinated cases 
n (PCV %) 
Total cases 
n 
VE (%) 95% CI (%) 
8–23 months 191 (34) 370 96.3 94.2 to 97.5 
24 years 408 (32) 849 92.7 90.3 to 94.5 
5–8 years 62 (27) 165 93.9 92.5 to 95.1 
9–13 years 566 (38) 942 91.3 89.2 to 92.9 
 
Health area and year of onset 
Health area was the most significant term in the base model (c 24 =101, p<0.0001), followed 
by year of onset (c 25 =32, p<0.0001). The interaction between year and area was also highly 
significant (c 220 =74, p<0.0001). In the base model, the parameter estimates for all the 
metropolitan areas (Central & South Eastern Sydney, Western Sydney and Wentworth) 
were not significantly different from one another. Similarly, the estimates for the rural 
health areas (Northern Rivers, Greater Murray and Southern) were not significantly 
different from one another but the rural estimates were significantly lower (ie, higher VE) 
than the metropolitan areas (p<0.0001). The VE estimates, adjusted for year, were higher in 
rural areas and lower in metropolitan areas (Table 6.11).  
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Table 6.11. Number of vaccinated cases (CV), total number of cases (n) and  
VE estimates by age and NSW health area, adjusted for year, 1993–1998 
Age group and area CV n VE (%) 95% CI (%) 
8–23 months     
Central & SE Sydney 14 32 91.6 86.6 to 94.8 
Western Sydney  10 47 90.0 84.1 to 93.7 
Wentworth  20 37 91.4 85.9 to 94.8 
Northern Rivers 10 24 97.6 95.5 to 98.7 
Southern & Greater Murray 8 25 97.9 96.7 to 98.7 
2–4 years     
Central & SE Sydney 47 91 83.7 76.5 to 88.6 
Western Sydney 31 104 80.4 72.0 to 86.3 
Wentworth 49 78 83.2 75.2 to 88.7 
Northern Rivers 43 64 95.4 91.9 to 97.3 
Southern & Greater Murray 21 33 96.0 93.0 to 97.7 
5–8 years     
Central & SE Sydney 109 197 86.3 81.5 to 89.9 
Western Sydney 41 241 83.6 77.9 to 87.8 
Wentworth 118 171 85.9 80.1 to 90.0 
Northern Rivers 79 124 96.1 93.3 to 97.7 
Southern & Greater Murray 61 116 96.6 94.3 to 98.0 
9–13 years     
Central & SE Sydney 137 254 80.4 73.6 to 85.4 
Western Sydney 42 182 76.5 68.1 to 82.7 
Wentworth 120 169 79.9 71.7 to 85.7 
Northern Rivers 159 185 94.4 90.4 to 96.7 
Southern & Greater Murray 108 152 95.2 91.9 to 97.1 
 
In the base model, the parameter estimates for the years 1993–1997 were not significantly 
different from one another but were significantly lower (ie, higher VE) than the 1998 
estimate (p<0.0001). Within each age group, the differences in VE estimates between 
health areas were greater in 1998 than in any other year (Tables 6.5 –6.8 ). The 1998 VE 
estimates were considerably lower than the 1996 and 1997 estimates (Table 6.4). However, 
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the 95% confidence intervals of the unadjusted VE estimates for the years 1997 and 1998 
overlapped in all areas except Southern/Greater Murray, for all age groups (Tables 6.6 –
6.9). The VE estimates in 1998 in the Greater Murray/Southern area were significantly 
lower than the 1997 estimates, for all age groups. VE estimates by year, adjusted for area, 
were also calculated (Table 6.12). 
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Table 6.12. Number of vaccinated cases (CV), total number of cases (n) and  
VE estimates by age and year, adjusted for NSW health area, 1993–1998 
Age group and year CV n VE (%) 95% CI (%) 
8–23 months     
1993 4 19 99.1 98.7 to 99.4 
1994 14 33 98.9 98.4 to 99.3 
1995 5 25 97.0 95.6 to 98.0 
1996 5 19 98.8 97.8 to 99.3 
1997 26 54 96.7 94.7 to 97.9 
1998 8 15 82.4 69.5 to 89.9 
2–4 years     
1993 19 44 98.3 97.8 to 98.7 
1994 32 76 97.8 97.2 to 98.3 
1995 34 58 94.2 92.4 to 95.5 
1996 14 32 97.6 96.1 to 98.5 
1997 63 124 93.5 90.7 to 95.4 
1998 29 36 65.7 45.2 to 78.6 
5–8 years     
1993 57 101 98.6 98.3 to 98.8 
1994 63 180 98.2 97.8 to 98.5 
1995 65 147 95.1 94.1 to 95.9 
1996 30 70 98.0 96.8 to 98.7 
1997 135 271 94.5 92.6 to 95.9 
1998 58 80 71.3 55.7 to 81.4 
9–13 years     
1993 57 102 97.9 97.5 to 98.3 
1994 40 116 97.4 96.9 to 97.8 
1995 75 147 93.0 91.7 to 94.1 
1996 44 68 97.1 95.5 to 98.1 
1997 218 361 92.1 89.5 to 94.1 
1998 132 148 58.8 37.2 to 73.0 
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Alternative models 
Epidemic versus non-epidemic years 
The model where the variable year was substituted with the variable period, which grouped 
1993 and 1997 together (the ‘epidemic years’) and 1994, 1995, 1996 and 1998 together 
(the ‘non-epidemic years’), was a poorer fit. Period was not significant (c 21 =1.89, p=0.17). 
Metropolitan versus rural areas 
In view of the finding that both the rural areas and the metropolitan areas had similar 
parameter estimates which were different from each other, a simplified model was run in 
which area had only two categories — metropolitan or rural. This model, which included 
the four age groups, year of disease onset, the two areas and the interaction between area 
and year, had a deviance of 191 with 105 df (deviance/df = 1.82). It was re-scaled in the 
same way as the earlier model and all the terms had p-values <0.01. In all age groups for 
the years 1993 to 1997, VE estimates were higher in the rural area than in the metropolitan 
area but in 1998 the situation was reversed, with the rural area having lower VE estimates 
than the metropolitan areas (Tables 6.13 to 6.16). After adjusting for year, the rural area 
had higher VE estimates than the metropolitan area (Table 6.17). 
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Table 6.13. Number of vaccinated cases (CV), total number of cases (n) and VE estimates 
for children aged 8–23 months in NSW metropolitan and rural areas by year, 1993–1998 
Area year CV n VE (%) 95% CI (%) 
Metropolitan 1993 17 36 92.6 86.8 to 95.9 
 1994 19 34 91.3 84.1 to 95.3 
 1995 23 28 88.0 76.7 to 93.9 
 1996 10 18 92.2 85.2 to 95.9 
 1997 51 94 92.2 87.2 to 95.3 
 1998 19 23 85.4 71.2 to 92.6 
Rural 1993 2 8 98.0 94.8 to 99.2 
 1994 13 42 98.6 97.4 to 99.3 
 1995 11 30 97.9 96.2 to 98.8 
 1996 4 14 98.7 96.9 to 99.5 
 1997 12 30 97.8 95.9 to 98.8 
 1998 10 13 83.3 62.3 to 92.6 
 
Table 6.14. Number of vaccinated cases (CV), total number of cases (n) and VE estimates 
for children aged 2 –4 years in NSW metropolitan and rural areas by year, 1993–1998  
Area year CV n VE (%)       95% CI (%) 
Metropolitan 1993 52 85 86.3 78.3 to 91.4 
 1994 47 80 83.9 73.4 to 90.3 
 1995 40 51 77.7 60.8 to 87.4 
 1996 25 44 85.5 74.6 to 91.8 
 1997 119 196 85.5 79.4 to 89.9 
 1998 23 36 72.8 50.9 to 85.0 
Rural 1993 5 16 96.3 90.9 to 98.5 
 1994 16 100 97.4 95.7 to 98.5 
 1995 25 96 96.0 93.6 to 97.5 
 1996 5 26 97.7 94.7 to 99.0 
 1997 16 75 95.9 93.1 to 97.5 
 1998 35 44 68.9 34.9 to 85.2 
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Table 6.15. Number of vaccinated cases (CV), total number of cases (n) and VE estimates 
for children aged 5 –8 years in NSW metropolitan and rural areas by year, 1993–1998  
Area year CV n VE (%) 95% CI (%) 
Metropolitan 1993 3 10 88.1 82.3 to 92.0 
 1994 10 15 86.0 78.2 to 91.1 
 1995 4 9 80.7 67.3 to 88.6 
 1996 4 14 87.4 79.0 to 92.5 
 1997 19 35 87.4 83.4 to 90.5 
 1998 4 10 76.4 59.0 to 86.4 
Rural 1993 1 9 96.8 92.3 to 98.7 
 1994 4 18 97.8 96.4 to 98.6 
 1995 1 16 96.6 94.8 to 97.7 
 1996 1 5 98.0 95.5 to 99.1 
 1997 7 19 96.4 94.3 to 97.7 
 1998 4 5 73.0 45.7 to 86.6 
 
Table 6.16. Nu mber of vaccinated cases (CV), total number of cases (n) and VE estimates 
for children aged 9 –13 years in NSW metropolitan and rural areas by year, 1993–1998 
Area year CV n VE (%) 95% CI (%) 
Metropolitan 1993 52 83 83.0 74.5 to 88.6 
 1994 27 38 80.0 67.9 to 87.5 
 1995 37 55 72.3 53.1 to 83.6 
 1996 37 50 82.0 69.9 to 89.2 
 1997 193 301 82.0 76.7 to 86.1 
 1998 70 81 66.1 42.0 to 80.2 
Rural 1993 5 19 95.4 89.0 to 98.1 
 1994 13 78 96.8 94.9 to 98.0 
 1995 38 92 95.1 92.6 to 96.7 
 1996 7 18 97.1 93.6 to 98.7 
 1997 25 60 94.8 91.8 to 96.7 
 1998 62 67 61.3 22.4 to 80.7 
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Table 6.17. Number of vaccinated cases (CV), total number of cases (n) and VE estimates 
by age group in NSW metropolitan and rural areas, adjusted for year, 1993–1998 
Age group Area CV n VE (%) 95% CI (%) 
8-23 months Metropolitan 44 93 90.6 85.0 to 94.2 
 Rural 18 72 97.4 95.5 to 98.5 
2 – 4 years Metropolitan 139 233 82.6 75.9 to 87.4 
 Rural 52 137 95.3 93.1 to 96.7 
5 – 8 years Metropolitan 306 492 84.9 80.8 to 88.1 
 Rural 102 357 95.9 94.4 to 96.9 
9 – 13 years Metropolitan 416 608 78.3 72.5 to 82.9 
 Rural 150 334 94.1 92.0 to 95.6 
 
Pooled regional population estimates  
The final model using the pooled PPV estimate had the same deviance as the model in 
which PPV for each area was used, but health area accounted for more of the variability (in 
the base model, c 24  was 271 compared with 232, p<0.0001 in both cases). Areas with lower 
PPV than the pooled estimate of 0.93 generally had higher VE estimates and vice versa.  
Changes in population coverage 
The model which used the higher PPV values (Table 6.4) had the same fit as the original 
model. The VE estimates for all ages, areas and years were higher with the greatest 
increase seen in the 1998 estimates (Appendix 6.1). 
Changes in case definition 
4 doses 
Requiring cases aged over 18 months to have received 4 doses of the vaccine to be 
considered fully vaccinated and excluding cases in this age group who had received only 3 
doses resulted in 2207 cases, 1108 (50%) of whom were vaccinated. The model was similar 
to the original model although it was a slightly poorer fit (deviance=122 on 87 df). VE 
estimates were slightly higher than the original estimates (Appendix 6.2).  
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Including partially vaccinated in the unvaccinated group 
Classifying partially vaccinated (1 or 2 doses) as unvaccinated resulted in 2447 cases, 1108 
(45%) of whom were vaccinated. The model was a marginally better fit than the original 
model (deviance=108 on 87 df) and the same explanatory variables were still highly 
significant (p<0.01). VE estimates from this model, adjusted for year and health area 
(Table 6.18) and the individual estimates (Appendix 6.3) were considerably lower. 
 
Table 6.18. VE estimates by age group, adjusted for year and NSW health area (partially 
vaccinated classified as unvaccinated), 1993–1998  
Age group Vaccinated 
cases (PCV %) 
Total cases     VE (%)     95% CI (%) 
8–23 months 60 181 91.4 87.3 to 94.2 
2–4 years 165 386 86.4 82.2 to 89.7 
5–8 years 376 900 86.8 83.9 to 89.2 
9–13 years 507 980 82.6 80.6 to 84.5 
 
Laboratory confirmed cases 
After excluding partially vaccinated cases and those of unknown vaccination status, there 
were 1713 laboratory confirmed cases, 903 of whom were vaccinated. The final model with 
all the explanatory variables was a better fit than the base model which did not require 
laboratory confirmation (deviance 98.8 with 83 df). Overall, VE estimates based on 
laboratory confirmed cases were higher than when all notified cases were included, 
although there was some individual variation (Appendix 6.4). Some combinations of age 
groups, areas and years did not have any notified cases and so VE for these combinations 
could not be calculated. As in the other models, the rural areas had higher VE estimates 
than the metropolitan areas (Table 6.19) and 1998 had the lowest VE estimates (Table 
6.20). After adjusting for area and year, VE in all age groups was 99% (Table 6.21). 
However, the parameter estimate for 1993 was at least 10 times lower than for the other 
years, so averaging the parameter estimates for year masks the differences between years. 
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Table 6.19. Number of vaccinated cases (CV), total number of cases (n) and VE  
estimates by age and NSW health area, adjusted for year, 1993–1998  
Age group and area CV n VE (%) 95% CI (%) 
8–23 months     
Central & SE Sydney 3 12 94.7 90.1 to 97.1 
Western Sydney  12 24 93.1 87.6 to 96.1 
Wentworth  8 18 94.0 89.7 to 96.5 
Northern Rivers 4 22 98.5 97.1 to 99.2 
Southern & Greater Murray 3 16 99.9 99.9 to 100 
2–4 years     
Central & SE Sydney 15 37 87.8 80.6 to 92.4 
Western Sydney 31 49 84.1 75.9 to 89.6 
Wentworth 28 46 86.3 80.8 to 90.2 
Northern Rivers 15 67 96.5 94.4 to 97.9 
Southern & Greater Murray 17 26 99.9 99.8 to 99.9 
5–8 years     
Central & SE Sydney 56 116 87.8 82.3 to 91.6 
Western Sydney 88 126 84.1 78.0 to 88.5 
Wentworth 67 101 86.3 82.6 to 89.2 
Northern Rivers 28 181 96.5 94.7 to 97.7 
Southern & Greater Murray 51 89 99.9 99.8 to 99.9 
9–13 years     
Central & SE Sydney 101 182 80.5 72.1 to 86.3 
Western Sydney 102 143 74.5 64.5 to 81.7 
Wentworth 141 167 78.0 68.7 to 84.5 
Northern Rivers 36 163 94.4 91.5 to 96.3 
Southern & Greater Murray 97 128 99.8 99.7 to 99.9 
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Table 6.20. Number of vaccinated cases (CV), total number of cases (n) and VE  
estimates by age and year, adjusted for NSW health area, 1993–1998  
Age group and year CV n VE (%) 95% CI (%) 
8–23 months     
1993 1 7 100 99.9 to 100 
1994 4 18 96.5 92.8 to 98.3 
1995 3 15 95.1 90.9 to 97.4 
1996 3 13 95.9 92.0 to 97.9 
1997 14 30 96.1 89.1 to 98.6 
1998 5 9 88.1 76.8 to 93.9 
2–4 years     
1993 9 27 99.9 99.8 to 99.9 
1994 17 49 91.9 85.6 to 95.5 
1995 16 36 88.8 81.9 to 93.0 
1996 9 19 90.7 84.1 to 94.6 
1997 35 68 91.0 77.1 to 96.5 
1998 20 26 72.8 53.6 to 84.0 
5–8 years     
1993 33 59 99.9 99.8 to 99.9 
1994 41 132 91.9 86.4 to 95.2 
1995 50 105 88.7 83.3 to 92.4 
1996 21 51 90.7 85.0 to 94.2 
1997 94 196 91.0 77.9 to 96.3 
1998 51 70 72.7 56.2 to 83.0 
9–13 years     
1993 38 70 99.8 99.7 to 99.9 
1994 35 103 87.0 78.2 to 92.3 
1995 62 122 81.9 73.6 to 87.6 
1996 40 58 85.0 76.1 to 90.7 
1997 183 298 85.6 80.1 to 89.5 
1998 119 132 56.3 30.7 to 72.4 
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Table 6.21. Age group: test statistics, number of vaccinated cases (CV), total number of 
cases (n) and VE for laboratory confirmed cases, 1993–1998 
Age group CV n c2 P-value VE (%) 95% CI (%) 
8–23 months 30 92 20.3 <0.0001 99.9 99.8 to 99.9 
2–4 years 106 225 6.1 0.01 99.7 99.6 to 99.8 
5–8 years 290 613 11.6 0.0007 99.7 99.7 to 99.8 
9–13 years 477 783 referent  99.6 99.5 to 99.6 
 
Discussion 
This study shows that pertussis vaccination is highly effective at preventing pertussis in 
NSW children, as measured by notified cases. The VE estimates presented here are really 
estimates of the effectiveness of pertussis vaccination at preventing pertussis notification, 
rather than disease per se. As we have no data on non-notified cases we are unable to 
determine the extent to which the VE estimates reflect the effectiveness of preventing 
pertussis infection or disease of differing severity due to pertussis infection. The estimates 
in this study are not vaccine-specific but largely represent whole-cell vaccines, as acellular 
pertussis vaccines have only been available free of charge for use in the primary course 
since February 1999.12 Although acellular vaccines were available in NSW prior to 1999, 
the proportion used was small (see Chapter 4) and infants who received all three doses of 
an acellular vaccine in 1998 would not be of an eligible age for this study until 1999. 
 
Although this study aimed to measure the effectiveness of three doses of a pertussis-
containing vaccine, most cases who had received three doses and were eligible for a fourth 
dose had received it. Assuming that four doses of the vaccine are more effective than three 
doses, the effectiveness of three doses may have been over-estimated. Not surprisingly, 
excluding cases aged over 18 months who had not received four or more doses of the 
vaccine increased the VE estimate. This increase was quite small, which is to be expected, 
as only 119 of the 2326 (5%) cases were excluded on the basis of this definition change. 
Half the 5–8 year old age group had received a fifth dose. In the future we would expect 
this proportion to rise with a corresponding increase in the VE estimate, both overall and 
relative to the 9–13 year olds.  
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Classifying partially vaccinated cases as unvaccinated had the effect of lowering the VE 
estimates. This is expected as partial vaccination against pertussis gives some protection 
against disease, thus reducing the risk of disease in the unvaccinated group. These 
estimates, which compare the risk of disease in the fully vaccinated with those partially 
vaccinated or unvaccinated, demonstrate the effectiveness of completing the primary 
vaccination schedule for pertussis versus not completing the schedule. In some countries 
and areas information on partial vaccination is not available and this is the only method of 
classification. Such is the case in New Zealand, so classifying cases this way allows 
comparison with the New Zealand VE estimates.5 The 1996 and 1997 VE estimates are 
similar to those reported in a New Zealand study which applied the screening method to 
notification data from the 1996 pertussis epidemic, although our estimates are higher in the 
youngest age group and lower in the2–4 year olds.5 
 
Including only cases in whom pertussis is laboratory confirmed increases the specificity of 
the case definition. Previous studies have found that increasing the specificity by including 
only clinically severe or culture positive cases has increased the VE estimates.7,13 In this 
study, including only laboratory confirmed cases did not have a big effect. This may be 
because 73% of the cases in the study were laboratory confirmed, a finding not surprising 
as laboratory confirmed cases are more likely to be notified. In addition, many of the 
notifications which are recorded as being notified on clinical grounds are likely to be 
severe cases. 
Possible sources of bias 
Possible sources of bias and the likely effect on VE estimates are summarised in Table 
6.22. 
Cases 
Cases with unknown vaccination status give rise to a potential selection bias. It is possible 
that cases who were not as readily followed-up to check their vaccination status were less 
likely to be fully vaccinated than cases who were able to be followed-up. However, 
excluding health areas where the vaccination status of a large proportion of cases was 
unknown minimises this bias. In health areas where vaccination status was known for at 
least 75% of notifications, the PCV was higher, resulting in lower VE estimates. If PCV in 
excluded areas was really lower (ie, if the distribution of vaccination status was similar 
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amongst those in whom it was unknown to what it was for those in whom it was known) 
and these areas were included, then the VE estimates would have been higher. 
 
It was not feasible for this study to validate vaccination status. As parental recall generally 
overestimates vaccination coverage, vaccination status of cases is more likely to be 
misclassified as vaccinated. 14 This would lead to an underestimate of VE. There could be 
variation in the way information on vaccination status is collected between health areas 
and/or over time. For the later notifications, and in the future, it is possible for public health 
units to check the vaccination status of a notified case on the ACIR. 
 
Information on the date of vaccination was not available. Some cases, particularly among 
eight and nine month olds, may have been vaccinated just prior to disease onset and hence 
there may have been insufficient time between vaccination and disease onset for 
development of an immunologic response. This might have been a greater problem if six 
and seven month old cases had been included. Although ideally these cases should be 
excluded, the effect (if any) is likely to be small. Firstly, most infants have completed the 
primary schedule by seven and a half months (see Chapter 4) and secondly, eight and nine 
month old infants comprise less than two percent of cases. 
 
Pertussis tends to be much milder in vaccinated than non-vaccinated cases, and milder 
cases are less likely to be diagnosed and notified. This has the effect of increasing VE 
estimates and what is being measured is the effectiveness of vaccination at preventing more 
serious illness. Ramsay et al,3 who used the screening method to estimate pertussis VE in 
the UK, found that estimates were generally lower in the epidemic period than in non-
epidemic periods. The authors offered two possible explanations for this. The first 
explanation is related to the increased reporting in epidemics of milder cases, who are more 
likely to be vaccinated, leading to an increased proportion of vaccinated cases. The 
alternate explanation is that protection by vaccination is less during periods of heavy 
exposure. Guris et al,4 who used the screening method to determine the effectiveness of the 
pertussis vaccination program in the United States from 1992 to 1994, reported the highest 
VE estimate in 1992. In 1993 and 1994 large outbreaks of pertussis were reported and the 
authors suggested the same explanations. The VE estimates in our study were not lower in 
epidemic years. However, it is possible that local outbreaks with subsequent increased 
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awareness of pertussis were responsible for some of the regional differences in VE 
estimates. 
 
Where VE estimates are derived from notifications, detection bias (ie, the tendency to 
suspect pertussis less in persons known to be fully vaccinated) is an important potential 
problem leading to falsely high VE estimates.3 Although it was not possible to determine 
the importance of this bias in NSW notifications, with the exception of possible increased 
reporting during epidemics, one would expect its effect to be constant over time. 
Coverage estimates 
The ACIR did not commence operation until January 1996, so coverage data were not 
available for all years in the study period. The cohort used for estimation of PPV was 
chosen in preference to earlier cohorts to allow time for improvement in reporting of 
vaccinations to the ACIR. There are no other sources of vaccination status of children by 
health area. The only comprehensive study to estimate the percentage of NSW children in 
receipt of three doses of a pertussis-containing vaccine, with which the ACIR data can be 
compared, is the 1995 Australian Bureau of Statistics (ABS) survey. 15 The ABS 1995 
survey estimated that 87% of NSW children aged 12 months had received 3 doses of DTP 
vaccine.16 A study conducted in northern Sydney in 1992 found that 86% of respondents 
(response rate 58%) stated that their child was fully vaccinated.17 In Northern Sydney, 84% 
of the cohort selected from the ACIR for this study had received 3 doses of DTP. These 
findings are consistent with the PPV values we used in the model. However, a NSW 
vaccination coverage survey conducted in 1992 found that, of 264 children aged 6–24 
months, only 62% could provide evidence of 3 doses of a pertussis-containing vaccine 
from a parent-held child health record.18 It is likely that PPV was over-estimated for the 
early part of the study period, hence VE for the earlier years and for the older age groups 
was over- estimated. In view of this, re-analyses of the data for the years 1996–1998 (ie, 
excluding 1993–1995) were undertaken and the results are presented in Part B of this 
chapter. It should be noted that the PPV values were incorporated into the model as fixed 
values, therefore the confidence intervals only relate to the error of the linear predictor and 
do not incorporate any error around the PPV values. 
 
Underestimation of vaccination coverage will reduce VE estimates. The ACIR data most 
likely underestimate true current coverage due to incomplete reporting of vaccination 
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status. In 1998 it was estimated that 50% or more children who were recorded on the ACIR 
as incompletely vaccinated were in fact fully vaccinated. 15 The effect of increasing the 
population estimates was seen to raise the VE estimates. However, if coverage has 
improved over the study period, then the ACIR estimates used may have overestimated 
coverage in the earlier part of  the study period and in the older age groups. True coverage 
may have increased as a number of incentive schemes have been introduced by the 
Commonwealth Government since 1997.19 This may be at least partly responsible for the 
apparently lower VE in 1998. Reporting to the ACIR may vary between health areas and 
could account for some of the regional differences in VE estimates. Coverage may have 
improved over the study period differentially between areas, which could explain the 
significance of the interaction between health area and year.  
 
Table 6.22. Potential sources of bias and the likely effect on VE estimates 
Potential source of bias 
Effect on VE 
estimate* 
Cases with unknown vaccination status more likely to be unvaccinated ¯ 
Non-differential misclassification of cases ¯ 
Unvaccinated cases more likely to be misclassified as vaccinated ¯¯ 
PPV underestimated (most likely in the latter years and younger age groups) ¯ 
Inclusion of cases who were vaccinated in the 2 weeks prior to disease onset ¯ (small) 
Vaccinated cases more likely to be notified due to better access to health 
care 
¯ 
Severe or typical cases who are more likely to be unvaccinated are more 
likely to be notified 
­ 
Unvaccinated cases more likely to be notified ­­ 
PPV overestimated (most likely for earlier years and in older age groups) ­­ 
*¯ indicates the bias would reduce the VE estimate and if it occurred the calculated VE estimations 
under-estimate true VE. 
Age 
VE estimates were consistently highest in the youngest age group and lowest in the oldest 
age group. If, as we suspect, PPV values were lower than those used in these analyses in 
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the oldest age groups then the true VE estimates would be even lower in these groups. Age 
is a proxy measure for time since vaccination and if vaccine-acquired immunity wanes with 
time then we would expect VE to be lowest in the older children. Although older children 
have a greater probability of having been exposed to the disease and therefore of having 
had the disease, the proportion of the population who have had the disease is relatively 
small and so the effect, if any, would be small. These results, together with the increasing 
rates of notified 10–14 year old cases in Australia (Chapters 2 & 3), suggest that childhood 
vaccination against pertussis is less effective against disease in adolescence. 
Area 
Much of the variation in VE between areas could be due to inaccuracies in PPV estimates 
for some or all of the study period. The use of pooled PPV figures in the model instead of 
individual figures for each health area increased the variation in VE between areas even 
further. However, differences in notification practices, handling and storage of vaccines 
and levels of exposure to pertussis may also account for some of the differences in VE. In 
addition, awareness of pertussis activity, for example local outbreaks, may affect the 
likelihood of suspicion, diagnosis and notification of pertussis. 
 
The reason VE estimates are consistently higher in rural than metropolitan areas is not 
clear. It may be that population coverage has increased more in rural areas than in 
metropolitan areas since the start of the study period. The finding that the difference 
between rural and metropolitan areas is less in 1998 than in previous years supports this 
suggestion. Alternatively, there may be less exposure in less densely populated rural areas 
and the vaccine may be less effective under conditions of heavy exposure, which may be 
more likely to be found in metropolitan areas. 
Year 
The VE estimates for cases with disease onset in 1998 were generally lower than for other 
years, particularly in the Southern/Greater Murray area. The population coverage figures 
used in the model may be a more accurate reflection of true PPV in 1998 than in previous 
years. If this is the case, then the 1998 VE estimates are more realistic than those for 1996 
and 1997. A study using similar methodology in the United States estimated pertussis VE 
between 1994 and 1996 in 7–18 month old children to be 82%,4 the same as our 1998 
estimate in the youngest age group. Alternatively, coverage may have improved over the 
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three-year period with coverage being underestimated for 1998, thus resulting in an 
underestimate of VE in 1998. The most likely scenario lies somewhere in between these 
two alternative explanations — that is, coverage has improved and was over-estimated for 
the years 1996 and 1997 and under-estimated for 1998.  
 
The possibility that VE did actually decrease in 1998 should not be completely dismissed. 
A recent paper from The Netherlands reported a downward trend in VE and in 1997, the 
final year in which VE was analysed, the PCV exceeded the PPV.1 The authors suggested 
two possible explanations for this. The first is that there may be a mismatch of the vaccine 
strain and the circulating Bordetella pertussis strains; the second is that the lower 
immunogenicity profile of the Dutch vaccine may have resulted in greater vulnerability to 
antigenic changes in Bordetella pertussis.1 Although there is no evidence to suggest that 
this is the case in Australia, the ongoing surveillance of pertussis including VE is of 
paramount importance. 
 
It is also possible that differences in VE over the time period were due to differences in 
notification practices, although we have no evidence of changes to the notif ication system. 
A UK study found that pertussis VE was significantly lower during epidemic than non-
epidemic periods.3 However, ‘epidemic period’ was not significant in our model and the 
VE estimates were lower in 1998, which was a ‘non-epidemic’ period. 
Other potentially confounding variables 
Other variables may be independently related to both the risk of being notified with 
pertussis and to vaccination status and thus confound the VE estimate. Unlike randomised 
controlled trials, where potential confounding variables, both known and unknown, are 
randomly distributed among the experimental and control groups, we can only control for 
other potential confounders if we have information on them, which in this study we do not. 
Other potential confounding variables may include socioeconomic status, level of 
education, ethnicity and attendance at institutions such as childcare. 
Conclusion 
Although the extent to which notified childhood cases of pertussis represent all childhood 
cases of pertussis is not known, the results of this study suggests that the pertussis 
vaccination program is highly effective, especially in younger children. Whilst the potential 
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for bias in this study would be unacceptable in many studies, trends in VE may still be 
monitored provided any bias remains constant over time. The strength of this methodology 
lies in its ease of application and the fact that it could be incorporated into routine 
surveillance of vaccine preventable diseases.  
 
As the ACIR matures, checking the immunisation status of cases will be easier and the 
population estimates more accurate. In addition, it will be possible to use the population 
coverage data of the cohort of children from which the cases arose, which will improve the 
precision of the VE estimates. In contrast to the previous studies which have used the 
screening method to estimate pertussis VE,1-5 we have been able to use regional coverage 
data. The United Kingdom study is the only previous study which has used a logistic 
regression model and, whilst it stratified by year and age, it did not stratify by area.3 The 
authors comment that the use of national coverage data may produce artificially high VE 
estimates3 and Farrington illustrates the confounding effect of pooling population coverage 
data.9 In Australia, regional coverage data are available from the ACIR and should be used 
in all future pertussis VE studies which use the screening method. 
 
A review of vaccine preventable diseases in Australia from 1993 to 1998 found that 
pertussis was responsible for more morbidity than any other vaccine preventable disease 
and that the nine deaths recorded in the years from 1993 to 1997 equalled the number in the 
previous decade.12 Reducing the morbidity associated with pertussis requires an 
understanding of the disease epidemiology in the population. Much of this understanding 
comes from notification data. The documentation of vaccination status of notified cases 
who would have been eligible for vaccination at the time of disease onset is essential for 
program evaluation and planning. The impact of the change to acellular pertussis vaccine 
and changes to the schedule must be monitored — such monitoring will assist future 
vaccine policy decisions. 
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Part B: Effectiveness of pertussis vaccination in NSW children, 
1996 to 1998 
Background 
The results of the previous study (Part A) suggest that PPV had been overestimated for the 
earlier years of the study period. As there are no data which measure population coverage 
by health area for the years 1993 to 1995, in this part of the study these years were 
excluded. 
Methods 
The methods are identical to the previous study except that dates of onset prior to 1 January 
1996, were excluded from analyses. The effect of excluding Southern/Greater Murray 
Health areas was examined, as was the effect of excluding the 9–13 year age group. 
Results  
Fitting the model 
The model with no explanatory variables remained a poor fit (deviance=240 with 59 df) but 
was still a better fit than the equivalent model in the previous study. The addition of each 
explanatory variable by itself significantly improved the fit of the model (Table 6.23). 
Health area was the most significant explanatory variable. All variables remained 
significant in the model in which all three were included (p<0.0001). 
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Table 6.23. Summary of models 
Explanatory variable(s) Dev*/ df† c2 df p-value 
None 4.06    
Age  3.70 32 3 <0.0001 
Year 3.38 47 2 <0.0001 
Area  2.54 100 4 <0.0001 
Age + year + area 1.49    
Age + year + area + year*area 1.11    
Age + year + area + year*area 
(excluding 9-13 year olds) 
0.95    
*Dev=deviance 
†df=degrees of freedom. 
 
 
The final model included age group, year of onset and area (base model) plus the 
interaction between area and year. This model had a deviance of 46 with 42 degrees of 
freedom suggesting that the model fitted the data (p=0.3), therefore there was no need to re-
scale the model. In the final model all variables were significant (p<0.001). Although still 
significant, health area, year and the interaction between area and year explained less of  the 
variability than when all years were included. 
VE Estimates 
VE estimates from the final model for each of the four age groups, stratified by health area 
and year, can be seen in Tables 6.24 to 6.27 . 
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Table 6.24. Number of vaccinated cases (CV), total number of cases (n) and VE  
estimates for children aged 8–23 months by health area, 1996–1998 
Area year CV n VE (%) 95% CI (%) 
Central & SE Sydney 1996 1 4 93.7 86.7 to 97.0 
 1997 4 13 94.8 91.2 to 96.9 
 1998 0 3 93.2 84.6 to 97.0 
Northern Rivers 1996 1 2 97.6 93.1 to 99.1 
 1997 3 11 98.3 96.7 to 99.1 
 1998 2 2 91.8 73.4 to 97.5 
Western Sydney 1996 1 6 92.6 85.2 to 96.3 
 1997 8 12 89.2 81.4 to 93.7 
 1998 4 6 82.9 60.2 to 92.7 
Wentworth 1996 2 4 84.6 55.6 to 94.6 
 1997 7 10 86.7 75.9 to 92.7 
 1998 0 1 75.9 43.9 to 89.6 
Southern & Greater Murray 1996 0 3 99.0 97.8 to 99.6 
 1997 4 8 96.8 93.8 to 98.3 
 1998 2 3 79.7 56.6 to 90.5 
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Table 6.25. Number of vaccinated cases (CV), total number of cases (n) and VE  
estimates for children aged 2–4 years by health area, 1996–1998  
Area year CV n VE (%) 95% CI (%) 
Central & SE Sydney 1996 1 2 89.2 78.5 to 94.6 
 1997 21 47 91.0 86.9 to 93.8 
 1998 2 4 88.3 75.2 to 94.5 
Northern Rivers 1996 3 9 95.8 89.2 to 98.4 
 1997 5 19 97.0 94.9 to 98.3 
 1998 2 4 86.0 56.6 to 95.5 
Western Sydney 1996 8 14 87.2 76.8 to 92.9 
 1997 20 32 81.5 71.8 to 87.9 
 1998 5 6 70.7 34.2 to 86.9 
Wentworth 1996 1 2 73.5 25.2 to 90.6 
 1997 10 15 77.2 62.2 to 86.2 
 1998 12 13 58.6 12.1 to 80.5 
Southern & Greater Murray 1996 1 5 98.3 96.4 to 99.2 
 1997 7 11 94.4 90.1 to 96.9 
 1998 8 9 65.1 31.2 to 82.3 
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Table 6.26. Number of vaccinated cases (CV), total number of cases (n) and VE  
estimates for children aged 5–8 years by health area, 1996–1998  
Area year CV n VE (%) 95% CI (%) 
Central & SE Sydney 1996 8 18 90.6 82.4 to 95.0 
 1997 37 86 92.2 89.4 to 94.2 
 1998 6 10 89.8 79.3 to 95.0 
Northern Rivers 1996 2 10 96.4 90.6 to 98.6 
 1997 7 56 97.4 95.9 to 98.4 
 1998 1 3 87.8 62.4 to 96.0 
Western Sydney 1996 11 19 88.9 80.5 to 93.7 
 1997 45 63 83.9 77.0 to 88.7 
 1998 9 12 74.5 44.6 to 88.2 
Wentworth 1996 6 7 76.9 37.0 to 91.6 
 1997 37 47 80.1 69.3 to 87.1 
 1998 8 14 63.9 25.4 to 82.6 
Southern & Greater Murray 1996 3 16 98.6 97.0 to 99.3 
 1997 9 19 95.2 91.7 to 97.2 
 1998 34 41 69.6 43.6 to 83.6 
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Table 6.27. Number of vaccinated cases (CV), total number of cases (n) and VE estimates 
for children aged 9 –13 years by health area, 1996–1998  
Area year CV n VE (%)     95% CI (%) 
Central & SE Sydney 1996 11 19 84.4 70.9 to 91.6 
 1997 69 140 87.0 83.0 to 90.0 
 1998 9 16 83.1 65.9 to 91.6 
Northern Rivers 1996 0 3 94.0 84.3 to 97.7 
 1997 9 34 95.7 93.1 to 97.4 
 1998 2 4 79.7 37.8 to 93.4 
Western Sydney 1996 14 18 81.5 67.5 to 89.5 
 1997 59 83 73.2 62.0 to 81.1 
 1998 12 15 57.6 8.0 to 80.5 
Wentworth 1996 12 13 61.7 -4.1 to 85.9 
 1997 65 78 67.0 49.5 to 78.4 
 1998 49 50 40.1 -21.5 to 70.4 
Southern & Greater Murray 1996 7 15 97.6 95.1 to 98.8 
 1997 16 26 91.9 86.4 to 95.2 
 1998 60 63 49.5 6.4 to 72.8 
 
Age group 
Age group was highly significant in the base model (c 23 =20, p<0.0001). The 8–23 month 
age group had the lowest parameter estimate (corresponding to the highest VE estimate). 
The VE estimate, after adjustment for area and year, remained highest in the 8 to 23 month 
age group and lowest in the 9–13 year group (Table 6.28). The relative magnitude of the 
parameter estimates was unchanged when the 9–13 year group was excluded from 
analyses, but the base model was a better fit (Table 6.23) and age group was no longer 
significant (c 22 =3.4, p=0.18). 
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Table 6.28. Age group: test statistics, number of vaccinated cases (CV), total number of 
cases (n) and VE estimates  
 CV n c 2 P-value VE (%)* 95% CI (%) 
8 to 23 month olds 39 80 12.4 0.0004 91.0 85.5 to 94.4 
2 to 4 year olds 106 192 3.78 0.052 84.5 78.3 to 88.9 
5 to 8 year olds 223 421 11.8 0.0006 86.5 82.7 to 89.5 
9 to 13 year olds 394 577 referent  77.6 71.7 to 82.3 
*Adjusted for year and health area 
 
Health area and year of onset 
As in Part A, health area was the most significant term in the base model (c 24 =91, 
p<0.0001) followed by year of onset (c 22 =41, p<0.0001). The interaction between year and 
area also remained highly significant (c 28 =28, p=0.0004). However, the test statistics for 
these three terms were lower, with corresponding higher p-values. There was not a clear 
metropolitan/rural divide as in Part A of the study. In the base model, the parameter 
estimates for Western Sydney and Wentworth were not significantly different from one 
another whilst the estimates for Northern Rivers, Greater Murray, Southern and Central and 
South Eastern Sydney were not significantly different from one another, but the latter 
estimates were significantly lower (ie, higher VE — Table 6.29) than the former areas 
(p<0.0001).  
 
As in Part A, the 1998 VE estimates, adjusted for health area, were considerably lower than 
the 1996 and 1997 estimates (Table 6.30). However, the 95% confidence intervals of the 
unadjusted VE estimates (Tables 6.24–6.27) for the years 1996 to 1998 overlapped in all 
areas except Southern/Greater Murray, in all age groups. When the model was run with the 
Greater Murray/Southern area excluded, the interaction term was no longer significant 
(p=0.6). Following removal of the interaction term, year accounted for less of the 
variability than the final model but was still significant (c 22 =6.3, p=0.04), with 1998 VE 
estimates lower than the previous years. 
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Table 6.29. Number of vaccinated cases, total number of cases and VE estimates  
by health area and age, adjusted for year, 1996–1998 
Age group and area 
Vaccinated 
cases 
Total cases VE (%) 95% CI (%) 
8–23 months     
Central & SE Sydney 5 20 93.9 89.5 to 96.5 
Northern Rivers 6 15 96.8 93.7 to 98.3 
Western Sydney  13 16 88.9 81.1 to 93.5 
Wentworth 9 15 83.0 68.8 to 90.7 
Southern & Greater Murray 6 14 96.0 94.5 to 97.1 
2–4 years     
Central & SE Sydney 24 53 89.6 83.8 to 93.3 
Northern Rivers 10 32 94.4 90.2 to 96.8 
Western Sydney  33 52 80.9 70.7 to 87.6 
Wentworth 23 30 70.7 50.7 to 82.6 
Southern & Greater Murray 16 25 93.1 89.1 to 95.7 
5–8 years     
Central & SE Sydney 51 114 90.9 87.0 to 93.7 
Northern Rivers 10 69 95.1 91.7 to 97.2 
Western Sydney  65 94 83.4 76.0 to 88.5 
Wentworth 51 68 74.5 59.5 to 84.0 
Southern & Greater Murray 46 76 94.0 91.2 to 95.9 
9–13 years     
Central & SE Sydney 89 175 84.9 78.7 to 89.3 
Northern Rivers 11 41 91.9 86.2 to 95.3 
Western Sydney  85 116 72.4 60.1 to 80.9 
Wentworth 126 141 57.7 33.9 to 72.9 
Southern & Greater Murray 83 104 90.1 85.5 to 93.2 
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Table 6.30. Number of vaccinated cases, total number of cases and VE estimates by year 
and age, adjusted for health area, 1996–1998 
Age group and area 
Vaccinated 
cases 
Total cases VE (%) 95% CI (%) 
8–23 months     
1996 5 19 94.2 89.9 to 96.6 
1997 26 54 93.0 88.7 to 95.7 
1998 8 15 82.0 68.5 to 89.7 
2–4 years     
1996 14 32 90.0 84.3 to 93.6 
1997 63 124 88.0 83.1 to 91.4 
1998 29 36 69.2 51.4 to 80.4 
5–8 years     
1996 30 70 91.3 87.2 to 94.0 
1997 135 271 89.5 86.6 to 91.8 
1998 58 80 73.2 60.0 to 82.0 
9–13 years     
1996 44 68 85.5 78.7 to 90.1 
1997 218 361 82.6 78.1 to 86.2 
1998 132 148 55.4 34.6 to 69.6 
 
Discussion 
The better fit of the model after restriction of year of onset suggests that the population 
estimates are a more accurate reflection of the latter years than the earlier years of the study 
period. This would also affect the older age groups and hence the estimates for the older 
age groups are likely to be lower than the calculated values. This is supported by the better 
fit of the model in which the 9–13 year old age group was excluded. However, even in this 
part of the study where the years are restricted, the VE estimates for cases with disease 
onset in 1998 were still lower than for other years. The PPV figures used in the model may 
be a more accurate reflection of true PPV in 1998 than in previous years. If this is the case, 
then the 1998 VE estimates are more realistic than those for 1996 and 1997. Alternatively, 
coverage may have improved over the three-year period with coverage being 
underestimated for 1998, thus resulting in an underestimate of VE in 1998. 
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The significantly lower VE estimate in the Southern/Greater Murray area in 1998 
compared with 1996 and 1997, together with the elimination of significant interaction upon 
removal of this area from the model, suggests that PPV increased more in this area than in 
the other areas. This, together with the finding that area and interaction between year and 
area is less significant in this model than in Part A, provides further evidence that some or 
most of the variation in VE between areas is due to inaccuracies in PPV estimates.
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Appendix 6.1 
Results of sensitivity analysis: VE estimates using higher values of PPV, 
1993–1998 notification data 
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Table A6.1.1. VE estimates for children aged 8–23 months by health area,  
1993–1998 
Area year CV n VE (%) 95% CI (%) 
Central & SE Sydney 1993 1 3 93.2 87.7 to 96.2 
 1994 6 6 91.5 82.7 to 95.8 
 1995 2 3 94.0 83.8 to 97.7 
 1996 1 4 96.3 91.8 to 98.3 
 1997 4 13 96.9 95.0 to 98.1 
 1998 0 3 96.0 90.4 to 98.3  
Northern Rivers 1993 0 6 98.6 96.8 to 99.4 
 1994 3 16 99.1 98.4 to 99.5 
 1995 1 10 98.9 98.0 to99.4 
 1996 1 2 98.7 95.8 to 99.6 
 1997 3 11 99.0 98.1 to 99.5 
 1998 2 2 95.3 82.6 to 98.7 
Western Sydney 1993 2 3 96.9 93.5 to 98.6 
 1994 4 8 94.2 88.3 to 97.1 
 1995 1 2 89.7 76.3 to 95.5 
 1996 1 6 95.7 91.2 to 97.9 
 1997 8 12 93.7 89.3 to 96.3 
 1998 4 6 90.0 74.7 to 96.0 
Wentworth 1993 0 4 98.2 95.9 to 99.2 
 1994 0 1 98.0 95.5 to 99.1 
 1995 1 4 94.3 87.9 to 97.3 
 1996 2 4 90.5 69.1 to 97.1 
 1997 7 10 91.9 85.2 to 95.5 
 1998 0 1 85.1 63.4 to 93.9 
Southern & Greater Murray 1993 1 3 99.6 95.4 to 100 
 1994 1 2 99.5 98.5 to 99.8 
 1995 0 6 98.4 97.0 to 99.2 
 1996 0 3 99.4 98.6 to 99.8 
 1997 4 8 98.1 96.2 to 99.0 
 1998 2 3 87.7 72.8 to 94.5 
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Table A6.1.2. VE estimates for children aged 2–4 years by health area,  
1993–1998 
Area year CV n VE (%) 95% CI (%) 
Central & SE Sydney 1993 10 19 86.7 78.2 to 91.9 
 1994 9 14 83.4 68.4 to 91.3 
 1995 4 5 88.2 69.7 to 95.4 
 1996 1 2 92.8 84.8 to 96.6 
 1997 21 47 94.0 91.4 to 95.8 
 1998 2 4 92.2 82.1 to 96.6 
Northern Rivers 1993 2 7 97.3 94.1 to 98.8 
 1994 12 39 98.3 97.3 to 98.9 
 1995 7 26 97.9 96.5 to 98.7 
 1996 3 9 97.4 92.3 to 99.1 
 1997 5 19 98.1 96.6 to 98.9 
 1998 2 4 90.8 67.1 to 97.5 
Western Sydney 1993 3 9 94.0 88.1 to 97.0 
 1994 5 9 88.7 78.3 to 94.1 
 1995 8 8 79.9 56.4 to 90.8 
 1996 8 14 91.6 83.9 to 95.6 
 1997 20 32 87.7 81.0 to 92.0 
 1998 5 6 80.4 52.0 to 92.0 
Wentworth 1993 4 8 96.4 92.4 to 98.3 
 1994 5 11 96.2 91.9 to 98.2 
 1995 11 15 88.9 78.0 to 94.4 
 1996 1 2 81.4 40.7 to 94.2 
 1997 10 15 84.1 73.1 to 90.6 
 1998 12 13 70.9 33.0 to 87.4 
Southern & Greater Murray 1993 0 1 99.3 91.0 to 99.9 
 1994 1 3 99.0 97.1 to 99.7 
 1995 4 4 96.9 94.5 to 98.3 
 1996 1 5 98.9 97.4 to 99.5 
 1997 7 11 96.2 92.9 to 98.0 
 1998 8 9 91.6 79.4 to 96.3 
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Table A6.1.3. VE estimates for children aged 5–8 years by health area,  
1993–1998 
Area year CV n VE (%) 95% CI (%) 
Central & SE Sydney 1993 34 47 88.8 82.5 to 92.9 
 1994 20 31 86.1 74.4 to 92.5 
 1995 4 5 90.1 74.9 to 96.1 
 1996 8 18 93.9 87.8 to 97.0 
 1997 37 86 95.0 93.1 to 96.3 
 1998 6 10 93.4 85.3 to 97.1 
Northern Rivers 1993 5 15 97.8 95.1 to 99.0 
 1994 15 90 98.5 97.8 to 99.0 
 1995 11 67 98.2 97.2 to 98.9 
 1996 2 10 97.8 93.5 to 99.2 
 1997 7 56 98.4 97.2 to 99.0 
 1998 1 3 92.3 72.5 to 97.9 
Western Sydney 1993 11 21 95.0 90.3 to 97.4 
 1994 22 32 90.5 82.6 to 94.8 
 1995 20 24 83.2 64.6 to 92.0 
 1996 11 19 93.0 86.8 to 96.3 
 1997 45 63 89.7 84.8 to 93.0 
 1998 9 12 83.6 60.6 to 93.2 
Wentworth 1993 7 17 97.0 93.8 to 98.5 
 1994 5 17 96.8 93.4 to 98.5 
 1995 16 22 90.7 81.9 to 95.2 
 1996 6 7 84.4 51.3 to 95.0 
 1997 37 47 86.7 78.5 to 91.7 
 1998 8 14 75.6 44.7 to 89.2 
Southern & Greater Murray 1993 0 1 99.4 92.5 to 99.9 
 1994 1 10 99.2 97.6 to 99.7 
 1995 14 29 97.4 95.6 to 98.5 
 1996 3 16 99.0 97.8 to 99.6 
 1997 9 19 96.8 94.2 to 98.2 
 1998 34 41 79.9 59.5 to 90.0 
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Table A6.1.4. VE estimates for children aged 9–13 years by health area,  
1993–1998 
Area year CV n VE (%) 95% CI (%) 
Central & SE Sydney 1993 34 53 84.0 75.0 to 89.8 
 1994 8 13 80.1 62.7 to 89.4 
 1995 6 13 85.8 64.4 to 94.4 
 1996 11 19 91.3 82.5 to 95.7 
 1997 69 140 92.8 90.3 to 94.6 
 1998 9 16 90.6 79.1 to 95.8 
Northern Rivers 1993 5 18 96.8 93.1 to 98.5 
 1994 10 69 97.9 96.8 to 98.6 
 1995 16 54 97.4 95.9 to 98.4 
 1996 0 3 96.8 90.7 to 98.9 
 1997 9 34 97.7 96.0 to 98.6 
 1998 2 4 89.0 60.7 to 96.9 
Western Sydney 1993 10 17 92.8 86.1 to 96.3 
 1994 10 14 86.4 74.6 to 92.7 
 1995 15 22 75.9 49.0 to 88.6 
 1996 14 18 89.9 81.0 to 94.6 
 1997 59 83 85.2 78.3 to 89.9 
 1998 12 15 76.5 43.6 to 90.2 
Wentworth 1993 8 13 95.7 91.1 to 97.9 
 1994 9 11 95.4 90.4 to 97.8 
 1995 16 20 86.6 74.0 to 93.1 
 1996 12 13 77.7 30.4 to 92.8 
 1997 65 78 80.9 69.4 to 88.1 
 1998 49 50 65.0 21.9 to 84.3 
Southern & Greater Murray 1993 0 1 99.1 89.2 to 99.9 
 1994 3 9 98.8 96.6 to 99.6 
 1995 22 38 96.3 93.7 to 97.8 
 1996 7 15 98.6 96.9 to 99.4 
 1997 16 26 95.4 91.8 to 97.5 
 1998 60 63 71.2 42.2 to 85.7 
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Appendix 6.2 
Results of sensitivity analysis: VE estimates where 4 doses required in 
children aged over 18 months to be considered fully vaccinated, 1993–1998 
notification data 
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Table A6.2.1. VE estimates for children aged 8–23 months by health area,  
1993–1998 
Area year CV n VE (%) 95% CI (%) 
Central & SE Sydney 1993 1 3 87.8 77.3 to 93.4 
 1994 6 6 85.1 68.7 to 92.9 
 1995 2 3 88.7 68.8 to 95.9 
 1996 1 4 94.7 87.4 to 97.8 
 1997 4 13 94.7 91.1 to 96.8 
 1998 0 3 93.0 82.4 to 97.2 
Northern Rivers 1993 0 6 97.7 94.2 to 99.0 
 1994 3 16 98.8 97.8 to 99.4 
 1995 1 10 98.6 97.3 to 99.3 
 1996 1 2 97.5 91.8 to 99.2 
 1997 3 11 98.7 97.3 to 99.4 
 1998 2 2 92.5 69.7 to 98.1 
Western Sydney 1993 2 3 94.8 88.5 to 97.6 
 1994 4 8 90.5 80.3 to 95.4 
 1995 0 1 82.2 57.3 to 92.6 
 1996 1 6 92.8 84.6 to 96.6 
 1997 8 12 89.3 81.3 to 93.8 
 1998 4 6 81.8 52.7 to 93.0 
Wentworth 1993 0 4 96.7 92.5 to 98.6 
 1994 0 1 96.8 92.4 to 98.7 
 1995 1 4 90.0 78.2 to 95.4 
 1996 1 3 85.1 49.2 to 95.6 
 1997 7 10 86.0 74.0 to 92.5 
 1998 0 1 74.1 34.3 to 89.8 
Southern & Greater Murray 1993 1 3 99.3 91.3 to 99.9 
 1994 1 2 99.4 97.7 to 99.8 
 1995 0 6 98.3 96.4 to 99.2 
 1996 0 3 99.2 97.9 to 99.7 
 1997 4 8 96.8 93.4 to 98.4 
 1998 2 3 79.5 53.0 to 91.0 
Chapter 6. Pertussis VE in NSW children using the screening method. Appendix 6.2  
 190 
Table A6.2.2. VE estimates for children aged 2–4 years by health area,  
1993–1998 
Area year CV n VE (%) 95% CI (%) 
Central & SE Sydney 1993 9 18 79.9 66.3 to 88.0 
 1994 8 13 75.6 52.1 to 87.5 
 1995 4 5 81.5 51.1 to 93.0 
 1996 1 2 91.3 80.2 to 96.2 
 1997 18 44 91.3 87.2 to 94.1 
 1998 2 4 88.5 72.5 to 95.2 
Northern Rivers 1993 2 7 96.2 91.0 to 98.4 
 1994 9 36 98.0 96.6 to 98.8 
 1995 5 24 97.8 96.0 to 98.8 
 1996 3 9 95.8 87.4 to 98.6 
 1997 3 17 97.9 95.8 to 98.9 
 1998 1 3 87.7 51.7 to 96.9 
Western Sydney 1993 2 8 91.5 82.4 to 95.8 
 1994 5 9 84.5 69.2 to 92.1 
 1995 7 7 70.8 34.5 to 87 
 1996 7 13 88.1 76.5 to 94 
 1997 19 31 82.4 72.3 to 88.8 
 1998 5 6 70.2 24.8 to 88.2 
Wentworth 1993 4 8 94.6 88.4 to 97.5 
 1994 4 10 94.8 88.5 to 97.7 
 1995 10 14 83.7 66.9 to 92.0 
 1996 1 2 75.6 18.6 to 92.7 
 1997 9 14 77.0 60.3 to 86.7 
 1998 11 12 57.6 -0.7 to 82.2 
Southern & Greater Murray 1993 0 1 98.9 85.7 to 99.9 
 1994 1 3 99.0 96.4 to 99.7 
 1995 3 3 97.2 94.5 to 98.6 
 1996 0 4 98.8 96.7 to 99.5 
 1997 5 9 94.7 89.8 to 97.3 
 1998 7 8 66.3 27.5 to 84.4 
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Table A6.2.3. VE estimates for children aged 5–8 years by health area,  
1993–1998 
Area year CV n VE (%) 95% CI (%) 
Central & SE Sydney 1993 33 46 81.5 70.5 to 88.4 
 1994 19 30 77.4 57.3 to 88.1 
 1995 4 5 83.0 55.5 to 93.5 
 1996 8 18 91.9 82.5 to 96.3 
 1997 33 82 91.9 88.8 to 94.2 
 1998 6 10 89.3 75.3 to 95.4 
Northern Rivers 1993 5 15 96.5 91.9 to 98.4 
 1994 11 86 98.2 97.0 to 98.9 
 1995 8 64 98.0 96.5 to 98.8 
 1996 2 10 96.2 88.4 to 98.7 
 1997 6 55 98.0 96.3 to 98.9 
 1998 1 3 88.7 55.8 to 97.1 
Western Sydney 1993 10 20 92.1 84.3 to 96.0 
 1994 19 29 85.7 72.8 to 92.4 
 1995 20 24 73.1 41.8 to 87.5 
 1996 10 18 89.1 78.8 to 94.3 
 1997 43 61 83.7 75.7 to 89.1 
 1998 9 12 72.5 32.2 to 88.8 
Wentworth 1993 7 17 95.0 89.6 to 97.6 
 1994 5 17 95.2 89.6 to 97.8 
 1995 16 22 84.9 70.2 to 92.4 
 1996 6 7 77.5 26.6 to 93.1 
 1997 36 46 78.8 65.2 to 87.1 
 1998 8 14 60.9   8.8 to 83.2 
Southern & Greater Murray 1993 0 1 99.0 86.9 to 99.9 
 1994 0 9 99.1 96.7 to 99.8 
 1995 7 22 97.4 95.1 to 98.6 
 1996 2 15 98.8 97.0 to 99.6 
 1997 9 19 95.1 90.9 to 97.4 
 1998 33 40 68.9 35.8 to 84.9 
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Table A6.2.4. VE estimates for children aged 9–13 years by health area,  
1993–1998 
Area year CV n VE (%) 95% CI (%) 
Central & SE Sydney 1993 33 52 74.7 59.8 to 84.1 
 1994 8 13 69.2 40.9 to 84.0 
 1995 6 13 76.8 40.0 to 91.0 
 1996 6 14 89.0 76.0 to 95.0 
 1997 66 137 89.0 85.1 to 91.9 
 1998 8 15 85.5 66.6 to 93.7 
Northern Rivers 1993 4 17 95.2 89.0 to 97.9 
 1994 6 65 97.5 96.0 to 98.5 
 1995 9 47 97.2 95.2 to 98.4 
 1996 0 3 94.8 84.1 to 98.3 
 1997 5 30 97.3 94.9 to 98.6 
 1998 2 4 84.5 39.9 to 96 
Western Sydney 1993 10 17 89.2 78.6 to 94.6 
 1994 9 13 80.4 62.3 to 89.8 
 1995 15 22 63.3 20.2 to 83.1 
 1996 13 17 85.1 71.0 to 92.3 
 1997 51 75 77.8 67.0 to 85.1 
 1998 12 15 62.5   7.6 to 84.8 
Wentworth 1993 8 13 93.2 85.8 to 96.8 
 1994 8 10 93.5 85.8 to 97.0 
 1995 16 20 79.5 59.2 to 89.7 
 1996 11 12 69.3   0.3 to 90.6 
 1997 63 76 71.1 53.0 to 82.3 
 1998 47 48 46.7 -22.4 to 76.8 
Southern & Greater Murray 1993 0 1 98.6 82.1 to 99.9 
 1994 2 8 98.8 95.5 to 99.7 
 1995 14 30 96.5 93.4 to 98.1 
 1996 6 14 98.4 96.0 to 99.4 
 1997 15 25 93.4 87.7 to 96.4 
 1998 54 57 57.6 12.8 to 79.4 
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Appendix 6.3 
Results of sensitivity analysis: VE estimates where partially vaccinated 
classified as unvaccinated, 1993-1998 notification data 
Chapter 6. Pertussis VE in NSW children using the screening method. Appendix 6.3  
 194 
Table A6.3.1. VE estimates for children aged 8–23 months by health area,  
1993–1998 
Area year CV n VE (%) 95% CI (%) 
Central & SE Sydney 1993 1 4 81.2 67.4 to 89.1 
 1994 6 7 77.3 56.4 to 88.2 
 1995 2 3 80.6 50.8 to 92.4 
 1996 1 4 92.4 83.4 to 96.5 
 1997 4 16 91.3 86.2 to 94.5 
 1998 0 3 89.0 74.6 to 95.2 
Northern Rivers 1993 0 7 96.1 91.0 to 98.3 
 1994 3 16 97.8 96.1 to 98.8 
 1995 1 10 97.7 95.7 to 98.8 
 1996 1 4 95.8 87.7 to 98.6 
 1997 3 11 97.6 95.2 to 98.8 
 1998 2 2 87.1 54.0 to 96.4 
Western Sydney 1993 2 4 89.5 78.5 to 94.8 
 1994 4 9 82.1 65.6 to 90.7 
 1995 0 2 68.7 33.8 to 85.2 
 1996 1 6 88.3 77.4 to 93.9 
 1997 8 12 81.8 70.3 to 88.8 
 1998 4 6 57.6 -3.7 to 82.7 
Wentworth 1993 0 4 92.6 84.1 to 96.6 
 1994 0 1 93.5 85.6 to 97.1 
 1995 1 5 83.3 67.5 to 91.5 
 1996 1 4 80.4 49.4 to 92.4 
 1997 7 12 75.6 58.3 to 85.7 
 1998 0 1 60.9 16.8 to 81.6 
Southern & Greater Murray 1993 1 3 97.9 76.8 to 99.8 
 1994 1 2 98.4 94.5 to 99.5 
 1995 0 6 96.5 93.2 to 98.2 
 1996 0 5 98.2 95.5 to 99.3 
 1997 4 8 92.9 86.6 to 96.2 
 1998 2 4 75.6 55.8 to 86.5 
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Table A6.3.2. VE estimates for children aged 2–4 years by health area,  
1993–1998 
Area year CV n VE (%) 95% CI (%) 
Central & SE Sydney 1993 9 20 70.3 53.2 to 81.2 
 1994 8 15 64.3 35.5 to 80.2 
 1995 4 5 69.4 25.6 to 87.5 
 1996 1 2 88.0 74.9 to 94.3 
 1997 18 47 86.3 80.5 to 90.3 
 1998 2 4 82.6 61.8 to 92.1 
Northern Rivers 1993 2 8 93.8 86.5 to 97.2 
 1994 9 39 96.5 94.3 to 97.9 
 1995 5 29 96.4 93.8 to 97.9 
 1996 3 9 93.4 81.5 to 97.6 
 1997 3 20 96.2 93.0 to 98.0 
 1998 1 4 79.7 29.8 to 94.1 
Western Sydney 1993 2 9 83.4 68.1 to 91.3 
 1994 5 9 71.7 48.2 to 84.6 
 1995 7 9 50.6 2.1 to 75.1 
 1996 7 15 81.5 66.8 to 89.8 
 1997 19 32 71.3 57.5 to 80.6 
 1998 5 6 33.2 -59.2 to 72.0 
Wentworth 1993 4 9 88.3 76.3 to 94.3 
 1994 4 11 89.8 78.9 to 95.0 
 1995 10 17 73.7 52.3 to 85.5 
 1996 1 4 69.2 22.5 to 87.7 
 1997 9 15 61.5 38.6 to 75.9 
 1998 11 13 38.4 -22.3 to 68.9 
Southern & Greater Murray 1993 0 1 96.8 63.4 to 99.7 
 1994 1 4 97.5 91.6 to 99.3 
 1995 3 4 94.5 90.0 to 97.0 
 1996 0 6 97.2 93.1 to 98.8 
 1997 5 11 88.8 80.2 to 93.7 
 1998 7 9 61.5 35.2 to 77.1 
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Table A6.3.3. VE estimates for children aged 5–8 years by health area,  
1993–1998 
Area year CV n VE (%) 95% CI (%) 
Central & SE Sydney 1993 33 52 71.2 56.6 to 80.9 
 1994 19 32 65.4 39.2 to 80.3 
 1995 4 6 70.4 28.8 to 87.7 
 1996 8 19 88.4 76.6 to 94.2 
 1997 33 90 86.7 82.1 to 90.1 
 1998 6 11 83.1 63.9 to 92.1 
Northern Rivers 1993 5 18 94.0 87.2 to 97.2 
 1994 11 93 96.6 94.7 to 97.9 
 1995 8 70 96.5 94.2 to 97.9 
 1996 2 10 93.6 82.2 to 97.7 
 1997 6 56 96.3 93.4 to 98 
 1998 1 3 80.3 32.2 to 94.3 
Western Sydney 1993 10 22 83.9 70.0 to 91.4 
 1994 19 32 72.6 51.7 to 84.5 
 1995 20 24 52.1 7.8 to 75.1 
 1996 10 24 82.1 68.5 to 89.8 
 1997 43 68 72.2 60.7 to 80.3 
 1998 9 12 35.2 -51.4 to 72.3 
Wentworth 1993 7 17 88.7 77.5 to 94.3 
 1994 5 18 90.1 79.9 to 95.1 
 1995 16 24 74.5 54.7 to 85.7 
 1996 6 7 70.1 26.2 to 87.9 
 1997 36 51 62.7 43.2 to 75.5 
 1998 8 14 40.2 -16.5 to 69.3 
Southern & Greater Murray 1993 0 1 96.8 64.6 to 99.7 
 1994 0 10 97.6 92.0 to 99.3 
 1995 7 30 94.6 90.7 to 96.9 
 1996 2 16 97.3 93.5 to 98.8 
 1997 9 25 89.1 81.4 to 93.6 
 1998 33 45 62.6 40.1 to 76.7 
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Table A6.3.4. VE estimates for children aged 9–13 years by health area,  
1993–1998 
Area year CV n VE (%) 95% CI (%) 
Central & SE Sydney 1993 33 53 62.1 42.7 to 74.9 
 1994 8 13 54.3 18.8 to 74.3 
 1995 6 13 60.9 6.9 to 83.6 
 1996 6 19 84.7 69.2 to 92.4 
 1997 66 147 82.4 76.8 to 86.7 
 1998 8 17 77.7 52.7 to 89.5 
Northern Rivers 1993 4 19 92.1 83.2 to 96.3 
 1994 6 70 95.5 93.0 to 97.2 
 1995 9 57 95.4 92.3 to 97.2 
 1996 0 5 91.5 76.5 to 97.0 
 1997 5 34 95.2 91.3 to 97.3 
 1998 2 4 74.0 10.8 to 92.4 
Western Sydney 1993 10 17 78.8 60.3 to 88.6 
 1994 9 14 63.9 35.4 to 79.8 
 1995 15 23 36.8 -21.9 to 67.3 
 1996 13 19 76.4 58.3 to 86.6 
 1997 51 88 63.3 48.5 to 73.9 
 1998 12 15 14.6 -99.3 to 63.4 
Wentworth 1993 8 13 85.1 70.3 to 92.5 
 1994 8 11 86.9 73.4 to 93.6 
 1995 16 21 66.4 40.1 to 81.2 
 1996 11 13 60.6 3.2 to 84.0 
 1997 63 79 50.8 25.8 to 67.4 
 1998 47 52 21.2 -50.9 to 58.8 
Southern & Greater Murray 1993 0 1 95.8 53.4 to 99.6 
 1994 2 9 96.8 89.4 to 99.0 
 1995 14 39 92.9 87.8 to 95.9 
 1996 6 18 96.4 91.4 to 98.5 
 1997 15 28 85.7 75.5 to 91.6 
 1998 54 69 50.8 21.6 to 69.1 
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Table A6.3.5. VE estimates by age and year, adjusted for health area,  
1993–1998 
Age group and year CV n VE (%) 95% CI (%) 
8–23 months     
1993 4 22 93.4 83.8 to 97.3 
1994 14 35 93.7 88.7 to 96.5 
1995 4 26 90.2 84.3 to 93.9 
1996 4 23 93.2 88.4 to 96.0 
1997 26 59 90.6 80.7 to 95.4 
1998 8 16 77.1 61.7 to 86.3 
2–4 years     
1993 17 47 89.5 75.1 to 95.6 
1994 27 78 90.0 83.6 to 94.0 
1995 29 64 84.6 77.6 to 89.4 
1996 12 36 89.3 83.1 to 93.2 
1997 54 125 85.2 71.3 to 92.4 
1998 26 36 63.9 44.3 to 76.6 
5–8 years     
1993 55 110 86.6 76.3 to 95.6 
1994 54 185 87.3 84.6 to 93.9 
1995 55 154 80.3 79.3 to 89.2 
1996 28 76 86.3 84.1 to 93.2 
1997 127 290 81.1 72.9 to 92.4 
1998 57 85 53.8 47.9 to 76.4 
9–13 years     
1993 55 103 86.60 68.8 to 94.3 
1994 33 117 87.27 79.6 to 92.1 
1995 60 153 80.31 72.9 to 85.7 
1996 36 74 86.33 79.2 to 91.0 
1997 200 376 81.10 75.4 to 85.5 
1998 123 157 53.82 32.2 to 68.6 
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Table A6.3.6. VE estimates by age and health area, adjusted for year,  
1993–1998 
Age group and year CV n VE (%) 95% CI (%) 
8–23 months     
Central & SE Sydney 14 37 86.5 78.9 to 91.3 
Western Sydney  19 39 84.3 70.0 to 87.4 
Wentworth  9 27 80.6 69.9 to 91.8 
Northern Rivers 10 50 96.3 94.0 to 97.7 
Southern & Greater Murray 8 28 96.1 92.9 to 97.9 
2–4 years     
Central & SE Sydney 42 93 78.7 70.0 to 84.9 
Western Sydney  45 80 75.3 57.2 to 78.1 
Wentworth  39 69 69.4 56.0 to 86.1 
Northern Rivers 23 109 94.2 91.4 to 96.1 
Southern & Greater Murray 16 35 93.8 89.3 to 96.4 
5–8 years     
Central & SE Sydney 103 210 79.4 72.5 to 84.5 
Western Sydney  111 182 76.0 60.8 to 77.5 
Wentworth  78 131 70.3 58.4 to 86.2 
Northern Rivers 33 250 94.3 91.9 to 96.0 
Southern & Greater Murray 51 127 94.0 90.0 to 96.4 
9–13 years     
Central & SE Sydney 127 262 72.8 64.0 to 79.4 
Western Sydney  110 176 60.9 48.1 to 70.5 
Wentworth  153 189 92.5 57.4 to 76.5 
Northern Rivers 26 189 72.8 89.4 to 94.8 
Southern & Greater Murray 91 164 68.4 86.9 to 95.3 
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VE estimates where cases are required to be laboratory confirmed, 1993-
1998 notification data  
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Table A6.4.1. VE estimates for children aged 8–23 months by health area, 1993–1998 
Area year CV n VE (%) 95% CI (%) 
Central & SE Sydney 1993 0 0 - - 
 1994 0 0 - - 
 1995 1 2 95.1 83.3 to 98.6 
 1996 1 4 96.0 90.0 to 98.4 
 1997 1 5 96.9 94.2 to 98.3 
 1998 0 1 95.4 85.8 to 98.5 
Northern Rivers 1993 0 1 98.3 95.1 to 99.4 
 1994 1 10 99.2 98.3 to 99.6 
 1995 0 4 98.7 97.3 to 99.4 
 1996 1 1 98.5 94.2 to 99.6 
 1997 0 4 99.5 98.6 to 99.8 
 1998 2 2 91.8 64.1 to 98.1 
Western Sydney 1993 1 1 96.5 91.4 to 98.6 
 1994 3 6 94.3 86.7 to 97.5 
 1995 1 2 89.7 74.3 to 95.8 
 1996 0 3 92.7 82.3 to 97.0 
 1997 5 8 92.1 84.9 to 95.8 
 1998 2 4 90.5 75.0 to 96.4 
Wentworth 1993 0 3 98.0 95.0 to 99.2 
 1994 0 1 97.3 93.5 to 98.9 
 1995 1 3 93.0 83.4 to 97.1 
 1996 1 3 91.6 72.1 to 97.5 
 1997 6 8 89.8 79.5 to 94.9 
 1998 0 0 - - 
Southern & Greater Murray 1993 0 2 100.0  100  to 100 
 1994 0 1 98.8 95.2 to 99.7 
 1995 0 4 98.2 96.0 to 99.2 
 1996 0 2 99.1 97.7 to 99.7 
 1997 2 5 98.0 95.7 to 99.1 
 1998 1 2 86.8 69.2 to 94.3 
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Table A6.4.2. VE estimates for children aged 2–4 years by health area, 1993–1998 
Area year CV n VE (%)  95% CI (%) 
Central & SE Sydney 1993 4 8 81.5 64.0 to 90.5 
 1994 2 3 76.8 41.8 to 90.8 
 1995 0 0 - - 
 1996 0 1 90.9 78.7 to 96.1 
 1997 9 24 92.9 89.0 to 95.5 
 1998 0 1 89.5 69.8 to 96.3 
Northern Rivers 1993 1 5 96.1 90.0 to 98.5 
 1994 7 29 98.1 96.8 to 98.9 
 1995 4 20 97.0 94.8 to 98.3 
 1996 1 5 96.5 87.8 to 99.0 
 1997 1 5 98.8 97.0 to 99.5 
 1998 1 3 81.3 21.3 to 95.6 
Western Sydney 1993 1 6 92.1 82.6 to 96.4 
 1994 2 5 86.9 71.7 to 93.9 
 1995 6 6 76.4 47.0 to 89.5 
 1996 6 7 83.3 63.5 to 92.4 
 1997 13 21 81.9 70.3 to 89.0 
 1998 3 4 78.3 46.2 to 91.3 
Wentworth 1993 3 7 95.4 89.9 to 97.9 
 1994 5 11 93.9 87.1 to 97.1 
 1995 4 8 84.0 65.9 to 92.5 
 1996 1 2 80.9 38.5 to 94.0 
 1997 7 9 76.7 58.0 to 87.1 
 1998 8 9 67.1 21.9 to 86.1 
Southern & Greater Murray 1993 0 1 100.0 100  to 100 
 1994 1 1 97.2 89.7 to 99.3 
 1995 2 2 95.9 91.7 to 98.0 
 1996 1 4 98.0 95.2 to 99.2 
 1997 5 9 95.5 91.2 to 97.7 
 1998 8 9 69.8 37.2 to 85.4 
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Table A6.4.3. VE estimates for children aged 5–8 years by health area, 1993–1998 
Area year CV n VE (%) 95% CI (%) 
Central & SE Sydney 1993 16 21 81.5 65.8 to 89.9 
 1994 12 17 76.8 44.7 to 90.3 
 1995 2 3 88.9 64.8 to 96.5 
 1996 4 11 90.9 79.8 to 95.9 
 1997 18 58 92.9 89.8 to 95.1 
 1998 4 6 89.4 71.0 to 96.2 
Northern Rivers 1993 4 9 96.1 90.3 to 98.5 
 1994 11 78 98.1 97.0 to 98.8 
 1995 9 48 97.0 95.1 to 98.2 
 1996 2 8 96.5 87.9 to 99.0 
 1997 1 36 98.8 97.2 to 99.5 
 1998 1 2 81.3 21.7 to 95.5 
Western Sydney 1993 8 15 92.1 83.3 to 96.2 
 1994 12 18 86.9 73.0 to 93.6 
 1995 15 19 76.4 49.4 to 89.0 
 1996 9 14 83.3 64.8 to 92.1 
 1997 36 49 81.9 72.3 to 88.1 
 1998 8 11 78.3 48.2 to 90.9 
Wentworth 1993 5 13 95.4 90.2 to 97.8 
 1994 5 14 93.9 87.4 to 97.1 
 1995 15 18 84.0 67.2 to 92.2 
 1996 4 5 80.8 40.1 to 93.9 
 1997 33 40 76.7 60.8 to 86.1 
 1998 5 11 67.0 23.9 to 85.7 
Southern & Greater Murray 1993 0 1 100.0 100  to 100 
 1994 1 5 97.2 90.0 to 99.2 
 1995 9 17 95.9 92.2 to 97.9 
 1996 2 13 98.0 95.4 to 99.2 
 1997 6 13 95.5 91.5 to 97.6 
 1998 33 40 69.7 40.6 to 84.5 
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Table A6.4.4. VE estimates for children aged 9–13 years by health area, 1993–1998 
Area year CV n VE (%) 95% CI (%) 
Central & SE Sydney 1993 19 30 70.3 45.4 to 83.8 
 1994 6 9 62.8 10.0 to 84.6 
 1995 5 10 82.2 44.4 to 94.3 
 1996 10 16 85.3 67.9 to 93.3 
 1997 55 106 88.7 84.2 to 91.9 
 1998 6 11 83.1 53.9 to 93.8 
Northern Rivers 1993 3 13 93.8 84.5 to 97.5 
 1994 10 67 96.9 95.2 to 98.1 
 1995 15 49 95.2 92.2 to 97.0 
 1996 0 3 94.4 80.5 to 98.4 
 1997 6 28 98.0 95.5 to 99.1 
 1998 2 3 70.0 -25.3 to 92.8 
Western Sydney 1993 8 13 87.3 73.2 to 94.0 
 1994 7 11 79.0 56.3 to 89.9 
 1995 12 18 62.1 18.4 to 82.4 
 1996 13 17 73.2 43.6 to 87.3 
 1997 51 70 70.9 55.9 to 80.9 
 1998 11 14 65.2 17.0 to 85.4 
Wentworth 1993 8 13 92.5 84.3 to 96.5 
 1994 9 11 90.2 79.7 to 95.3 
 1995 16 20 74.4 47.4 to 87.5 
 1996 10 11 69.2 4.6 to 90.1 
 1997 56 69 62.6 37.7 to 77.5 
 1998 42 43 47.1 -19.8 to 76.7 
Southern & Greater Murray 1993 0 1 100.0 100  to 100 
 1994 3 5 95.5 84.0 to 98.8 
 1995 14 25 93.5 87.6 to 96.6 
 1996 7 11 96.9 92.7 to 98.7 
 1997 15 25 92.7 86.5 to 96.1 
 1998 58 61 51.4 5.0 to 75.2 
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Although mortality and morbidity from pertussis declined dramatically following the 
introduction of mass vaccination programs in 1953, this thesis demonstrates that 
pertussis remains an important public health problem in Australia. The 1997 pertussis 
epidemic, which affected a large proportion of Australia, resulted in six infant deaths, 
over 1000 hospitalisations and almost 11 000 notifications. During the period 1993 to 
1998, more children were hospitalised with pertussis than with any other vaccine 
preventable disease and pertussis had the highest notification rate, both in children 
and overall.1 
 
The data presented in this thesis confirm that, despite the high notification rates for 
pertussis in the 1990s in Australia, notifications considerably underestimate the true 
incidence. Estimating the incidence of pertussis in any given geographical area and 
time period is difficult. Moreover, under-notification may not remain constant over 
time and between areas. The extent of under-notification among infants is highlighted 
in Chapters 2 & 3 in the comparison of notifications and hospitalisations. The extent 
of under-notification in adolescents and adults is likely to be even greater than in 
younger age groups. The implementation of laboratory notification and the 
widespread use of a commercially available serological kit by diagnostic laboratories 
in the early 1990s has resulted in notification of a much higher proportion of cases in 
older children than in comparable industrialised countries. However, data presented in 
this thesis show that notification rates in adolescents have continued to increase, 
despite the proportion of serologically diagnosed cases remaining constant since 1994. 
 
Notification and hospitalisation data are currently under-utilised in Australia. This 
thesis has highlighted their usefulness in monitoring disease incidence. Despite the 
limitations of routine data collections, these data provide valuable information about 
the epidemiology of pertussis and the impact of vaccination programs. In view of the 
continued burden of disease from pertussis and the changes in vaccination policy in 
Australia it will be important to continue and improve surveillance and to make better 
use of the data collected. Improvements include the incorporation into the national 
database of data available at a State/Territory level, such as date of birth, method of 
diagnosis and vaccination status. Additional research projects could be undertaken to 
determine the validity of various aspects of the notification and hospitalisation data.  
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Hospitalisation data in particular are under-utilised. This thesis demonstrates the value 
of hospitalisation data in examining variations in reporting practices, and suggests that 
hospitalisation data may be more useful for monitoring trends and making interstate 
and international comparisons in infant pertussis than notification data. 
 
The case definition for pertussis notification in Australia is currently under review, yet 
we have no idea to what extent notified cases meet the current case definition or 
whether this varies between the States and Territories. Problems with the available 
method of diagnosis data in NSW were identified in Chapter 3 — validation of these 
data would be useful and could result in improved recording. Two studies undertaken 
in NSW have examined the notifying practices of general practitioners,2,3 but no 
studies have examined the notifying practices of hospital doctors. Anecdotal evidence 
suggests that doctors in hospitals are less likely to notify, as it is less clear whose 
responsibility it is to notify the local public health unit. Such validation studies would 
assist the interpretation of routinely collected data. 
 
Although complete vaccination of all children is the most important preventive 
measure in maintaining control of pertussis,4 prior to this thesis, no published data on 
the effectiveness of pertussis vaccines used in Australia were available. Since 1993 
there have been significant changes in the Australian standard vaccination schedule 
with respect to pertussis control. In 1994, a fifth dose of DTP for children aged 4–5 
years was added to the schedule. The impact of this additional booster dose on 
notifications in the 5–9year age group is evident from the detailed age-specific data 
presented in Chapters 2 & 3. The 5–9 year age group now has lower notification rates, 
compared with historical data and relative to 10–14 year olds, whose notification rates 
currently exceed those of any other age group, including infants.  
 
In children aged less than two years there is an association between eligibility for 
vaccination and notification/hospitalisation rates (Chapter 3). The decrease in 
notification and hospitalisation rates strongly suggests an effect of vaccination. The 
analyses which demonstrated this would not have been possible without information 
on the date of birth and/or the age in months at disease onset. In the future, as the 
national data collection improves, these analyses should be repeatable at a national 
level and should become part of routine notification reports. 
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The other important change in the Australian vaccination schedule was the licensing 
of acellular pertussis vaccines in 1997. It was hoped that these vaccines, which have 
fewer side effects than whole -cell vaccines, would result in improved uptake of 
pertussis vaccine. Coverage at 12 and 24 months of age, as recorded on the ACIR, has 
improved since acellular vaccines were licensed but the contribution of acellular 
vaccines to this improved coverage cannot be distinguished from that of other 
program initiatives using the available data. Since 1999, acellular vaccines have been 
funded nationally for all doses. The ability to track changes in vaccine type over time 
at a national level, as shown in Chapter 4, would not have been possible before the 
ACIR was established. In the year 2000, the ACIR recorded use of only a very small 
proportion of whole-cell pertussis vaccines (Chapter 4). It will be important to 
monitor trends in pertussis hospitalisation and notification rates among infants, using 
methods similar to those described in this thesis, to evaluate the combined impact of 
pertussis vaccine coverage and acellular vaccine effectiveness in this target group. 
 
The importance of monitoring the vaccine effectiveness of routinely used, publicly 
funded vaccines was highlighted by the presentation in Chapter 6 of previously 
unavailable VE estimates for pertussis in New South Wales. VE estimations should be 
incorporated into routine analyses of notification data using coverage data from the 
ACIR. The impact of the introduction of the fifth dose on pertussis notification rates 
in 10–14 year olds will need to be closely monitored. Uptake of the new booster dose 
for adolescents and adults also needs to be monitored to determine its effect. The 
ACIR records only vaccines given to children below the age of seven years, so 
alternative methods of measuring vaccine uptake will need to be used for adolescents 
and adults. 
 
More important than the individual pertussis vaccine effectiveness figures presented 
in this thesis is the process involved in their calculation. The methodology developed 
in Chapter 6 for the routine monitoring of pertussis vaccine effectiveness, involved 
linkage of previously isolated data sets (pertussis notification data and ACIR data). 
This has the potential to be incorporated into routine evaluation of other diseases for 
which vaccines are available. One of the main drawbacks of the VE study presented 
here was difficulty in determining whether the measured differences in VE (between 
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areas and over time) were real or attributable to inaccuracies in vaccine coverage data. 
In the future, as the ACIR matures, this will be less of a problem, as it will be possible 
to use population coverage data of the cohort of children from which the cases arose, 
thus improving the precision of the VE estimates. In addition, checking the 
immunisation status of cases will be easier and the population estimates will be more 
accurate. 
 
In spite of high levels of vaccination amongst infants, pertussis continues to challenge 
Australian public health authorities. Factors responsible for difficulties in pertussis 
control include the limited duration of protection, problems associated with diagnosis 
of pertussis, especially in older or vaccinated persons and during the early most 
infectious phase. The data presented in this thesis can be used as a baseline for the 
assessment of future strategies aimed at pertussis control. 
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This appendix contains an application to the Ethics Committee of the Children’s 
Hospital at Westmead. I was responsible for writing most of this study proposal but 
not the parts which address aims 4 & 5 (the utility of clinical symptoms as a screening 
tool for pertussis and validating the test properties of symptomatology as a screening 
tool against serology). The analyses of some of the data resulting from this study form 
the major part of another student’s masters thesis. 
 
Short Title of Project:   
Survey of cough and pertussis immunisation status in children 
 
Investigators: 
1. Dr Raina MacIntyre MAppEpid, PhD, FRACP, FAFPHM, Senior lecturer. Email 
address: RainaM@chw.edu.au  
2. A/Prof Peter McIntyre PhD FRACP FAFPHM, Deputy Director. Email address: 
Peterm@chw.edu.au  
3. Ms Michelle Cagney BSc – Third year Graduate Medical Program student of 
University of Sydney, undertaking an MPH program in 2000. Email address: 
MichelC5@chw.edu.au  
4. Ms Siranda Torvaldsen GradDipHSci(Epi&Stats), MAppEpid, Research 
Officer/PhD Candidate. Email address: SirandaT@chw.edu.au 
 
National Centre for Immunisation Research and Surveillance of Vaccine Preventable 
Diseases 
The Children’s Hospital at Westmead 
Telephone: (02) 9845 0520 
Facsimile: (02) 9845 3082 
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SCIENTIFIC PROTOCOL 
Aims 
1. To estimate the incidence of pertussis in New South Wales children aged 5–14 
years.  
2. To determine vaccination coverage in children aged 5–14 years. 
3. To estimate the effectiveness of pertussis vaccination.  
4. To assess the utility of clinical symptoms as a screening tool for pertussis. 
5. To validate the test properties of symptomatology as a screening tool against 
serology. 
Simple description 
Whooping cough (pertussis) is epidemic in Australia, with an increasing proportion of 
cases in older children and adolescents. The study has two parts: 
1. A cross-sectional telephone survey will be conducted to determine cough 
symptomatology, history of respiratory illness, vaccination history and risk factors 
in 2000 children aged 5–14 years in Western Sydney Area Health Service 
(WSAHS).  All children will be invited to participate in the second part of the 
study. 
2. A cross-sectional serosurvey will be conducted to determine exposure to pertussis 
in 200 consenting subjects from part (1). 
Background 
Pertussis in NSW 
In terms of morbidity and mortality, pertussis is the most important vaccine 
preventable disease in Australia. Pertussis has been epidemic in Australia since 19931 
and has been responsible for six infant deaths in New South Wales since late 1996. 
Immunisation has changed the epidemiology of pertussis, with an increasing 
proportion of cases now seen in older children, adolescents and adults. These 
populations may then transmit pertussis to neonates and infants who are most 
vulnerable. 
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Symptoms as a screening tool 
Attempts have been made to develop clinical definitions of pertussis based on the 
associated symptoms.  An American study by Wright et al2 (1995) found that 21% of 
people ³18 years presenting to the emergency room of an urban university hospital 
had evidence of pertussis infection. Similar results were reported by Schmitt-Gohe et 
al3 (1995) who also found a weak association with the presence of a whoop (38% of 
subjects, 24/64). A Sydney-based study4 examining the spectrum of symptoms in 
adults with notified pertussis aged ³20 years found that 82% (60/73) experienced 
paroxysms, 66% (48/73) an inspiratory whoop and 62% (47/73) reported post-tussive 
vomiting.  
 
Whilst various clinical case definitions exist, there is no universal consensus as to 
which definition should be accepted. It has been well documented that the sensitivity 
of laboratory-based diagnostic tools decreases in an individual with a history of 
pertussis immunisation.5 To this end, a more sensitive clinical diagnosis may help to 
diagnose and treat adolescent and adult cases of pertussis which, although endemic, 
are under-diagnosed. 
Vaccine effectiveness 
Vaccine effectiveness (VE) studies become particularly important when disease 
incidence does not predictably decrease with increased vaccine coverage, when high 
proportions of fully immunised cases are reported or when issues arise that were not 
predicted in pre-licensure evaluations.6 At present one of the investigators of this 
proposed study is also undertaking a study which aims to estimate VE in New South 
Wales children using the screening method. The screening method estimates VE by 
comparing the proportion of persons with the disease who are vaccinated with the 
proportion of the population who are vaccinated.7-10  
Justification for this study 
The study will enable us to determine the rate of pertussis disease and vaccination 
coverage in older children and adolescents, and to evaluate the sensitivity of various 
clinical algorithms in the diagnosis of pertussis. Symptomatology may be an 
important screening tool in the adolescent and adult populations, where pertussis is 
poorly diagnosed.   
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Using vaccine coverage information, VE estimates could be calculated and compared 
with estimates using notified cases. The study will provide information on the effect 
of case ascertainment bias and help predict true VE figures. There was a change to the 
standard immunisation schedule in 1994 with the introduction of a 5th dose for 4-5 
year olds. Some of the study subjects will have been eligible for this dose, thus 
allowing its effectiveness to be evaluated. 
Methods 
Subjects  
Children aged 5–14 years living in the general community in WSAHS. The first part 
of the study will involve a telephone survey of 2000 such children. In the second part 
of the study, 10% of subjects will be tested for pertussis by serology. This will 
comprise of 50 (cough) and 150 controls (no cough). 
Recruitment of subjects and controls 
Two thousand households with at least one child aged 5–14 years of age will be 
selected from WSAHS. Where a household has more than one child of eligible age, 
the child with the birth date closest to the interview date will be selected. Consenting 
parents or guardians will be interviewed using a structured questionnaire (attached). 
Two hundred subjects (50 cases with cough and 150 controls without cough) will be 
selected for serological testing. If >200 subjects consent, 50 cases and 150 age-
matched controls will be randomly selected. A nurse experienced in venesection will 
do home visits, will provide a plain language statement, obtain consent and collect 
blood. Written, informed consent will be sought from the parent/guardian. However, 
if the child refuses, venesection will not be performed.  
Power analysis and sample size  
Sample size was calculated to detect a prevalence of cough of 5% with a 95% 
confidence interval and 80% power. Allowing for a refusal rate of 20%, 2000 
households in WSAHS with at least one child aged 5–14 years of age will be 
randomly selected from the White Pages for the telephone survey. 
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Measuring instruments: 
A. Questionnaire & interview  
The telephone survey will be conducted using computer assisted telephone interviews 
(CATI). These will be undertaken by the NCS Australasia Ply Ltd. A pilot survey will 
be conducted prior to the commencement of the study.  
Outcome variables measurement 
The questionnaire will determine risk factors for cough, a history of ever having had a 
cough lasting 2 weeks or longer, and whether the coughing illness was in the previous 
12 months and associated with any other symptoms such as a ‘whoop’ or post-tussive 
vomiting. Respiratory disease history and DTP immunisation history will also be 
sought.  
Validation of symptomatology 
The symptoms reported by study subjects will be validated using pertussis serology 
from children who reported a cough history suggestive of pertussis and from those 
who did not report cough.  Various symptom clusters will be analysed against results 
of serology to determine the most sensitive method of diagnosing pertussis clinically. 
B. Laboratory methods 
An ‘in house’ enzyme linked immunosorbent assay (ELISA) will be used to measure 
antibodies (IgG) to pertussis antigens (pertussis toxin and filamentous 
haemagglutinin) at the serology laboratory of the Children’s Hospital at Westmead.  
Analysis of data 
Rates of cough 
The following rates in children aged 5–14 years will be calculated: 
1. Cough lasting 2 or more weeks 
2. Cough lasting 3 or more weeks 
3. Cough lasting 2 or more weeks with one other symptom 
4. Cough lasting 3 or more weeks with one other symptom  
5. Doctor-diagnosed pertussis 
6. Age-specific rates of all the above. 
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Immunisation status 
The proportion of subjects fully immunised, partially immunised and unimmunised 
will be calculated. Also, the proportion of children whose parents can verify the 
immunisation status by referring to the dates in a written record will be calculated. 
These proportions will also be calculated by age group. 
Vaccine effectiveness (VE) 
VE will be estimated by age group by the formula VE = 1-[PCV/(1-PCV) x 1-
PPV/PPV], where PCV is the proportion of the vaccinated population with the disease 
and PPV is the proportion of the population vaccinated.  
Validation of symptoms against serology 
Symptom clusters will be analysed in cases and controls to determine their test 
characteristics as a screening tool for pertussis using 2 x 2 tables for diagnostic tests, 
and by using serology and clinical history of pertussis, alternatively, as the gold 
standard. 
 
The data collected will be analysed by the statistical software “EpiInfo version 6.04” 
and SAS. Statistical significance will be defined as a p-value of 0.05 or less. 
Interpretation and application of results 
The effect of applying different case definitions will be examined. The utility of 
symptoms as a screening tool for pertussis in older children will be evaluated. Some 
of the results of this study will be included in Michelle Cagney’s masters thesis. The 
study results will also be submitted for publication in a peer-reviewed journal. 
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ETHICAL ANALYSIS 
Potential risks 
This study poses no risk for participants of the telephone survey. A blood sample will 
be taken from those respondents who agree to the serology test. The disadvantage of 
performing venesection is the possibility of minor pain and possible bruising at the 
needle site. The rate at which these side effects occur is operator dependent but they 
occur at a low frequency. EMLA patches will be provided.  
Potential benefits  
Successful completion of this research topic will provide a number of benefits. Firstly, 
it would provide an estimate of the prevalence of pertussis and vaccine coverage 
among children aged 5–14 years in NSW. Secondly, a sensitive and specific clinical 
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definition of pertussis will allow the doctor to order the appropriate laboratory-based 
tests earlier in the disease than at present, increasing the chance of obtaining a true-
positive result. It would also make it possible to estimate the effectiveness of the 
current vaccine schedule, with recommendations being made to the appropriate 
governing bodies on the introduction of an adolescent booster dose of the pertussis 
vaccine. 
Research plan 
Proposed date of commencement  
The proposed commencement date for the interviews is at the end of June and 
throughout July 2000 (after peak pertussis activity has ceased). 
Estimated duration 
It is estimated that the serology samples will be collected by August, with analysis and data 
cleaning occurring in November. A report is to be prepared by the end of December 2000. 
Budget  
CATI survey (by NCS, including pilot, including GST)        $  74,800 
Serology (reagents only, including GST)                  $    8,800 
Nurses for venesection                                           $  20,000 
Laboratory staff time                                             $  10,000 
Telephone, stationary, miscellaneous         $    2,000 
TOTAL                                $155,600 
Source of funds 
The project is being funded by SmithKline Beecham Biologicals, whom we approached for 
funding.  It is an investigator-driven study and SmithKline Beecham has had no input into the 
study aims, design or execution, and will not have any such input. 
Staffing 
Telephone surveys will be conducted by experienced staff at NCS Australasia Pty Ltd, 
a market research company selected by competitive  tender. Blood samples will be 
obtained by the clinical nurses working for the NCIRS, whilst serology will be 
Appendix 1. Study proposal for a cough and pertussis immunisation status survey  
 
 
219 
performed by the microbiology department at the Children’s Hospital at Westmead. 
Analysis will be conducted by Michelle Cagney, a student at the NCIRS. 
Care of participants  
This study will not affect the child’s relationship with this hospital. Parent information 
and consent forms have been drafted and are attached to this application. The serology 
performed on those who agree to the test will be informed of their anti-pertussis 
antibody titre and what that means to their immunity against pertussis.  This would be 
of benefit in terms of preventing spread of pertussis within the family/household by 
immunisation. Non-immune individuals will be advised to be immunised. 
Additionally, participants are free to contact Michelle Cagney or Dr Raina MacIntyre 
if they have any concerns. NCS Australasia are experienced in health surveys and 
may also be available to help with distressed parents during the interviews. 
Review of progress 
Weekly survey updates will be supplied by NCS Australasia for preliminary analysis 
and approach of parents re the serologic survey. It is not envisioned that there will be 
any need to prematurely terminate the study. 
Management of adverse events  
Concerned parents are encouraged to call NCIRS if they think that their child has 
been adversely affected by participation in this study. If the child becomes ill or is 
injured as a result of participation, then reasonable costs of medical treatment will be 
paid by the Children’s Hospital at Westmead 
Winding up procedures 
This study does not involve any long-term, on-going care of participants. Feedback 
from this study to participating families will be in terms of their child’s antibody 
levels against pertussis. The serology performed on those who agree to the test will be 
informed of their anti-pertussis antibody titre and what that means to their immunity 
against pertussis.  This would be of benefit in terms of preventing spread of pertussis 
within the family/household by immunisation. Non-immune individuals will be 
advised to be immunised. 
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Access to data 
Data will be kept on password protected computer files for the duration of the 
research. Hard copies of the questionnaire will be kept in a locked filing cabinet. Only 
the study investigators will have access to the computer and paper files. The computer 
files will be kept long term in a password protected database. All identifying data will 
be coded and de-identified for participant’s privacy.  
Will data be collected from a government agency? 
No data will be obtained from any government agency for use in this study. 
Storage or disposal of data 
Data will be kept on password protected computer files for the duration of the 
research. The computer files will be kept long term in a password protected database. 
Hard copies of the questionnaire will be kept in a locked filing cabinet. The paper 
files will be retained for five years and will be disposed of using a document shredder. 
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DECLARATION 
We undertake to carry out the research project (Survey of cough and pertussis 
immunisation status in children) as described in this application and to comply with 
the general and specific conditions laid down by the Ethics Committee. 
 
We do not have a commercial interest in the outcome of this study 
 
We also undertake to notify the Ethics Committee should any changes to the protocol 
be necessary, should any unexpected complications or adverse events take place, or 
should the study be abandoned for any reason. 
 
The results of the study will be reported to the Ethics Committee annually during the 
course of the study and at its conclusion. A copy of any abstracts or publications 
resulting from the project will be submitted to the Research and Development Office. 
Signatures: 
 
Dr Raina MacIntyre ________________________ Date _________ 
 
Dr Peter McIntyre __________________________ Date _________ 
 
Ms Michelle Cagney ________________________ Date _________ 
 
Ms Siranda Torvaldsen ______________________ Date _________ 
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NSW Cough Survey Questionnaire 
“Hello, my name is ____________. I am calling about an important study on chest 
problems and immunisation in children aged 5–14 years in Western Sydney, on behalf 
of the New Children’s Hospital at Westmead.  We would like to interview the person 
most involved with the children in the household. We don’t need to know any names 
or personal details. Could you spare a little time to answer some quick questions?  
1  Agreed ®  go to question CIN1 
2  Refused ® EXIT 
3  Business ® EXIT 
4  Institution ® EXIT 
5  Fax machine ® EXIT BUT COME BACK FOR ONE CALL BACK 
6 Answering machine ® EXIT BUT COME BACK FOR ONE CALL BACK 
7 No answer ® EXIT  
8  Not a resident of WSAHS ® EXIT 
9  Hang up – thinks we want money ®CALL BACK  
10  No children aged 5–14 years ® EXIT 
 
CIN1 Thank you very much. The study will help us in understanding some common 
chest problems in children. Just to let you know, your phone number has been 
randomly selected from the phone numbers in your area.  
 
CIN2: Do you have any children aged 5 to 14 years that usually live in this 
household?  (“live in this household” means all 5 days of the school week)  
Yes   1 ® go to CIN3  
No   2   ® thank you but this study is only about children aged 5–14,  
goodbye 
Refused 3 ® Encourage to participate  
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CIN3 How many children live in the household? 
a. Fixed number ______  
b. Variable number  ® go to CIN4 
 
CIN4 If the number of children living in the household varies, could you tell me why?
     
 
CIN5 We would appreciate your involvement in this study, is now a convenient time? 
Yes  ®  go to CIN6 
No, now is not a good time ® make an appointment  
Refusal ® encourage to participate 
 
CIN6  
IF ONE ELIGIBLE CHILD: Automatic selection of that child 
IF MORE THAN ONE ELIGIBLE CHILD: We are collecting information about one 
child from each selected household and now we would like to select that child.  
Select child whose birthday is next. 
We would like to interview the parent/carer of the child X. Could I have that child’s 
first name? ____________________ (you can use a pretend name for the interview) 
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CIN7 Because this survey is about child health we need to speak to the parent or carer 
who knows most about the child’s health. Is that you? 
(If necessary prompt: “knows most” is the one who took to child to get immunised or 
to the doctor when the child was sick) 
1 Yes: I know most about the child’s health 
3 No: I’ll get them 
4 No: not at home at present ® make an appointment 
5 Refusal: ENCOURAGE TO PARTICIPATE ®  ask for reason 
why________________________ ®  thank you and goodbye® exit 
6 Unavailable for duration of survey ® exit 
7 Main carer doesn’t speak English ® Which language? ____________®thank you 
and goodbye® exit 
 
CIN8  What is your relationship to the child? 
Mother 
Father 
Stepmother 
Stepfather 
Grandmother 
Grandfather 
Sibling 
Legal guardian 
Other __________________  
Don’t know 
Refused 
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Section 1:Questions about cough 
COU1 Has your child been diagnosed with having any of the following illnesses by a 
doctor or at a hospital? 
a. Pneumonia ever 
     Yes 1  (go to pn1)  
No 2   go to COU 1b 
Unsure3 
pn1: how many times has your child been diagnosed with pneumonia? 
Once   1 
More than once 2 
 Answer the below questions for the most recent episode. 
pn2: What year was this (or how old was your child) __________________  
pn3: Was your child admitted to hospital for pneumonia?   
Yes 1   
No 2   go to COU 1a pn5 
Unsure3 
pn4: Length of stay: 
 Overnight 
 More than one night 
pn5: Where was pneumonia diagnosed: 
 Doctor’s surgery 
 Hospital: ward 
 Hospital: emergency department 
 Other (including self) ____________  
 
pn6: Was your child given antibiotics? Yes 1  No 2   Unsure3 
pn7: Was a chest x-ray done?   Yes 1  No 2   Unsure3 
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b. Bronchitis in the last year? 
      Yes  1   
No  2   go to COU 1c 
Unsure3 
Was hospital admission required  Yes 1  No 2   Unsure3 
 
c. Whooping cough ever? 
       Yes    1  
No     2  go to COU 1d 
Unsure3 
wc1: How many times was your child diagnosed with whooping cough? Answer the 
below questions for all episodes 
wc2: What year was this (or how old was your child)? ___________________ 
wc3: In what month was whooping cough diagnosed? ______________________ 
wc 4: Was hospital admission required Yes 1  No 2   Unsure3 
wc5: What, if any, were done for whooping cough (one or more)? 
 Blood test 
Nose swab 
Yes, but unsure of the test 
Other 
No tests were done 
Unsure 
wc6: Which, if any, of the tests show whooping cough (one or more)? 
Blood test 
Nose swab 
Yes, but unsure of the test 
Other 
No  tests showed whooping cough 
Unsure 
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d. Croup in the last year? 
       Yes  1   
No  2  go to COU 1e 
Unsure  3 
Was hospital admission required  Yes 1  No 2   Unsure3 
 
e. Asthma ever? 
Yes  1   
No  2   go to COU 1f 
Unsure 3 
 
as1 Age at diagnosis    ____ years 
as2 Was this in the last year    Yes 1  No 2   Unsure3 
as3 Was hospital ever  required  Yes 1  No 2   Unsure3 
as4 Has your child needed to take any asthma medication or “puffer” (such as 
ventolin, flixotide or atrovent ) in the last year?    
Yes 1  No 2   Unsure3 
 as5 How many episodes of wheezing has your child had in the last year? ______ 
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f. Has your child ever been diagnosed with any other lung problem ? 
   If yes ® Please specify: Diagnosis  
   Cystic fibrosis 
   Pleurisy 
   Pneumothorax 
   Pleural effusion 
   Bronchiestasis 
   Tuberculosis 
   Bronchiolitis 
   Allergic bronchopulmonary aspergillosis 
   Lung transplant 
Bronhopulmonary dysplasia (Hyaline membrane 
disease/chronic lung disease of infancy) 
   Post-cancer or post-cancer therapy lung disease 
   Foreign body 
   Pneumocystis carinii Pneumonia  
   Immotile ciliary syndrome 
   Other, please specify _______ 
    
No  2   go to COU 1g 
Unsure  3 
 
g. Does your child have any other long-term health problem(s) which he/she has to 
visit a doctor or hospital regularly for? 
Yes      1  
No      2® go to COU2 
Unsure     3® go to COU2 
If yes ® Please specify: Diagnosis ___________________ 
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COU2 Has your child had a continuous cough that lasted for 2 weeks or more in the 
last year? 
Yes      1  
No      2® go to section 2 
Unsure     3® go to section 2 
 
COU3  On how many occasions did your child have a cough of 2 weeks or more 
followed by at least 1 week without coughing? 
a. Once   1 
b. More than once  2  
 
COU4  
a. How many weeks was the longest coughing illness your child had in the last year? 
______ weeks  
b. Do you remember what month of the year in which the cough started? ________ 
 
COU5  During this or these coughing illness(s) in the last year, did your child 
experience any of the following? 
a. Wheeze    Yes 1  ® go to COUa1 
No 2® go to COU5 b 
    Unsure 3® go to COU5 b 
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a 1: If yes, did your child’s wheezing frequency change during the coughing illness? 
      Yes 1   
     No 2    
     Unsure3 
 
b. A visit to the doctor about the cough Yes1  
No 2    
Unsure3 
 
c. Pains in the muscles and joints  Yes 1  No 2   Unsure3 
 
d. Bursts of coughing for minutes at a time Yes 1  No 2   Unsure3 
 
e. Rash      Yes 1  No 2   Unsure3 
 
f. Nasal congestion     Yes 1  No 2   Unsure3  
 
g. Coughing so hard that he/she had to draw breath suddenly (a whoop) 
      Yes 1  No 2   Unsure3 
 
h. Fever       Yes 1  No 2   Unsure3 
 
i. Sore throat      Yes 1  No 2   Unsure3 
 
j. Sore ribs/chest/back due to coughing?  Yes 1  No 2   Unsure3  
 
k. Shortness of breath     Yes 1  No 2   Unsure3 
 
l. Coughing followed by vomiting  Yes 1  No 2   Unsure3 
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m. Fever      Yes 1  No 2   Unsure3 
 
n. Headache     Yes 1  No 2   Unsure3 
 
o. Sinus      Yes 1  No 2   Unsure3 
 
p. Night cough     Yes 1  No 2   Unsure3 
 
q. Fatigue      Yes 1  No 2   Unsure3 
 
r. Flushed face     Yes 1  No 2   Unsure3 
 
s. Did the coughing bring anything up? Yes 1  No 2   Unsure3 
 
t. Hoarseness or loss of voice    Yes 1  No 2   Unsure3 
 
u. Stopped breathing for a short time following coughing  
      Yes 1  No 2   Unsure3 
 
v. Going blue about the mouth following coughing  
      Yes 1  No 2   Unsure3 
 
COU6  This question only for those who answered “yes” to question COU 5b: What 
was the coughing illness diagnosed as?  
Asthma  (do logic check) 
Pneumonia (do logic check) 
Viral illness (do logic check) 
Bronchitis (do logic check) 
Sinusitis (do logic check) 
Whooping cough (do logic check) 
Laryngitis (do logic check) 
Upper respiratory tract infection (do logic check) 
Other ______________ 
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 COU7 In the month before your child started coughing, had he/she been around 
anyone else who had:     
a. a troublesome cough  Yes 1 ® COU8 
  No 2   go to COU 7b 
Unsure3 
 
b. been recently diagnosed with whooping cough? 
Yes 1 ® COU 9 
No 2   go to COU 10 
Unsure3 
 
COU8 What is the relation of that person to your child? 
Mother/stepmother 
Father/stepfather 
Legal guardian 
Sibling 
Grandparent 
School mate 
Teacher 
Other ______________________ 
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COU9 What is the relation of that person to your child? 
Mother/stepmother 
Father/stepfather 
Legal guardian 
Sibling 
Grandparent 
School mate 
Teacher 
Other ______________________ 
 
COU10 After your child started coughing, did anyone else:  
a.  develop a troublesome cough Yes 1 ® COU13 
No 2   go to COU10b 
Unsure3 
 
b.  have a diagnosis of whooping cough? 
Yes 1 ® COU14 
No 2   go to section 2 
Unsure3 
 
COU13 What is the relation of that person to your child? 
Mother/stepmother 
Father/stepfather 
Legal guardian 
Sibling 
Grandparent 
School mate 
Teacher 
Other ______________________ 
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COU14 What is the relation of that person to your child? 
Mother/stepmother 
Father/stepfather 
Legal guardian 
Sibling 
Grandparent 
School mate 
Teacher 
Other ______________________  
 
Section 2: Demographic questions: children 5–14 years 
DEM1 What is your child’s date of birth? _ _ /_ _ /19 _ _ 
If respondent does not wish to give DOB, ask: 
What was your child’s age at his/her last birthday? _____ years 
 
DEM2 Is your child male or female?  
 Female   1 
 Male   2 
 
DEM3 Residence: 
a.   What is the postcode of your usual address? _____ 
(Normally means in the preceding school year) 
b. What suburb do you usually live in? _________ 
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DEM4 In which country was your child born? 
Australia ® go to DEM5 
New Zealand 
Pacific Islands     go to DEM 6 
Asia 
Europe 
Africa 
North America 
South America 
Other _____________________ 
 
DEM5 Is your child of Aboriginal or Torres Strait Islander origin? 
Yes   1  
No   2    
Unsure  3 
 
DEM6 Does your child speak a language other than English? (use full list of 
languages) 
Arabic 
Chinese 
Italian 
Greek 
Spanish 
Filipino 
Other _____________________________ 
 
DEM7 What type of educational institution (if any) does your child attend? 
Preparatory school 
Kindergarten 
Primary school 
Secondary school 
None 
Refused 
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DEM8 How many other people live in your household other than (name of surveyed 
child)? _______ 
Number of children younger than _______ (name of surveyed child)  
Number of children older than  _______ (name of surveyed child)  
Number of parents _________ 
Number of other adults ________ 
 
SECTION 3: Social context and Smoke exposure 
 
SE1 Does anyone in the household have a Health Care Card?  
Yes  1 
No  2 
Unsure 3 
Refused 4 
 
SE2 Does anyone in the household smoke? 
Yes  1 
No  2 
Unsure 3 
Refused 4 
 
Section 4:Questions about immunisation 
VAC1: We will ask you to refer to your child’s immunisation records (such as the 
“blue book”) later in the questionnaire, are you able to get these? 
Yes, I can get it now ® go to VAC 2       
 1 
Yes, but it will take some time ® Get a time to call them back   
 2 
No ® Let them know that it is not essential and encourage to continue   
 3 
Refused          
 4 
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The next few questions are about your child’s immunisation. The whooping cough 
immunisation is usually given to babies and preschool children in the same needle as 
diphtheria and tetanus and is called the “DTP” or “Triple antigen” vaccine. It is 
possible some children were not immunised against whooping cough and were only 
given a vaccine for diphtheria and tetanus known as the  “CDT” vaccine. 
 
VAC2 Did your child ever receive any vaccinations against whooping cough? 
Yes      1 ® go to VAC 4 
No      2 ® go to VAC 3 
Unsure      3 ® go to VAC 4 
 
VAC3 What were your reasons for not vaccinating your child against whooping 
cough? 
I don’t believe in immunisation/ disagree with immunisation 
Medical reasons 
Religious reasons 
Out of country 
Doctor didn’t offer the immunisation 
Forgot 
Other ____________ 
Refused 
 Now go to VAC8 
 
VAC4 Do you have your child’s immunisation records in front of you? 
Yes 1 
No 2 ® Encourage them to continue on, trying to recall the dates of 
immunisation 
 
VAC5 Has your child received: 
 
    The first dose due at approximately 2 months of age: 
 Yes    1 
Date of first dose and type from record   _ _/_ _/19 _ _ CDT 
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DTP 
Recalled date and type of vaccine    _ _/_ _/19 _ _  CDT 
Or age__ DTP 
No    2 
Unsure    3 
Refused   4 
 
The second dose due at approximately 4 months of age: 
Yes    1 
Date and type of second dose from record   _ _/_ _/19 _ _ CDT 
DTP 
Recalled date and type of vaccine    _ _/_ _/19 _ _  CDT 
Or age__ DTP 
No    2 
Unsure    3 
Refused   4 
 
The third dose due at approximately 6 months of age: 
Yes    1 
Date and type of third dose from record   _ _/_ _/19 _ _ CDT 
DTP  
Recalled date and type of vaccine     _ _/_ _/19 _ _ CDT 
Or age__ DTP 
No    2 
Unsure    3  
Refused   4 
 
The fourth dose due at approximately 18 months of age: 
Yes    1 
Date and type of fourth dose from record   _ _/_ _/19 _ _ CDT 
DTP 
Recalled date and type of vaccine    _ _/_ _/19 _ _  CDT 
Or age__ DTP 
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No    2 
Unsure    3 
Refused   4 
 
For children who turned 6 years  in 1995 or later: 
Did your child receive the fifth dose vaccine due at approximately 4 years of age or 
just before school entry: 
Yes    1 
Date of fifth dose from record    _ _/_ _/19 _ _  
Recalled date        _ _/_ _/19 _ _ or age 
No    2  
Unsure    3 
Refused   4 
 
For children who turned 4 years old in 1997 or later:  
The new “acellular” whooping cough vaccine became available in the middle of 1997. 
Until the beginning of 1998 having your child immunised with the acellular vaccine 
would have incurred an extra cost. Do you know the name of the vaccination your 
child received as the fifth dose?  
(PROMPT: did you pay for the 5th dose?) 
What type of vaccination did your child receive as the 5th dose? 
Whole cell DTP/‘Triple antigen’ 1  
CDT       2  
Tripacel (or acellular DTP)   3 
Infanrix (or acellular DTP)  4  
Unsure     5 
Other     6 
 
The following two questions concern possible side effects following the whooping 
cough vaccine:  
Appendix 1. Study proposal for a cough and pertussis immunisation status survey  
 
 
240 
VAC6 Did your child experience any side effects or reactions following the whooping 
cough vaccination, including redness and swelling about injection site, pain in arm 
where they had the needle, fever, irritability, inconsolable crying, loss of appetite? 
Yes   1 ® go toVAC7  
No   2® go toVAC8 
Unsure   3 ® go toVAC8 
 
VAC7 
Which of these reaction(s) did your child have in the day or two following the 
whooping cough immunisation? (One or more answers): 
Redness about injection site  
Swelling about injection site 
Pain in arm where they had the needle  
Fever 
Irritability 
Inconsolable crying 
Loss of appetite 
Other, please specify ___________ 
Did you seek medical attention for the reaction? 
Yes   1 
No   2 
Unsure   3 
 
With what dose did your child have a reaction? 
Dose 1   1 
Dose 2   2 
Dose 3   3 
Dose 4   4 
Dose 5   5 
All doses   6 
More than one dose 7 
Unsure   8 
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ASK ALL: 
VAC8 I would like to thank you for your time and co-operation with this survey. 
Would you mind to having one of the members from the Children’s research team 
contact you in the next couple of months? This will be about participation in further 
research on childhood coughs. They will explain more when they get in touch. 
Yes:  
Name of person to contact ____________ 
Phone number _________________  
Preferred time to call: Day/Evening 
Child’s name _______________________ 
 
No 2 
 
END OF QUESTIONNAIRE 
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Summary  
Background: Notifications of pertussis have increased recently in Australia and other 
industrialised countries. This study estimates the effectiveness of pertussis vaccination 
in New South Wales children aged less than 14 years, during a period when an 
Australian whole-cell pertussis vaccine was in routine use.  
Methods: Cases notified with pertussis between 1996 and 1998 and pertussis vaccine 
coverage estimates from the Australian Childhood Immunisation Register were used. 
Vaccine effectiveness (VE) was calculated using the screening method in a logistic 
regression model which included age group, year of disease onset and area of 
residence.  
Results: VE was highest (91%) in the youngest age group (8-23 months) and lowest 
(78%) in the oldest age group (9-13 years). VE estimates were lower in 1998 than in 
the previous two years, particularly in one area.  
Conclusions: Pertussis vaccination, primarily with the Australian whole-cell pertussis 
vaccine, is highly effective at preventing pertussis in New South Wales children, as 
measured by notified cases. Although the screening method has many potential biases, 
trends in VE may still be monitored over time assuming these biases remains 
constant. Such ongoing monitoring will be important to evaluate VE following 
Australia’s change to an acellular vaccine based program. The approach described 
here enables this to be incorporated into routine surveillance. 
 
Keywords: vaccine effectiveness, pertussis, screening method 
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Introduction 
Pertussis (whooping cough) is the most important vaccine preventable disease, in 
terms of morbidity and mortality, in Australia1 and many other industrialised 
countries. In addition to the analysis and interpretation of disease surveillance and 
vaccination coverage data, there is a need for a monitoring system capable of 
detecting major shifts in the effectiveness of the pertussis vaccination program. 
Further indications for monitoring pertussis vaccine effectiveness (VE) include 
evidence of a major change in VE elsewhere,2 a lack of effectiveness data for the 
whole-cell vaccine previously used in Australia and the recent introduction of 
acellular vaccines. In Australia, pertussis vaccines are given with diphtheria and 
tetanus (DTP) at two, four and six months of age with a booster at 18 months of age. 
In 1994, a fifth dose of DTP was introduced, initially at 4-5 years and subsequently at 
4 years of age. A whole-cell vaccine, produced in Australia, was used exclusively 
until 1997, when acellular pertussis vaccines became available. In 1998, acellular 
vaccines replaced the whole-cell vaccine for the fourth and fifth dose and in 1999 for 
all doses. 
 
This study aims to estimate the effectiveness of the primary course (doses 1-3 due at 
2, 4 & 6 months of age) of the pertussis vaccination program in New South Wales 
(NSW) children  between 1996 and 1998, using the screening method. During this 
time period the whole-cell vaccine accounted for the great majority of pertussis 
vaccines used. The screening method compares the proportion of cases who are 
vaccinated (PCV) with the proportion of a comparable group in the popula tion who 
are vaccinated (PPV). It is a simple and rapid method which has been used to estimate 
pertussis VE in Nova Scotia,3 the United Kingdom,4 the United States,5 New Zealand6 
and the Netherlands.2 In Australia it has been used to estimate the effectiveness of 
Haemophilus influenzae type b vaccination7 but not pertussis vaccination. 
Methods 
Study Subjects  
All cases of pertussis notified to NSW Health from January 1, 1996 to December 31, 
1998 aged less than 14 years at the date of disease onset were selected from the 
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Notifiable Diseases Database (NDD) of the NSW Department of Health. Cases aged 
less than eight months were excluded to allow time for infants to complete the 
primary vaccination schedule for pertussis. 
 
The NDD includes information on the method of pertussis diagnosis and the number 
of doses of vaccine received, but not date of vaccination or type of vaccine 
administered (whole-cell or acellular). In this study, fully vaccinated cases are defined 
as in receipt of at least three doses of a pertussis-containing vaccine. Incompletely 
vaccinated children were excluded from VE analyses which were comparisons of 
fully vaccinated with unvaccinated groups, as described by Orenstein.8  
 
NSW is divided into eight rural and nine metropolitan health areas. Health areas in 
which vaccination status was not recorded for more than 25% of notified cases were 
excluded. Some geographically adjacent areas were combined. The areas studied 
include three metropolitan (Central & South Eastern Sydney, Western Sydney, and 
Wentworth) and two rural areas (Southern & Greater Murray, and Northern Rivers), 
which together comprise 46% of the NSW population.  
Population estimates 
Population coverage estimates were taken from the Australian Childhood 
Immunisation Register (ACIR). The ACIR contains information on the vaccination 
status of children born since January 1, 1996 (when the register commenced), who are 
either registered with the universal health insurer in Australia (Medicare) or have had 
a vaccination encounter reported by a vaccine provider to the ACIR.9 A 12-month 
cohort of 87 564 children born between 01/04/97 and 31/03/98 was selected from the 
ACIR and vaccination status at 12 months of age assessed as of 31/03/99. This time 
period was chosen to allow sufficient time since the ACIR commenced for accurate 
population estimates of immunisation coverage. Health area was determined by 
postcode of residence. PPV for each area was calculated by dividing the number of 
children fully vaccinated by the sum of the number of children fully vaccinated and 
unvaccinated (that is, incompletely vaccinated children were excluded). It was 
assumed that PPV did not change over the study time period. 
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VE estimation 
VE was estimated by fitting a logistic regression model using the method described by 
Farrington, whereby the number of vaccinated cases is treated as derived from a 
binomial distribution, with PCV as the parameter and number of cases (N) as the 
index.10 Proc Genmod  in the software package SAS11 was used for modelling. Logit 
PPV was specified as an offset in the model, and the variables age group, health area 
of residence and year of disease onset were included as potential confounders. The 
base model containing the three potentially confounding variables was fitted and the 
significance of each one tested (using the type3 option in SAS). The effects of all 2-
way interactions were tested for statistical significance (p<0.05) by adding them in 
turn to the base model. VE was calculated for each combination of age group, area 
and year by subtracting the exponentiation of the estimated linear predictor (XBETA 
in SAS) from one. Confidence intervals were calculated in a similar way using the 
standard error of the linear predictor (STD in SAS). 
 
In order to obtain overall estimates by area and age group, the average of the relevant 
parameter estimates for year, including the interaction terms, was calculated. To 
obtain overall estimates by year and age group, the parameter estimates for area, 
including the interaction terms, were weighted by population. The adjusted estimates 
of year and area were used to calculate VE for each age group, adjusted for year and 
area. The variances of these adjusted parameter estimates were calculated from the 
covariance matrix using Excel. 12 Confidence intervals were calculated using these 
variances.  
Results  
Pertussis notifications 
In NSW from 1996 to 1998, 3371 cases of pertussis in children aged 8 months to 13 
years from a known health area were notified. Of the 3371 cases, 1609 cases (48%) 
were resident in areas which were included in VE analyses. There was considerable 
variation among health areas in both notification rate and vaccination status of cases 
(Figure 1). After excluding the 256 cases whose vaccination status was unknown and 
the 75 cases who had received only one or two doses of the vaccine, there were 1278 
notified cases eligible for the VE analyses. 1997 was an epidemic year for pertussis in 
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NSW, with most areas experiencing an epidemic that year. Of the 1278 eligible cases, 
810 (63%) had a date of onset in 1997. 
 
Of the 1278 cases eligible for inclusion in the study, 6% were diagnosed based on a 
positive culture result, 70% on serology, 23% clinically and in 1% of cases the 
method of diagnosis was unknown. The proportions diagnosed by culture decreased 
with increasing age, from 30% in children aged less than two years to 4% in children 
aged 9-13 years, whilst the proportions diagnosed by serology increased with 
increasing age. 
Vaccination status of notified cases 
Of the 1278 cases eligible for inclusion in the study, 762 (60%) had received at least 
three doses of a pertussis-containing vaccine. Most (92%) of the vaccinated cases 
aged two years or older had received a fourth dose, while 51% of vaccinated 5–8 year 
olds and 21% of vaccinated 9-13 year olds had a fifth dose of vaccine recorded. 
Population estimates 
Vaccination coverage varied by area, with Southern and Greater Murray health areas 
having the highest coverage and Northern Rivers having the lowest (Table 1). 
The model 
The final model included age group, year of onset and health area, plus the interaction 
between health area and year. This model had a deviance of 46 with 42 degrees of 
freedom, suggesting that the model is an adequate fit of the data (p=0.3). In this model 
all variables were significant (p<0.001).  
Age group 
Age group was highly significant in the base model (c 23 =20, p<0.0001). The VE 
estimate, after adjustment for area and year, was highest in the 8 to 23 month age 
group and lowest in the 9 to 13 year group (Table 2).  
Health area and year of onset 
Health area was the most significant term in the base model (c 24 =91, p<0.0001) 
followed by year of onset (c 22 =41, p<0.0001). The interaction between year and area 
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was also highly significant (c 28 =28, p=0.0004). Estimates by area, adjusted for year 
(Table 3) and by year, adjusted for area (Table 4), were calculated.  
 
The 1998 VE estimates were considerably lower than the 1996 and 1997 estimates 
(Table 4). This effect was most marked in the Greater Murray/Southern area. When 
the model was run with the Greater Murray/Southern area excluded, the interaction 
term was no longer significant (p=0.6). Following removal of the interaction term, 
year accounted for less of the variability but was still significant (c 22 =6.3, p=0.04), 
and the 1998 VE estimates remained the lowest. 
Discussion 
This study shows that pertussis vaccination is highly effective at preventing pertussis 
in NSW children as it is measured by notified cases. The estimates in this study are 
not vaccine-specific but largely represent whole cell vaccines, as acellular pertussis 
vaccines have only been available free of charge for use in the primary course since 
February 1999. 1 The 1996 and 1997 VE estimates calculated in this study are similar 
to those reported in a New Zealand study which applied the screening method to 
notification data from the 1996 pertussis epidemic.6  
 
The degree to which notified cases represent all pertussis cases was not evaluated, but 
notified cases are clearly not a random sample and are likely to represent the more 
severe end of the disease spectrum. Over three-quarters of the notifications were 
laboratory confirmed, mostly by serology. Although not undertaken on these data, the 
effect of including only laboratory confirmed cases on VE estimates using pertussis 
notifications from 1993 to 1998 was examined.13 Including only laboratory confirmed 
cases slightly increased the VE estimates. The greatest increase was in the youngest 
age group who also had the greatest proportion of culture confirmed cases. Previous 
studie s have found that increasing the specificity by including only clinically severe 
or culture positive has increased the VE estimates.8,14 
 
Since the early 1990s, a commercially available enzyme-linked immunosorbent assay 
(ELISA) for IgA against whole -cell B. pertussis has been widely used in diagnostic 
laboratories throughout Australia. Although the validity of these tests are difficult to 
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evaluate without a diagnostic reference standard, a study undertaken in western 
Sydney found that cases notified on the basis of positive whole-cell serology had 
symptoms clinically consistent with pertussis almost uniformly, suggesting that 
notifications based on positive serology under-estimate, rather than over-estimate, the 
true incidence of pertussis.15  
 
Although this study aimed to measure the effectiveness of three doses of a pertussis-
containing vaccine, most cases who had received three doses and were eligible for a 
fourth dose had received it. Assuming that four doses of the vaccine is more effective 
than three doses, the effectiveness of three doses may have been over-estimated. Half 
of the cases in the 5 to 8 year old age group had received fifth dose. In the future we 
would expect this proportion to rise with a corresponding increase in the VE estimate, 
both overall and relative to the 9 to 13 year olds. 
Possible sources of bias 
Cases 
Cases with unknown vaccination status give rise to a potential selection bias. It is 
possible that cases who were not as readily followed up to check their vaccination 
status were less likely to be fully vaccinated than cases who were able to be followed 
up. However, excluding health areas where the vaccination status of a large 
proportion of cases was unknown minimises this bias. As parental recall generally 
over-estimates vaccination coverage, vaccination status of cases is more likely to be 
misclassified as vaccinated. 16 This would lead to an under-estimate of VE. 
 
Where VE estimates are derived from notifications, detection bias (ie the tendency to 
suspect pertussis less in persons known to be fully vaccinated) is an important 
potential problem leading to falsely high VE estimates.4 Although we are unable to 
determine the importance of this bias in NSW notifications, with the exception of 
possible increased reporting during epidemics, we would expect its effect to be 
reasonably constant over time. 
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Coverage estimates 
The ACIR did not commence operation until January 1996 so estimates of coverage 
are not available for all years in the study period. The cohort used for estimation of 
PPV was chosen in preference to earlier cohorts to allow time for improvement in 
reporting of vaccinations to the ACIR. Although estimates from the ACIR show that 
overall coverage with 3 doses of DTP in NSW increased from 75% in March 1997 
(the first cohort) to 84% in December 1998, most of this increase is believed to be due 
to increased reporting. It should be noted that the PPV values were incorporated into 
the model as fixed values, therefore the confidence intervals only relate to the error of 
the linear predictor and do not incorporate any error around the PPV values. 
 
Underestimation of vaccination coverage will tend to reduce VE estimates.5 The 
ACIR data most likely under-estimate current coverage due to incomplete reporting of 
vaccination status.9 However, if coverage has improved over the study period then the 
ACIR estimates used are most likely to have over-estimated coverage in the earlier 
part of the study period and in the older age groups. If coverage has increased, 
possibly due to a number of incentive schemes introduced by the Commonwealth 
Government since 1997,17 then this may be at least partly responsible for the 
apparently lower VE in 1998. Reporting to the ACIR may vary between health areas 
and could account for some of the regional differences in VE estimates. Coverage 
may have improved over the study period differentially between areas, which could 
explain the significance of the interaction between health area and year. From the 
results it seems likely that coverage increased more in the Greater Murray/Southern 
area than in other areas, if coverage increased at all in other areas. 
Age 
VE estimates were consistently highest in the youngest age group and lowest in the 
oldest age group. If true vaccine coverage was lower in the oldest age group then the 
VE estimates would be reduced even further in this group. Age is a proxy measure for 
time since vaccination. Vaccine-acquired immunity wanes with time18,19 so it is not 
surprising that VE is lowest in the older children. These results, together with the 
increasing median age of notified cases in Australia,1 suggest that childhood 
vaccination against pertussis is less effective against disease in adolescence. 
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Area 
Much of the variation in VE between areas could be due to inaccuracies in coverage 
estimates for some or all of the study period. However, differences in notification 
practices, handling and storage of vaccines and levels of exposure to pertussis may 
also account for some of the differences in VE. A comparison of NSW infant pertussis 
hospitalisation and notification data by health area suggests that some of the 
differences in notification rates between areas reflect differences in notification 
practices, as opposed to differences in pertussis incidence.13 
Year 
The VE estimates, adjusted for area, in 1998 were generally lower than in the 
previous two years, particularly in the Greater Murray/Southern area. The population 
coverage figures used in the model may be a more accurate reflection of true coverage 
in 1998 than in previous years. If this is the case, then the 1998 VE estimates are more 
realistic than those for 1996 and 1997. A study using similar methodology in the 
United States estimated pertussis VE between 1994 and 1996 in 7-18 month old 
children to be 82%,5 the same as our 1998 estimate in the youngest age group. 
Alternatively, coverage may have improved over the three year period with coverage 
being under-estimated for 1998, thus resulting in an under-estimate of VE in 1998. 
The most likely scenario lies somewhere in between these two alternative 
explanations, that is coverage has improved and was over-estimated for the years 
1996 and 1997 and under-estimated for 1998. It is also possible that differences in VE 
over the time period are due to differences in notification practices, although we have 
no evidence of changes to the notification system. 
 
The possibility that VE did actually decrease in 1998 should not be completely 
dismissed. A recent paper from the Netherlands reported a downward trend in VE and 
in 1997, the final year in which VE was analysed, the PCV exceeded the PPV.2 
Although there is no evidence of a mismatch of the vaccine strain and the circulating 
Bordetella pertussis strains in Australia, the ongoing surveillance of pertussis, 
including VE, is of paramount importance. 
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Conclusion 
Although the extent to which notified childhood cases of pertussis represent all 
childhood cases of pertussis is not known, the results of this study suggests that the 
pertussis vaccination program is highly effective, especially in younger children. 
Whilst the potential for biases inherent in the screening method is substantial, this 
approach has been used extensively elsewhere and is particularly useful for 
monitoring trends in VE, provided any bias remains constant over time. The strength 
of this methodology lies in its ease of application and the fact that it could be 
incorporated into routine surveillance of vaccine preventable diseases. 
 
As the ACIR matures, checking the immunisation status of cases in Australia will be 
easier and the population estimates more accurate. In addition, it will be possible to 
use the population coverage data of the cohort of children from which the cases arose, 
which will improve the precision of the VE estimates. In contrast to the previous 
studies which have used the screening method to estimate pertussis VE,2-6 we have 
been able to use regional coverage data. Although logistic regression has been used in 
one previous screening method study which included year and age as potential 
confounders, it did not include area or use area-specific population coverage values.4 
In the United Kingdom it was felt that the use of national coverage data may have 
produced artificially high VE estimates4 and Farrington illustrates the confounding 
effect of pooling population coverage data.10 In Australia, the regional coverage data 
available from the ACIR should be incorporated in all future pertussis VE studies 
which use the screening method. This will be particularly important in monitoring the 
impact of the change to acellular pertussis vaccines as well as shifts in vaccine 
effectiveness possibly attributable to other factors such as population shifts in 
prevalent strains of Bordetella pertussis. 
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Figure 1. Pertussis notifications by health area and vaccination status in NSW 
children aged 8 months to 13 years, 1996-1998  
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Table 1. Pertussis vaccination coverage by NSW health area(s) for children aged 12 
months of age, 1996-1998  
Health area(s) % fully 
vaccinated* 
% partially 
vaccinated† 
% 
unvaccinated‡ 
PPV 
(full/(full+none)) 
Central & SE Sydney 82 8 10 0.893 
Western Sydney  83 9 7 0.920 
Wentworth  87 7 6 0.939 
Northern Rivers 81 10 10 0.893 
Greater Murray & Southern  88 8 4 0.957 
Total 85 8 6 0.930 
*3 doses, †1-2 doses, ‡0 doses 
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Table 2. VE estimates by age group, adjusted for year and NSW health area, 1996-
1998  
 Vaccinated cases 
(PCV %) 
Total cases VE (%) 95% CI (%) 
8 to 23 month olds 39 (49) 80 91.0 85.5 to 94.4 
2 to 4 year olds 106 (55) 192 84.5 78.3 to 88.9 
5 to 8 year olds 223 (53) 421 86.5 82.7 to 89.5 
9 to 13 year olds 394 (68) 577 77.6 71.7 to 82.3 
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Table 3. VE estimates by NSW health area(s) and age, adjusted for year, 1996-1998 
 Vaccinated 
cases 
Total cases VE (%) 95% CI (%) 
8 to 23 month olds     
Central & SE Sydney 5 20 93.9 89.5 to 96.5 
Northern Rivers 6 15 96.8 93.7 to 98.3 
Western Sydney  13 16 88.9 81.1 to 93.5 
Wentworth 9 15 83.0 68.8 to 90.7 
Southern & Greater Murray 6 14 96.0 94.5 to 97.1 
2 to 4 year olds     
Central & SE Sydney 24 53 89.6 83.8 to 93.3 
Northern Rivers 10 32 94.4 90.2 to 96.8 
Western Sydney  33 52 80.9 70.7 to 87.6 
Wentworth 23 30 70.7 50.7 to 82.6 
Southern & Greater Murray 16 25 93.1 89.1 to 95.7 
5 to 8 year olds     
Central & SE Sydney 51 114 90.9 87.0 to 93.7 
Northern Rivers 10 69 95.1 91.7 to 97.2 
Western Sydney  65 94 83.4 76.0 to 88.5 
Wentworth 51 68 74.5 59.5 to 84.0 
Southern & Greater Murray 46 76 94.0 91.2 to 95.9 
9 to 13 year olds     
Central & SE Sydney 89 175 84.9 78.7 to 89.3 
Northern Rivers 11 41 91.9 86.2 to 95.3 
Western Sydney  85 116 72.4 60.1 to 80.9 
Wentworth 126 141 57.7 33.9 to 72.9 
Southern & Greater Murray 83 104 90.1 85.5 to 93.2 
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Table 4. VE estimates by year and age, adjusted for health area 
 Vaccinated 
cases 
Total cases VE (%) 95% CI (%) 
8 to 23 month olds     
1996 5 19 94.2 89.9 to 96.6 
1997 26 54 93.0 88.7 to 95.7 
1998 8 15 82.0 68.5 to 89.7 
2 to 4 year olds     
1996 14 32 90.0 84.3 to 93.6 
1997 63 124 88.0 83.1 to 91.4 
1998 29 36 69.2 51.4 to 80.4 
5 to 8 year olds     
1996 30 70 91.3 87.2 to 94.0 
1997 135 271 89.5 86.6 to 91.8 
1998 58 80 73.2 60.0 to 82.0 
9 to 13 year olds     
1996 44 68 85.5 78.7 to 90.1 
1997 218 361 82.6 78.1 to 86.2 
1998 132 148 55.4 34.6 to 69.6 
 
